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 Glioblastoma is the most common primary malignant brain tumor in adults. It is 
characterized by extensive invasion, an aberrant local blood brain barrier, and increased 
intercerebral pressure due to edema.  Although there have been several advances in 
therapeutic strategies to treat gliomas, the current median survival for glioblastoma 
remains less than 2 years. A major impediment to the treatment of glioblastoma is the 
lack of drugs that can overcome the blood brain barrier, treat cancer cells, and not affect 
nearby glia and neurons. Additionally, most therapeutic strategies against cancers merely 
target cancer growth without affecting invasion, angiogenesis and metastasis.  
Glycosaminoglycans, particularly heparan sulfate and chondroitin sulfate, are 
responsible for regulating several pathological processes associated with the progression 
of glioblastoma. They interact with growth factors, chemokines, and other molecules in 
the extracellular matrix and within cells, to modulate aberrant cell signaling pathways 
that influence cancer invasion, metastasis, angiogenesis, and growth.  
In this dissertation, a therapeutic strategy based on glycosaminoglycan biology is 
designed and developed to treat gliomas and other cancers in vivo. The strategy is 
composed of two parts: glycosaminoglycan-based drugs (xylosides and 
glycosaminoglycan mimetics) and a glycosaminoglycan-based drug delivery vehicle 
conjugated to doxorubicin. Xylosides are small sugar monomers attached to aglycone 





protein attached. It is shown that upon treatment of gliomas by xylosides, the released 
glycosaminoglycans dramatically reduce tumor-associated invasion and angiogenesis in 
vitro. As xylosides are nontoxic even at high dosages, they are an incredibly powerful 
means to curb tumor invasion and angiogenesis. In addition to xylosides, an optimized 
heparin-based drug delivery vehicle, composed of heparosan conjugated to aprotinin and 
doxorubicin, is developed to deliver toxic doses of doxorubicin across the blood brain 
barrier to gliomas. This conjugate is an exciting therapeutic not only because it can curb 
glioma growth, but also because it is biodegradable and easy to produce in large 
quantities. Based on exciting in vivo results in mice, it is expected that this strategy will 
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Abstract
Heparan sulfate proteoglycans (HSPGs) play vital roles in every step of tumor progression allowing
cancer cells to proliferate, escape from immune response, invade neighboring tissues, and metastasize
to distal sites away from the primary site. Several cancers including breast, lung, brain, pancreatic,
skin, and colorectal cancers show aberrant modulation of several key HS biosynthetic enzymes such
as 3-O Sulfotransferase and 6-O Sulfotransferase, and also catabolic enzymes such as HSulf-1,
HSulf-2 and heparanase. The resulting tumor specific HS fine structures assist cancer cells to
breakdown ECM to spread, misregulate signaling pathways to facilitate their proliferation, promote
angiogenesis to receive nutrients, and protect themselves against natural killer cells. This review
focuses on the changes in the expression of HS biosynthetic and catabolic enzymes in several cancers,
the resulting changes in HS fine structures, and the effects of these tumor specific HS signatures on
promoting invasion, proliferation, and metastasis. It is possible to retard tumor progression by
modulating the deregulated biosynthetic and catabolic pathways of HS chains through novel chemical
biology approaches.
Keywords
Proteoglycan; Cancer; Heparanase; Sulfotransferase; Sulfatase; Heparan Sulfate
Introduction
It has been known for decades that heparan sulfate proteoglycans (HSPGs) and chondroitin
sulfate proteoglycans (CSPGs) are involved in the progression of cancer at various stages [1–
3]. Many excellent reviews have described cancer growth, development, and metastasis [4–
6]. However, knowledge on the detailed molecular interactions between tumor cells and ECM
components including HS chains has only recently been devolved. In lieu of this new
knowledge, this review article focuses on the role of HSPGs in several types of cancer and
provides insights into how future cancer therapies can be developed based on changes in HS
biosynthesis and catabolism.
Tumor Transformation, Growth, Invasion and Metastasis
The development of cancer typically involves four distinct stages: transformation into a
cancerous phenotype, sequestration of nutrition through angiogenesis, invasion into nearby
tissue, and metastasis to distal sites away from the primary location. While the transformation
of normal cells into a cancerous phenotype hasn’t yet been linked to HSPGs, there is an
*Address correspondence: Kuberan Balagurunathan, University of Utah, 30 S 2000 E, Skaggs Hall Room 307, Salt Lake City, UT 84112,
USA, Phone: (+1) 801-587-9474; Fax: (+1) 801-585-9119; KUBY@pharm.utah.edu.
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abundance of evidence relating HSPG fine structures to cancer growth, invasion, and
metastasis.
Tumor cells upregulate the production of several angiogenic factors such as fibroblast growth
factor (FGF) and vascular endothelial cell growth factor (VEGF) [7]. In order to support altered
growth patterns and metabolism, these molecules trigger angiogenesis, the growth of blood
vessels, which provides nearby cells with increased nutrition and oxygen-supply [8].
Malignant cancers are characterized by their invasiveness into nearby tissues and metastasis
to distal locations away from the primary tumor site. In order for these processes to take place,
tumor cells breakdown the surrounding ECM by activating or releasing various proteases such
as matrix metalloproteases (MMPs) and serine proteases [9–12]. These proteases make the
ECM more permeable for invading cells to pass through established ECM boundaries [13].
Malignant cancers can even invade into the blood stream and metastasize to distal locations in
the body by cleaving off their adhesions to the ECM, entering the bloodstream, and then binding
to ECM at a distal location. Since HSPGs are implicated in the above-mentioned critical
processes, controlling their fine structures can significantly impact the growth, invasion and
metastatic properties of tumor cells.
Common HSPG- Growth factor and Cytokine interactions
One of the primary methods by which HSPGs control cancer progression is by regulating the
interactions between cells and signaling molecules such as growth factors and cytokines.
Several insightful reviews discuss the roles that HSPGs play in binding to signaling molecules
and localizing them to their cognate receptors on cell surfaces, storing them in tissues for later
use, and/or helping to form molecular gradients for directional cellular activities during the
development [14–16].
FGF2-HS interactions are well-studied example of GAG-growth factor interactions. The
binding of FGF2 to its receptor causes autophosphorylation of the receptor’s tyrosine kinase
domains and leads to increased growth, migration and differentiation in several cancers [17,
18]. HSPGs play an integral role in the FGF2-FGFR interactions by localizing FGF2 near the
receptor and forming a bridge that stabalizes the ligand-receptor complex and allows for signal
transduction [19,20].
However, only specific HS fine structures allow FGF2-FGFR-mediated signaling. To bind
FGF2, HS chains require N-Sulfated glucosamine units and 2-O-Sulfonated iduronic acid units
[21–23]. Concurrently, for HS chains to bind FGFR, they require 6-O-Sulfonated glucosamine
residues in addition to 2-O-Sulfonated iduronic acid and N-Sulfonated glucosamine residues
[21,23,24].
Similar to HS-FGF2 interactions, HSPGs are essential to the signaling pathways triggered by
other growth factors and cytokines as well. The following are some particularly important
signaling molecules affected by HSPG interactions: VEGF, Heparin binding epidermal growth
factor (HB-EGF), Transforming growth factor (TGF), Bone morphogenic protein (BMP), and
FGF. Manipulating HS biosynthesis and catabolism can drastically affect several of these
signaling pathways.
Proteoglycans: Biosynthesis and Catabolism
Cancer cells have inherently altered proteoglycan fine structures that allow them to invade,
metastasize and grow uncontrollably [25,26]. These fine structural changes are due to errors
in the regulation of biosynthetic and catabolic enzymes that control proteoglycan fine
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structures. The following section details several of the enzymes that are responsible for PG
synthesis and catabolism.
Proteoglycans are composed of a core protein substituted with one or more glycosaminoglycan
(GAG) polysaccharide side chains [27,28]. PG assembly involves the following steps: (1)
assembly of the linkage tetrasaccharide (2) concurrent elongation and modification of the GAG
backbone such as epimerization, deacetylation and N-/O- sulfonation (Fig. 1).
Synthesis begins with the transfer of xylose residues to certain serine amino acids in the core
protein. Next, transfer of galactose and glucuronic acid residues by glycosyl transferases such
as GalT-I, GalT-II, and GlcAT-I results in the formation of a tetrasaccharide linkage region
[29,30]. Subsequently, the GAG chain is elongated via the alternate addition of D-glucuronic
acid (GlcA) and N-acetyl-D-hexosamine (N-acetyl-D-glucosamine, GlcNAc or N-acetyl-D-
galactosamine, GalNAc) to the tetrasaccharide linker [31–34]. HS contains GlcNAc and GlcA/
Iduronic acid (IdoA), CS contains GalNAc and GlcA, and dermatan sulfate (DS) contains
GalNAc and GlcA/IdoA disaccharide units.
Subsequently EXT enzymes and CS synthases elongate HS and CS chains, respectively, by
adding the appropriate sugar building blocks [35–40]. While the elongation is in progress, parts
of the GAG chain are modified via sulfonation and epimerization to yield the final complex
PG structure [41–43]. A host of HS biosynthetic and catabolic enzymes that have been
implicated in cancer progression are listed below:
HSulf-1 and HSulf-2
A set of HS 6-O-endosulfatases that are secreted from the Golgi and localized in the ECM.
HSulfs selectively remove 6-O sulfate groups on GlcN residues of HS; preferentially catalyzing
the desulfonation on trisulfated disaccharides (Fig. 2) [44–48].
3-O Sulfotransferase (3-OST)
A group of 7 related enzyme isoforms that catalyze the 3-O sulfonation of GlcN residues, a
rare HS modification [49–52].
6-O Sulfotransferase (6-OST)
A group of three enzyme isoforms that catalyze the 6-O sulfonation of GlcNAc as well as
GlcNS residues [53–56].
Heparanase (Hpa)
The Heparanase (Hpa) family consists of endo-?-D-glucuronidases that cleave HS into several
smaller chains ~5–7 kDa in size (Fig. 3) [57–59].
In several cancer cells, these enzymes and their isoforms are either up- or down- regulated.
Bret et al. found that RT-PCR analysis of several melanoma cells revealed a significant
difference in the expression of genes encoding for EXT2, HS3ST2 (3-OST-2), HS2ST1(2-
OST-1), HPSE (Heparanase), and SULF2 (HSulf-2) between normal and malignant plasma
cells [60]. Determining enzymes and their isoforms that are misregulated, decoding their
respective PG fine structural modifications, and understanding how these changes affect cancer
progression, are essential for directing future research endeavors that could lead to the
development of anti-cancer drugs.
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Roles of HS and Important HS-Protein Interactions in Cancer
Growth
Cell-surface HSPGs, especially glypican-1 (Gpc1) and syndecan-1 (Sdc1), are greatly
upregulated in late-stage (malignant) breast cancer tissue [61]. It is possible that these changes
allow increased growth factor signaling since certain sulfated residues of HS are required for
FGF receptor (FGFR) activation [62,63]. These HSPGs could also be responsible for protecting
the cancer cells from natural killer cell (NK) recognition [64]. Since NK cells recognize
particular HS fine structural patterns, cancer cells modify their HS patterns to evade NK cells
and the immune system. Emerging evidence suggests that interactions between HS and
HSulf-1, HSulf-2, and 3-OST, may also play an important role in breast tumor growth. The
gene encoding HSulf-1 is down regulated in breast cancer cells [46]. Lower HSulf-1 expression
increases autocrine activation of the EGFR-ERK (epidermal growth factor receptor-
extracellular signal regulated kinase) pathway and stimulates cell growth [46]. Breast
carcinoma cells also express 8-fold more HSulf-2 mRNA than normal tissues [65] Increased
HSulf-2 mRNA correlates with increased angiogenesis and FGF binding capacity [65]. Several
cancers also demonstrate 3-OST-2-gene silencing via methylation [66]. While it is unknown
how 3-OST-2 specifically modulates growth factor binding to HS, it is possible that 3-OST-2
has anti-tumor properties that are stifled in cancer cells.
Invasion and Metastasis
Over expression of Hpa, which cleaves HS chains and facilitates migration of tumor cells
through the ECM, is a key indicator of malignant breast cancers. In a clinical study, Hpa-1
expression was significantly upregulated in microinvasive lesions in ductal carcinoma in situ
(DCIS) [67]. Hpa over-expressing breast tumors are 7 times larger and significantly more
vascularized [68]. Increased Hpa also induces shedding of cell surface Sdc-1, which forms a
paracrine signaling complex and in-turn signals distal breast cancer cells to proliferate [69,
70]. Surprisingly, breast cancer can increase Hpa expression throughout the body.
Lymphocytes in peripheral blood mononuclear cell fractions (PBMCs) from breast cancer
patients express Hpa [71]. When serum containing these leukocytes is introduced to fresh
lymphocytes, Hpa expression is stimulated in the normal lymphocytes [71]. Such tumor-system
interactions lead to increased systemic heparanase expression in breast cancer [71]. Given the
multitude of functions of Hpa, systemic Hpa amplification can perpetuate the tumor-promoting
autocrine, paracrine, and growth factor signaling. Heparanase inhibitors can be effective
against invasive cancers. However, it is also possible to control Hpa activity by controlling HS
sulfonation since Hpa substrate recognition requires certain sulfonation and acetylation
patterns [72].
Pancreatic Cancer
Growth—HSPGs such as Gpc-1 and Sdc-1 play key roles in the interactions between stromal
elements and pancreatic cancer cells. Pancreatic ductal adenocarcinoma (PDAC) cells and
adjacent fibroblasts over express Gpc-1, which is involved in FGF2, HB-EGF, VEGF, BMP,
activin, and TGF-? signaling [73–76]. Down-regulation of Gpc-1 in PANC-1 cells attenuates
tumor growth, angiogenesis, and metastasis in vivo in athymic mice [75]. Both HSulf-1 and
HSulf-2 are also significantly upregulated in PDAC cell lines and stimulate autocrine Wnt
signaling, which augments cancer growth [77]. HSulf-2 silencing blocks Wnt signaling and
significantly reduces PDAC cell growth in an immuno-compromised mouse model. As with
breast cancer, pancreatic cancer cells also protect themselves from NK activity. Since NK cells
can only recognize cancer cells exhibiting certain 6-O-Sulfonation and N-Acetylation patterns,
pancreatic cancer cells that express increased extracellular Hpa and aberrant HSulf activity
exhibit much lower NK cell recognition [78].
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Invasion and Metastasis—Sdc-1 is overexpressed in the majority of the pancreatic cancer
tissue, surrounding metastatic lesions, and a significant amount is shed into serum [79]. Sdc-1
shedding correlates with increased mitogenic activity and cell invasive potential [79]. Hpa
plays an important role in pancreatic cancer invasion and metastasis as well. Hpa1 mRNA is
upregulated 7.9- and 30.2-fold in chronic pancreatitis and pancreatic cancer cells, respectively
[80,81]. Hpa mRNA over expression is preferentially higher in primary tumor sites and
correlates with decreased postoperative survival of patients [80]. Overexpression of Hpa leads
to Sdc-1 and Gpc-1 cleavage, which in-turn leads to cellular growth via FGF-2 signaling and
invasion of surrounding tissue [3].
Skin Cancer
Growth—Smetsers et al. found that melanoma cells only displayed certain GAG epitopes
with particular sulfonation patterns on their cell-surface [82]. While the identity of these GAGs
wasn’t devolved in their findings, it is possible that the GAGs represented a combination of
fragments from Glypican, Syndecan, and Perlecan (Plc) HSPGs. Gpc, Sdc, and Plc are involved
in growth factor binding. Plc, overexpressed (upto 150 fold) in human melanoma samples, also
acts as a co-receptor for growth factors such as FGF-2 and FGF-7 [83,84]. Plc knockdown
greatly inhibits murine melanoma tumor growth and neovascularization [85].
Invasion and Metastasis—Exogenous Hpa and cell-surface Gpc expression moderate the
ability of skin cancer to metastasize. Lung metastatic melanoma cells overexpress Hpa1 mRNA
(upto 29-fold) compared to normal lung tissue [86]. In melanoma patients with lung metastases,
Hpa1 is found around vascularized regions and in blood vessels near the invasion front, whereas
tumor nodules contain very little Hpa [86,87]. Hpa1-expressing melanoma cells demonstrate
increased invasion in vitro and metastasis to lung and liver in vivo [88,89]. Gpc expression also
affects melanoma invasion and metastasis characteristics since antisense-mediated-Gpc1-
knockdown reduces B16-F10 melanoma cell pulmonary metastasis by attenuating Gpc1-
HBGF (Heparin binding growth factor) signaling [75]. In combination with Hpa
overexpression, melanoma cells exhibit 3-OST gene hypermethylation and subsequent gene
silencing [90]. While the implications of this modification are not yet known, it is possible that
certain patterns of 3-O sulfonation impart cancerous phenotypic changes. Ma et al. have found
that P-Selectin, a cell adhesion molecule, bound to HS-like molecules on melanoma cells even
in the absence of its recognition motif [91]. Interplay between 3-OST, 6-OST, and HSulf-1/2
might play a role in modifying HS to confer P-Selectin binding ability and hence promote
metastasis by allowing cells to migrate to secondary sites.
Colorectal Cancer
Growth—In human colorectal cancers, Sdc-1 and Sdc-4 are downregulated while Sdc-2 is
upregulated [92,93]. In conjunction with these HSPGs, 6-OST-2 is also upregulated. Sdc-2
knockdown leads to G0/G1 cell cycle arrest, increased expression of tumor suppressor proteins,
and consequentially reduced tumorigenic activity [93]. In contrast, Sdc-2 expression in
colorectal cancer cells contributes to cell evolution into a migratory mesenchymal-like
phenotype (flatter shape, more membranal projections, and loss of intercellular contacts)
[94]. 6-OST-2 mRNA is also significantly upregulated in colonic mucinous adenocarcinoma
whereas 6-OST-3 is the predominant isoform present in normal mucosa [95]. Evidence from
ovarian cancer suggests that 6-OST overexpression correlates with FGF-2 signaling and cell
proliferation [96].
Invasion and Metastasis—Hpa over- expression correlates with increased colon cancer
proliferation, invasion, and metastatic potential. Friedmann et al. have found high levels of
Hpa in lung, liver, and lymph tumor metastases, while the highest amounts were found in
deeply invading colon carcinoma cells [97]. Hpa activity is critical in colon cancer progression
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because stored FGFs attached to cell-surface HS are released by Hpa and MMP-7 [98]. Thus,
in addition to making the ECM more permeable and susceptible to invasion, Hpa expression
promotes cell proliferation and other growth factor related signals.
Lung and Brain Cancer
Growth—The roles of HS in lung and brain cancer are largely unknown, perhaps due to the
delicacy of lung and brain tissue. Furthermore, since both these tissues are highly vascularized,
cancers here are usually secondary metastases [99]. For lung cancer patients, serum Sdc-1 (S-
Sdc-1) levels decline following tumor resection; whereas recurrent lung cancers demonstrate
elevated S-Sdc-1 levels [100]. High S-Sdc-1 levels probably indicate high Hpa activity and
extensive paracrine growth and proliferation signals.
Similarly, malignant glioma cells express high levels of Sdc-1 whereas nonneoplastic tissues
do not [101]. Cell-surface Sdc-1 expression may correspond with FGF based growth factor
signaling. It is also possible that overexpression of Sdc-1 and similar HSPGs is a distinguishing
mark of cancer. Steck et al. generated antibodies that bound favorably to HSPGs from higher-
grade gliomas [102]. From this they hypothesized that alternate HSPG expression patterns,
and possibly sulfonation patterns, pertained to malignant transformation and growth potential
of glial-cells. However, it is uncertain whether these alterations in HSPG expression are a cause
or an effect of the transformation process.
Invasion and Metastasis—Hpa activity and mRNA are upregulated in lung and brain
cancers as well. In a clinical study involving 114 lung cancer patients, cancer cells from 75%
of the patients overexpressed Hpa [103]. Hpa over expression indicates increased invasive
potential since Hpa knockdown in A549 lung cancer cells decreases their invasive potential
in vivo [104]. Similarly in brain tumors, melanoma cells that are highly metastatic to the brain
overexpress Hpa1 [105]. Hpa1 pretreated cells invade brain tissue in greater numbers and to
greater tissue depths [105].
Other Cancers
While the focus of this review is on cancers of the brain, breast, lung, skin, pancreas, and colon,
aberrant HS biosynthesis and catabolism play a role in several other cancers as well. EXT-1
and EXT-2, involved in heparan sulfate biosynthesis, are known tumor suppressor genes
involved in preventing progression of osteochondromas to chondrosarcomas [106]. Several
cancers, including ovarian cancer and head and neck squamous carcinoma, demonstrate
extensive HSulf-1 silencing [107,108]. Re-expression of HSulf-1 in these cancers suppresses
proliferation, enhances apoptosis in vitro and reduces angiogenesis [109]. Chen et al. found
that the HSulf-1 promoter was more frequently methylated in DNA samples from cell-free
serum samples of gastric cancer patients (55%) compared to healthy patients (19%) [109].
They proposed that this methylation-induced silencing of HSulf-1 could be used as an early
diagnostic tool for cancer. Hpa is overexpressed in the invading front of endometrial cancers
in humans where Hpa expression correlates with tumor-associated angiogenesis and invasion
into lymph vascular space and myometrium [110,111]. It is also over expressed in renal cell
carcinomas and head and neck carcinomas [112,113].
Underlying patterns of HSPG involvement in all cancers
Based on the previously stated roles of HS biosynthetic and catabolic enzymes in cancer, it is
now possible to see several overarching patterns (Table 1, Fig. 4). Hpa, the sole mammalian
enzyme to degrade HS, is overexpressed in most cancers. Hpa activity breaks down
proteoglycans, increases endothelium permeability, releases stored cell-surface FGFs, and
permits serum-HS to interact with FGFs. 3-OST, an enzyme that moderates rare HS fine
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structural changes, is silenced by hypermethylation in several cancers [66]. Although
demethylation of 3-OST in breast cancer cells didn’t produce any visible changes, there must
be a reason behind 3-OST silencing in such an array of cancers [66]. HSulf-1 also seems to be
downregulated (via methylation) in several cancers. Since re-expressing HSulf-1 decreases
cancer mitogenesis, cancer cells probably utilize hyper-sulfated residues that are normally
controlled by HSulf-1 for growth signaling via FGF-2 signaling [114]. Interplay between Hpa
and Sdc-1 in several cancers is also noteworthy. Both entities seem to act together to induce
proliferation and autocrine growth signaling. Changes in HS biosynthetic and catabolic
enzymes are essential to cancer growth. HS is a profound target for developing novel cancer
therapeutics because modifying HS chains would affect Hpa, HSulf-1, HSulf-2, and 3-OST
activity in tumor cells, which in turn would affect angiogenesis, growth-factor signal over-
amplification, and tumor growth, invasion, and metastasis.
Current HS-based treatments
It has been known for decades that HS and other GAGs modulate tumor biology and are
essential to cell survival. However, HS-specific treatments have only recently begun
preliminary clinical trials. Several different treatment strategies have been the focus of recent
research efforts. These strategies include: inhibition of Hpa with HS analogs such as PI-88,
inhibition of tumor invasion and metastasis using non-anti-coagulant LMWH analogs, and
inhibition of tumor growth using carbodiimide modified GAGs or ‘neoglycans’.
Difficulties associated with cancer treatment
Treating cancer poses a challenge because cancer cells have several inherent defense
mechanisms. Not only do cancer cells originate from the host system, but they also use natural
cellular metabolic pathways to grow. Additionally, due to the genetic errors that manifest
cancer, tumors are composed of heterogeneous populations of cells that respond differently to
treatments and impart multi-drug resistance to tumors [115]. Moreover, cancer patients exhibit
a hyper-coagulable state because cancer cells employ platelets and modified HS to evade
immune cells. Several insightful studies implicate platelets in forming barriers that prevent NK
cells from recognizing and destroying tumors by coagulating around cancer cells [116–118].
Depletion of platelet P-Selectins, which allow platelets to adhere to tumor cells, leads to
reduced tumor dissemination, and increased tumor cell death [119]. To further complicate
cancer diagnosis, there is an epigenetic aspect to the development of cancer. The probability
of being diagnosed with cancer increases with age, as published by the American Cancer
Society [120]. Since the disease manifests at varying ages, it is not yet possible to predict the
onset of cancer. To combat such a variety of defense mechanisms employed by cancer cells,
effective cancer therapies should be based on multiple anti-tumor mechanisms while utilizing
pathways that are essential to survival of all cells.
Heparanase, a potent anti-cancer target
Hpa is a potent anti-cancer target because it is upregulated in a majority of cancers and plays
a major role in tumor-induced angiogenesis, invasion and metastasis (Fig. 5). Based on
available information, it is possible to propose one comprehensive pathway by which Hpa aids
cancer by providing tumor cells with a self-induced proliferation loop. During hypoxia, cancer
cells overexpress Hpa well above their normal Hpa levels [121]. Overexpressed Hpa is secreted
in a pro-enzyme form. After reuptake, the proenzyme is cleaved, activated, and secreted once
again [57,122]. The active enzyme then cleaves cell surface HS (i.e. Sdc-1 shedding) to form
paracrine and autocrine signaling complexes [69].
Autocrine signaling complexes enhance FGF-HS-FGFR interactions and upregulate cellular
signaling pathways. On one hand shed Sdc-1 are taken up by cancer cells and localized to the
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nucleus where they affect expression of MMP-9, VEGF, and tissue factors [123,124]. On the
other hand, shed Sdc-1 form trimeric complexes to stabilize FGFR-1 and FGF-1 interactions
[114] Paracrine signaling complexes induce other tumor cells to proliferate as in breast cancer.
The MMP activity then potentiates tumor invasion whereas VEGF and FGF activity increase
tumor lymph node metastasis, angiogenesis and growth. Moreover, tissue factors promote
clotting, angiogenesis, and platelet barrier formation around the tumor [125–129]. Newly
formed cancer cells and improved nutrient supply then perpetuate tumor growth and heparanase
production so that the self-proliferation loop continues (Fig. 5).
PI-88 and related Heparan Sulfate analogs
The structures, advantages, and disadvantages of several Hpa inhibitors have been discussed
in detail by Ferro et al.[130] One particularly interesting Hpa inhibitor is PI-88 (Fig. 6), a highly
sulfated oligosaccharide mixture, which is currently undergoing phase II clinical trials for
treating patients with metastatic melanoma [131,132]. It prevents angiogenesis and tumor
growth by blocking FGF-1, FGF-2, and VEGF interactions with their receptors and HS [131]
PI-88 reduces the growth of invasive rat mammary adenocarcinoma cells by 50%. It also
reduces lymph node and blood metastases [133]. Among 400 patients already tested, PI-88 has
shown minimal side-effects and excellent efficacy whereby one patient with melanoma had a
partial response for >50 months [131]. Based on improvements to PI-88 chemistry, several
new analogs of PI-88, known as the PG500 series, have been developed [134]. Some
advantages of these new molecules include improved inhibition of FGF- and VEGF- induced
endothelial cell tube formation and lower plasma clearance levels compared to PI-88 [131]
Low molecular weight non-anticoagulant heparins
Another current HS-based treatment strategy is based on heparin’s natural anti-cancer
properties. While the molecular details of heparin’s effects on cancer have not been completely
resolved, it is believed that heparin inhibits tumor metastasis by inhibiting Hpa activity,
preventing P-Selectin mediated cell-platelet interactions, and releasing tissue factor pathway
inhibitor, a potent endogenous anti-angiogenic agent [135,136]. However, heparin is also a
potent anti-coagulant and cannot be used to treat cancer patients for a prolonged period of time
because it may lead to bleeding complications. Several groups have prepared low molecular
weight anti-coagulant heparin (LMWH) derivates to mimic heparin’s anti-mitogenic activity
without its anti-coagulant properties. Non-anticoagulant LMWH are produced by separating
the anti-thrombin binding sequence from unfractionated heparin, chemically desulfating
heparin at the 2-O and 3-O sulfonation sites or by using periodate oxidation (also known as
the ‘glycol split’) to decrease the number of glucuronic acid residues which are critical for
binding to antithrombin III [136] Dalteparin, a 5kD non-anticoagulant LMWH, has been shown
to improve 1- year survival of cancer patients with small cell lung cancer by 11% and 2-year
survival by 17% in clinical studies without presenting bleeding complications [137]. Anti-
coagulant LMWHs have shown promise in mouse models but have not yet entered clinical
trials [136].
Neoglycan and carbodiimide modified GAGs
Pumphrey et al. have developed a new class of anti-cancer agents, termed ‘neoglycans’, based
on carbodiimide-modified CS and heparin chains. While the actual structure of these chains is
unclear, carbodiimide modification of GAG chains could produce crosslinked chains that form
GAG complexes via reaction of the free amine groups. These crosslinked meshes may resemble
multimeric arrays of GAGs found on syndecans/glypicans. However, it is essential to note that
GAG chains have abundant carboxyl groups and limited amine functionality. Therefore, the
carbodiimide reaction may not go to completion and thus may produce highly sulfated
neoglycans functionalized with several O-acylisourea groups along the chains.
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These molecules significantly reduce myeloma and breast cancer cell viability in vitro in a
dose dependent manner [138]. NeoCS treatment at 32 µg/ml reduced ARP-1 cell viability by
96%. As reported in this study, the IC50 values for neoHeparin and neoCS on ARP-1 myeloma
cells are 21.94 µg/ml and 14.79 µg/ml, respectively. These molecules trigger apoptosis in
ARP-1 and MDA-MB-231 (breast cancer) cells, however the mechanism of their action and
uptake are still not known. neoCS was a more potent inhibitor for a majority of cell lines tested
in vitro and a single dose of neoCS completely eliminated MDA-MB-231 tumors implanted
into BALB/c nu/nu mice. After treatment with the neoCS, only 1 tumor reemerged out of 15
separate in vivo tests. These modified GAGs show promise for future anti-cancer drug
development. However, one should exercise caution because these modified GAG chains are
unlikely to be metabolized in vivo and therefore may possess toxicity.
There are also several other therapeutic strategies based on HS-like molecules. Other areas of
research include: developing FGF-2 inhibitors that prevent FGF-HS-induced cellular growth,
developing drug delivery vehicles that utilize HS-mediated internalization into cells, and
modulating HS-GAG production in cancer cells using novel drugs [139–142]. Suramin, a non-
heparin Hpa inhibitors, has also shown promise in vitro and has undergone several phase I
clinical trials [143]. Preliminary results from these studies are promising and reinforce our
hypothesis that modulating HS fine structures, their biosynthesis and interactions with the
tumor microenvironment will lead to potential drug therapies for cancer in the near future.
Future Directions
HS-based treatments can be more effective against cancer
Cancer cells have been suggested to mimic misbehaving stem cells where erroneous cellular
machinery causes cells to trigger abnormal signals, misinterpret incoming signals, and
differentiate into several families of cancerous cells [144]. HS chains, ubiquitously expressed
on cell-surfaces and in ECM throughout the body, act as molecular antennae that send and
receive signals through binding to a wide variety of molecules such as FGF-2, VEGF, HB-
EGF, P-Selectin, MMP-7 and MMP-9 [15,123,135,145,146] or releasing these sequestered
molecules from the cell surface/ECM. Thus, therapeutics that modify HS will be able to attack
cancer cells on multiple fronts because they can target P-Selectin interactions, growth factor
binding, the coagulation cascade, protease activation and inhibition, Heparanase activation and
activity, and possibly tumor evolution/differentiation [147].
Novel chemical biology approaches to treating cancer
Future research should utilize knowledge of the downstream effects of fine structural changes
in HS to invent novel therapeutics that affect a wide range of tumor-specific pathological
processes. Unraveling the mysteries of ‘GAGOSOMES’, which are responsible for forming
and controlling the HS biosynthesis enzyme complex, may also yield a valuable target [148,
149]. Modulating HS fine structures will affect HS-ECM, HS-FGF, and HS-protein
interactions and prevent cancer growth without causing any adverse downstream effects.
It is possible to inhibit HS/CS biosynthesis by utilizing 4-deoxy-4-fluoro-xylosides [150].
Decreasing overall levels of HS may reduce FGF and VEGF signaling and affect tumor
proliferation, invasion and metastasis. Inhibiting HS production may also prevent Hpa
activation and hence restrain Hpa activity [122]. It is also possible to stimulate HS and CS
GAG production by utilizing xylosides to prime GAG chains in vitro or in vivo [151].
Increasing HS can render cancer cells more adherent and less metastatic due to enhanced
integrin binding [152]. However, these methods produce a wide array of GAGs with no specific
properties. Further research into the chemistry and biology of these xylosides is necessary to
make treatments from xyloside-induced GAGs with fine structural elements that can compete
Raman and Kuberan Page 9

























with endogenous GAGs made by cancer cells and disrupt cancer growth factor signaling and
Hpa activity.
In summary, this article proposes that controlling GAG biosynthesis and catabolism in general,
and HS biosynthesis and catabolism in particular, may be a powerful tool to design effective
treatments against cancer and perhaps even other diseases. Key enzymes involved in `HS
biosynthesis and catabolism include HSulf-1, HSulf-2, Hpa, 3-OST, and 6-OST; each of these
enzymes is differentially expressed in various cancers. By changing HS structure, these
enzymes affect several downstream cellular processes that are integral to cancer progression.
However, there are still several unanswered questions relating to the use of HS in treating
cancer. Which Xylosides prime GAGs with fine structural elements that prevent FGF binding
and inhibit cancerous phenotype changes? What is the role of 3-O sulfation, a rare HS
modification, in cancer progression? In a novel experiment, Liu et al. injected Heparinase I
and III into mice with B16BL6 melanoma and found that the specificity of the enzymes dictated
whether tumors regressed (Heparinase III) or advanced (Heparinase I) due to enzymatic
cleavage of cellular HS [153]. They found that the tumor cell GAG fragments produced by
Heparinase III digestion caused upto 75% tumor growth inhibition whereas fragments
produced by Heparinase I digestion significantly enhanced growth. This experiment reinforces
the concept that there is an incredible specificity to the structural/biological relationships
between HS fine structures and the biological effects of these molecules on cancers. However,
the metaphorical HS elephant has many facets that need to be extensively studied before we
can develop any effective anti-cancer drugs [154]. Thus, chemical biologists, who are at the
interface of understanding both the biological as well as the chemical roles of HS, have ample
opportunity to research and collaborate in order to find an effective HS-based scaffold for
treating cancer without any side effects.
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HSPG Heparan Sulfate Proteoglycan





HSulf HS 6-O Endosulfatase
3-OST 3-O Sulfotransferase
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FGF Fibroblast Growth Factor
VEGF Vascular Endothelial Cell Growth Factor
HBGF Heparin Binding Growth Factor
HB-EGF Heparin Binding Epidermal Growth Factor
FGFR Fibroblast Growth Factor receptor
VEGFR Vascular Endothelial Cell Growth Factor Receptor
BMP Bone Morphogenic Protein





DCIS Ductal Carcinoma in situ
PBMC Peripheral blood mononuclear cell fraction
NK Natural Killer Cell
LMWH low molecular weight heparin
Raman and Kuberan Page 19



























Fig. 1. Proteoglycan Biosynthesis
Biosynthesis begins with the addition of xylose to serine residues of the core protein.
Subsequently, glycosyl transferases add two Gal residues and one GlcA residue. EXT-1 and
EXT-2 then extend the GAG chain by alternatively adding GlcNAc and GlcA. While
elongation takes place, NDST-1 and NDST-2 convert certain GlcNAc to GlcNS residues.
Epimerization and 2-O Sulfonation also occur in parallel; certain GlcA are converted to IdoA
while 2-OST acts on certain GlcA and IdoA residues. Subsequent action of 6-OST and 3-OST
yields the final PG chain that contains regions that have several N-Sulfated residues (NS
Domain), others that have several N-Acetylated residues (NA Domain), and short regions that
have a mixture of both (NA/NS Domain).
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Fig. 2. HSulf 1 & 2 Enzymatic Activity
HSulfs provide arylsulfatase activity selectively removing 6-O-Sulfate groups from GlcNAc
and GlcNS residues. Deviant H-Sulf mRNA expression is present in several cancers.
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Fig. 3. Hpa I Enzymatic Activity
The Heparanase family is the only mammalian enzyme family that can cleave HS to form
oligosaccharride units. Due to its unique activity, Hpa modulates growth factor signaling, ECM
permeability and remodeling, cell clustering and adhesion, and several other cancer-related
functions. Increased extracellular Hpa is an early indicator of malignant carcinomas.
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Fig. 4. The roles of HS in cancer
From gathered evidence presented in this article, HS is involved in several key functions
regarding cancer progression. Cell metastasis depends on HS to provide P-Selectin binding so
cells can adhere. As an antenna molecule, HS also plays a role in transducing signals from
external growth factors by forming complexes with growth factor receptors. Additionally it is
necessary for efficient activation of Heparanase, which is necessary for invasion, angiogenesis,
and inflammation. By binding P-Selectins on platelets, HS also protects cancer cells from
natural killer (NK) cell activity. Systemically, shed cell-surface HS can form paracrine
signaling complexes FGFRs. Additionally, though not completely understood, cancer cells
instigate circulating lymphocytes to upregulate heparanase activity; as an antenna molecule,
HS is probably involved in this pathway as well.
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Fig. 5. Current HS-Based drug development strategies and their target signaling pathways in the
Heparanase-induced self-proliferation loop
PI-88 and related oligosaccharides are potent anti-cancer agents because they interrupt
Heparanase activity and also affect several growth signaling pathways such as the FGF2
pathway. Heparin and its low molecular weight anti-coagulant derivatives are natural Hep
inhibitors that competitively inhibit Heparnase enzymatic activity by acting as the enzyme
substrate. However, it is possible to affect both Heparanase as well as HS binding growth
factors by utilizing modified HS and xylosides to tailor endogenous HS on cells to resist Hpa
enzymatic activity and growth factor binding.
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Fig. 6. Chemical Structure of PI-88
A potent Heparanase inhibitor, PI-88 is a hyper-sulfated oligosaccharide that blocks Hpa and
several HS/Growth factor interactions.
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1.2 Glioma Biology and Drug Delivery to the Brain 
  
1.2.1 Glioma Introduction 
 
Gliomas are a group of heterogeneous and highly invasive brain tumors. They are 
known for their diffused growth patterns, hypoxia, and disintegrated local blood brain 
barrier (BBB).1 Glioblastoma Multiforme, classified by the WHO as a grade IV glioma, 
is one of the most common primary gliomas and is a particularly aggressive cancer.2 
Fewer than 5 percent of patients survive more than 5 years despite a variety of aggressive 
treatment strategies.   
 
1.2.2 The Current Standard of Care for Gliomas 
 
The current standard of care for newly diagnosed GBM patients is to maximally 
resect the tumor and follow up with a 6-week course of radiotherapy along with 
concomitant systemic dosing of temozolomide (TMZ).2 Following this 6-week course, an 
additional 6-month treatment with TMZ is prescribed as an adjuvant therapy. Some 
patients are prescribed TMZ therapy for 12 months due to its excellent tolerability.  
 
1.2.3 Challenges Faced in the Clinic 
 
Unfortunately, the current standard of care has several disadvantages. Patients 
with gliomas in difficult- to-operate regions of the brain have poorer prognosis.2, 3 Areas 
such as the eloquent cortex, basal ganglia, and brain stem are typically difficult to treat 
due to the sensitive nature of nearby healthy brain tissue. Additionally, the sensitivity of 
tumors to TMZ therapy is linked to the methylation of the methylguanine 
methyltrasferase (MGMT) promoter.4 Tumors with methylated MGMT are more 




available as most chemotherapeutics are unable to cross the BBB in therapeutic 
concentrations. The size of the molecule, its lypophilicity, the presence of drug efflux 
pumps, and the integrity of the BBB all affect the antiglioma activity of 
chemotherapeutics.5 Furthermore, most patients with gliomas also receive treatments for 
other CNS-related illnesses such as epileptic seizures and inflammation. These other 
therapies may reduce the effect of chemotherapeutics that are being utilized.  
Recurrent gliomas represent another barrier to cancer-free survival of patients. 
Currently there is no standard of care for patients with recurrent GBM.6 A second dose of 
radiation or surgery may be employed when safe. However, radiation necrosis and the 
dangers of a second surgery preclude many patients from receiving any additional 
treatments. Drug resistance also poses a major hurdle to the treatment of recurrent 
gliomas. Bevacizumab, an antiVEGF antibody, was recently approved for the treatment 
of recurrent GBM. In combination or as a single treatment, it significantly reduces 
glioma-associated edema and “normalizes vasculature.”6, 7  
 
1.2.4 The Blood Brain Barrier 
 
The blood brain barrier (BBB) is crucial in regulating the passage of molecules 
from the plasma into the brain parenchyma and for maintaining a biochemical balance in 
the brain.8 It is formed by endothelial cells that line capillaries in the spinal cord and the 
brain. Additionally, several perivascular cells such as smooth muscle cells, pericytes, 
microglial cells, and astrocytes help to enforce that only certain molecules are able to 
permeate into the brain. These cells form not only a physical barrier, but also metabolic, 
transport, and immunological barriers.  




between adjacent endothelial cells. Small molecules that are less than 4Å may cross tight 
junctions if they have an appropriate ionic charge density while larger molecules require 
specific transporter proteins or disrupted tight junctions.9 The metabolic barrier is formed 
by a variety of ecto-enzymes like peptidases and intracellular enzymes such as 
monoamine oxidase which can change drug structures to inactivate them or restrict their 
permeability. Transport barriers in the BBB are composed primarily of ATP-binding 
cassette (ABC)-transporters. Examples of transporters that are part of this family include: 
Multiple drug resistance protein 1(MDR1), Permeability glycoprotein (P-gp), and Breast 
cancer resistance protein (BCRP). Several medicinal drugs such as doxorubicin, 
tenofovir, methotrexate, and topotecan are actively effluxed out of the brain by these 
efflux pumps. Molecules that overcome all of these barriers finally have to evade the 
brain’s immunological barrier which is composed of microglia, perivascular 
macrophages, and mast cells that phagocytose molecules and provide both innate and 
adaptive immunity.10   
 
1.2.5 Local Delivery Strategies for Treating Brain Tumors 
 
Due to the blood brain barrier, chemotherapeutics are unable to effectively treat 
gliomas. While tumors receive low doses of drugs, they quickly develop resistances 
against known brain-partitioning chemotherapeutics. Therefore, there is a need for more 
effective drug delivery strategies across the BBB and into the brain to improve the 
probability of giving a therapeutic dose to tumors.  Several local and systemic delivery 
strategies have been developed to tackle the difficulties of treating gliomas.11, 12 Local 
delivery strategies include injections, infusions, and local implants. Systemic delivery 




the drug, and modification with certain polymers or other brain partitioning molecules.  
Local delivery strategies offer enormous advantages to the therapeutic dosing of 
tumors with drugs. By utilizing injections it is possible to directly attack a tumor with 
cytotoxic drugs. Previously it has been shown that interneoplastic injections of BCNU 
can significantly reduce the tumor load and increase rat survival.13 Conjugation to a 
controlled-release polymer combined with interneoplastic injection further improves rat 
survival due to the prolonged duration that the drug maintains therapeutic concentration 
in the tumor. Injections may also be administered after resection to prolong the time to 
tumor resurgence.14 Similar to injections, chemotherapeutic drugs may be infused directly 
into brain tissue using pumps and a catheter system. An infusion system minimizes the 
probability of an edema while still maintaining similar efficacy. More recently, several 
research groups have utilized implanted biomaterials as a means to control tumor growth. 
Gliadel wafers consisting of polifeprosan 20 and carmustine have been utilized in several 
clinical trials.15 Currently, gliadel is indicated as an adjunct to surgery and radiation for 
newly diagnosed and recurrent glioblastoma multiforme patients. Other releaseable drugs 
tested as part of implanted systems in clinical studies for treatment of gliomas include 
AP12009 and IL13-PE38QQR.16, 17 However, the use of local delivery strategies for 
treatment in the clinical setting is limited by their inherent disadvantages. Local 
injections and infusions are prone to infection, edemas, and backflow of the solution into 
the catheter (in the case of infusions). Additionally, if treatments need to be administered 
multiple times, the side effects and risks of local injections/infusions are exponentially 
increased. Furthermore, access to deep tissue tumors or tumors in sensitive areas of the 




challenge of repeat injections being necessary for treatment. However, while implants are 
able to effectively release drugs for prolonged periods of time, there is a need for repeat 
implantation procedures once the drug reservoir is completely exhausted.11, 12 
Additionally, drug penetration into nearby tissue is restricted to very short distances from 
the implant region. These complications are common to implanted polymers, gels, 
wafers, and particulate systems. However, systemic delivery solutions overcome several 
of the drawbacks of local delivery solutions and effectively treat tumors. 
 
1.2.6 Systemic Delivery Strategies for Treating Brain Tumors 
 
Systemic delivery of chemotherapeutics presents clinicians with a strategy to 
target gliomas that are deep within tissue or too invasive to resect. Systemic delivery 
approaches include chemical modification to increase lipophilicity, increasing BBB 
permeability transiently, and modification of drugs with polymers/other macromolecules 
which enable brain targeting. As a general rule, highly hydrophobic small molecules 400-
600 Da in weight are able to diffuse across the blood brain barrier.12 One strategy to 
increase brain partitioning of drugs is to increase their lipophilicity via chemical 
modification. Researchers have previously functionalized small molecule drugs with fatty 
acyl groups, methyl groups, chloro groups, and other hydrophobic groups. Maintaining a 
strict balance between hydrophobicity and hydrophilicity while also keeping the 
molecular weight low, it is possible to greatly enhance the antiglioma efficacy of 
chemotherapeutics. However, these molecules are also able to diffuse into other tissues 
easily and therefore exhibit significant toxicity. Recently, several research groups have 
attempted to overcome the BBB using transient and partial opening of the BBB which 




been known to increase BBB permeability.18 Additionally, bradykinin analogs, 
surfactants, and several different chemokines, are able to effectively improve BBB 
traversal of therapies.12 Through temporary openings, small molecules as well as larger 
macromolecules such as antibodies and viruses may access the brain parenchyma. 
Furthermore, researchers have found that such vasoactive compounds are especially 
effective at tumor vasculature due to its aberrant structure. However, clinical use of this 
strategy is difficult because of the need for interarterial infusions. A third method to 
deliver chemotherapeutics across the BBB using systemic therapy is to use brain 
targeting peptides (TAT, LDL receptor peptides, aprotinin/angiopep etc.) and 
macromolecular drug delivery systems (liposomes, PBCA nanoparticles, polysorbate 80 
nanoparticles, etc.). Brain targeting peptides such as TAT and Angiopep utilize receptor 
mediated endocytosis to transport drugs across the BBB.19, 20 Angiopep is a 19 amino-
acid sequence, derived from Aprotinin, which is designed to utilize LRP-1 to transcytose 
across the BBB. Ang1005, a conjugate of Angiopep and Paclitaxel, has shown significant 
promise in clinical trials involving the treatment of glioblastoma multiforme and other 
brain cancers.21 Whereas Paclitaxel does not cross the BBB in therapeutic quantities, 
Ang1005 has shown to increase BBB penetration of the drug by 100 fold. Together with 
targeting peptides, macromolecular drug carriers increase accumulation of drugs in the 
brain and within tumors due to the enhanced permeability and retention (EPR) effect. 
Without targeting peptides, macromolecules are only acutely effective against brain 
tumors when given via intrathecal injection, intranasal injection, or direct spinal cord 
injection. With targeting peptides, macromolecular carriers can be given intravenously or 




trials have evaluated the effectiveness of liposomes in the treatment of gliomas and other 
cancers. Currently ongoing trials include NCT00992602 (high dose methotrexate together 
with liposomal cytrabine) and NCT01386580 (glutathione enriched pegylated 
doxorubicin in combination with transtuzumab or as a single agent).     
 
1.3 Research Objectives 
 
It is clear that a “one glove fits all” strategy is not effective against gliomas. Since 
tumor resection is technically challenging, systemic therapy with free drugs is inhibited 
by the BBB, tumor recurrence is common, and drug resistance effectively decreases the 
efficacy of singular therapies, a more effective strategy to treat gliomas requires a 
multitarget approach which requires minimal surgical intervention. Proteoglycan-based 
therapeutics offer the advantage of affecting several cellular pathways concurrently.  
In this dissertation, we design a novel treatment regime for attacking cancers, 
including brain cancer, by reengineering the tumor microenvironment in addition to 
attacking tumor growth. This goal is achieved by utilizing xylosides to modify GAG 
biosynthesis and by employing a heparin-like drug delivery vehicle (DDV) to deliver 
doxorubicin to tumor cells.  To optimize this treatment strategy for brain tumors, 
aprotinin is attached to the polymer to ensure that it can overcome the blood brain barrier 
and attack F98 glioma growth in mouse flanks as well as brains. The following specific 
aims outline the development of this novel treatment strategy:  
 
1.3.1 Specific Aim I 
 
Evaluate the in vitro efficacy of xylosides and glycosaminoglycan mimetics in 




modification of GAG production or GAG-growth factor binding ability in the glioma 
microenvironment can prevent tumor progression in vitro. In order to test this hypothesis, 
several types of xylosides are tested for their ability to modify GAG chain production in 
U87 Mg glioma cells and endothelial cells and to affect cellular invasion and 
angiogenesis. Additionally, GAG mimetics such as sulfonated aromatic scaffolds and 
chemically modified heparin are examined for their ability to inhibit tumor associated 
angiogenesis.  
 
1.3.2 Specific Aim II 
 
Develop a Heparin-based polymer-DOX conjugate and test its in vitro 
efficacy. The working hypothesis is that heparin’s sulfation pattern can be modified to 
generate a heparin-like DDV that will enter tumor cells to a greater extent than heparin 
alone. This conjugate will be able to deliver its cytotoxic cargo directly into cellular 
nuclei similar to natural proteoglycans such as Syndecan-1. To test this hypothesis, a 
library of chemically modified heparins and heparosans are generated and tested for their 
ability to enter multiple cancer cells. The internalization properties of each polymer are 
also analyzed to determine the localization, rate, mechanism, and maximum 
accumulation in cells. Next, doxorubicin is conjugated with the most promising 
polysaccharide and these conjugates are analyzed for their cellular localization, effect on 
cell viability, and mechanism of action.  
 
1.3.3 Specific Aim III 
 
Probe the in vivo and in vitro efficacy of a combination therapy consisting of 




therapy with xylosides and a HLP-dox conjugate will effectively diminish tumor 
progression in vivo in CD-1 nu/nu athymic mice. To confirm this hypothesis, the most 
promising vehicle from aim 2 is first modified with aprotinin to enable LRP-mediated 
transcytosis across the BBB. After in vitro testing, mice are then inoculated with F98 in 
the flank. Various treatment regimens that combine the use of promising xylosides from 
aim 1 and an aprotinin conjugate of the most effective DDV from aim 2 are then used to 
treat mice. At the end of the study, animals are sacrificed and treatment regimens that 
show efficacy in the flank model are then retested in mice with intracranial gliomas. 
Analysis of tumor volume and animal weight are performed to determine if the treatment 
is efficacious.  
The results of the dissertation research provide a new clinical strategy to treat 
vascularized cancers without significant systemic toxicity. A combinatorial treatment 
utilizing nontoxic xyloside-based drugs and a biocompatible HLP-Doxorubicin conjugate 
modifies the tumor environment and eradicates tumors. It is expected that the proposed 
treatment regimen will be significantly more effective than current clinical anticancer 
practices.  
 
1.4 Dissertation Overview 
 
The central goal of this dissertation is to develop a novel treatment regime for 
attacking cancers that include brain cancers. To achieve this goal, experiments are 
performed to achieve a series of specific aims and organized as chapters in this 
dissertation. GAGs are utilized as key backbones for developing new therapeutics 
because of their inherent biocompatibility and biological activity.  




invasion and tumor-associated angiogenesis including click-xylosides, fluoro-xylosides, 
sulfonated GAG mimetics, and chemoenzymatically synthesized GAGs. It is found that 
click-xylosides, which cause cells to produce and release GAGs outside the cell, are 
effective antiinvasive small molecules. Additionally, fluoro-xylosides, which prevent 
cells from producing GAGs altogether, are shown to reduce tumor-associated 
angiogenesis in vitro. Such xyloside-based therapies are clinically-advantageous because 
xylosides do not affect cell viability even at high doses. Sulfonated GAG mimetics are 
also developed and found to reduce tumor-associated angiogenesis. The advantages of 
these molecules include their size, hydrophilicity, and ease of synthesis. Finally, the 
chapter also describes the design and production of an Acharan Sulfate-like GAG which 
hinders tumor-associated angiogenesis. This polymeric antiangiogenic agent is expected 
to be more biocompatible and have a longer circulation time than other state of the art 
antiangiogenic small molecules.  
In Chapter 3, a GAG-based drug delivery vehicle is synthesized and tested in vitro 
for its ability to deliver doxorubicin in vitro. Whereas xylosides, developed in Chapter 2, 
are antiinvasive and antiangiogenic molecules, the administration of a cytotoxic drug is 
expected to work synergistically with xylosides in vivo to attack tumors using multiple 
approaches. GAGs make excellent drug delivery vehicles because of their 
biocompatibility, biological activity, ease of functionalization, and hydrophilicity. 
Therefore, initially a series of GAGs are tested for their ability to internalize into a 
variety of normal and tumor cells. It is determined that NA and NS polymers internalize 
into cells to the greatest extent and NA polymers are even able to target cellular nuclei. 




mediated endocytosis, dynamin-mediated endocytosis, and micropinocytosis. GAG 
sulfation patterns determine their internalization efficacy in a variety of cell types. In the 
next part of the chapter, doxorubicin is conjugated to NA and NS polymers and tested for 
its ability to affect cell growth. In comparison to free doxorubicin, NA and NS polymers 
are equally effective, but since they are polymeric in nature, their circulation time and 
tumor-targeting capability in vivo is expected to be significantly better. Heparin-DOX 
conjugates are also compared to the NA and NS polymers to show that sulfation patterns 
affect the drug-delivery efficacy of GAGs. Heparin-DOX conjugates are not as effective 
at reducing cell viability relative to NA-DOX, NS-DOX, or free DOX. Surprisingly, all 
the GAG-DOX conjugates are able to shuttle DOX to cellular nuclei and affect cell 
viability without utilizing cleavable linkers to link the polymer to the drug. Against 
DOX-resistant cells, NA-DOX and free DOX are not effective even at high dosages. 
However NS-DOX and HEP-DOX are able to reduce cell viability whereby NS-DOX is 
significantly more potent as a DDV. Therefore, sulfation patterns are found to affect the 
ability of GAGs to overcome DOX resistance as well.  
In Chapter 4, NA-DOX conjugates are modified with Aprotinin to enable drug 
delivery across the blood brain barrier and tested in vivo for their anticancer efficacy. A 
combination of these NA-DOX-APRO conjugates (HDA) and click-xylosides is also 
evaluated for its anticancer activity in vivo in nude mice. In the initial portion of the 
chapter, the synthesis and in vitro evaluation of HDA conjugates is described. These 
conjugates are shown to reduce glioma viability and to enter cellular nuclei to deliver 
doxorubicin. In combination with xylosides, HDA conjugates are effective at reducing 




no antagonistic interactions between the two therapies. In the next section, in vivo 
experiments are utilized to show the effectiveness of various combinations of HDA and 
xyloside against F98 gliomas in the flank and in the brain. It is found that HDA 
conjugates localize to flank tumors and the brain more than free DOX. They also localize 
to the heart less than DOX and are therefore expected to be less cardiotoxic. Furthermore, 
HDA conjugates are equally effective against flank tumors as DOX and XYL alone. 
However, a combination of HDA and XYL seems to have antagonistic effects in vivo 
against flank gliomas since tumor growth is not hindered when a combination therapy is 
utilized for treatment. Against orthotopic gliomas, it is found that neither DOX, XYL, nor 
HDA is effective. The use of bradykinin and elacridar to chemically open the blood brain 
barrier and prevent drug efflux also has no effect on the efficacy of HDA conjugates 
against orthotopic gliomas. Nonetheless, HDA conjugates and xylosides are novel 
antitumor therapeutics that warrant further investigation due to their efficacy against 
flank tumors and their lower toxicity compared to state of the art drugs like DOX.  
   In Chapter 5, the dissertation is concluded and future directions are discussed. 
The appendix includes additional information related to heparan sulfate biosynthesis that 
was a byproduct of the dissertation research. Overall, this dissertation describes the 
design and development of several novel GAG-based antitumor therapeutics that show 
promise in vivo and in vitro. Utilizing the inherent advantages of GAGs it is possible to 
target and treat cancers with a multipronged treatment approach that includes xylosides 
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EVALUATION OF THE IN VITRO EFFICACY OF XYLOSIDES  
 
AND GLYCOSAMINOGLYCAN MIMETICS IN  
 
TREATING GLIOMA-ASSOCIATED  
 





In order to develop an efficient anticancer therapy based on proteoglycan biology, 
it is necessary to first determine if proteoglycan-based therapeutics are effective in vitro. 
Proteoglycans serve critical roles in angiogenesis, invasion, and growth due to their 
ability to bind to growth factors and chemokines, among other molecules. Therefore, if 
one were able to develop molecules that competed with or modified proteoglycan 
synthesis, it would be possible to alter proteoglycan biology in the local environment. 
Xylosides, sulfonated GAG mimetics, and chemically/chemoenzymatically synthesized 
GAGs represent a diverse set of therapeutic molecules that show promising anticancer 
activity in vitro.  
Xylosides provide the ability to reengineer the tumor microenvironment. Click-
xylosides are small scaffolds consisting of xylose residues attached to aglycone moieties. 
Click-xylosides compete with endogenous proteoglycan production and cause cells to 
release GAGs instead of attaching them to proteoglycans. In Figure 1 of “Chemical 




physiological conditions, a xylose attaches to the serine residue of the core protein to 
initiate GAG synthesis. When treated with click-xylosides, the xylose moiety of the click-
xyloside serves as the initiator for GAG synthesis and does not bind to the serine of a 
core protein. These xyloside-primed GAGs are then released outside the cell where they 
can bind to growth factors and chemokines without being attached to cell surfaces. While 
the correlation between xyloside structure and their biological activity is still unclear, it is 
known the aglycone structure and linkage affect the stability and priming ability of 
xylosides. For example, a triazole linkage between the aglycone and the xylose is 
expected to improve blood stability whereas ester linkages are labile and cleaved by 
hydrolysis.1 Additionally, it has been found that “cluster” xylosides, with multiple xylose 
residues per scaffold, are able to prime multiple chains per scaffold and affect FGF-8 
signaling in zebrafish even though similar xylosides with one chain per scaffold do not 
have the same effect.2 
In normal physiology, GAG synthesis begins on the 4-O position of xylose after it 
attaches to a serine residue on a core protein; 4-fluoro-xylosides have fluorine residues 
instead of hydroxyl residues at the 4-O position and thus inhibit the attachment of GAG 
chains onto the xyloside scaffold. By competing with endogenous xylose in cells, 4-
fluoro-xylosides can perturb normal GAG biosynthesis. Previously it has been found that 
4-fluoro-xylosides inhibit PG biosynthesis by outcompeting endogenous xylose and 
preventing chain attachment to the core protein. In this chapter we also show that 
treatment with various 4-fluoro-xylosides inhibits angiogenesis in vitro in a dose 
dependent manner.    




and development of novel GAG mimetics that can effectively alter proteoglycan biology 
in the cellular environment in vitro. Acharan sulfate is a newly discovered GAG from the 
giant African snail Achatina Fulica. It has a unique structure that is unlike heparin or 
heparan sulfate. Heparin is primarily composed of trisulfated disaccharides of 2N-
sulfamido-6-O-sulfo-α-D-glucopyranoside (1à4)- 2-O-sulfo-α-L-idopyranosyluronate, 
whereas the primary structure of acharan sulfate is composed of 2N-acetamido- α-D-
glucopyrnoside (1à4)- 2-O-sulfo- α-L-idopyranosyl uronate. However, natural acharan 
sulfate is difficult to isolate in large quantities and can be contaminated with other GAGs 
during the purification process. We synthesize an acharan sulfate mimetic chemically by 
modifying heparin’s sulfation pattern. This mimetic is able to alter tumor associated 
angiogenesis in vitro and can easily be produced in large quantities.   
Furthermore, several sulfonated small molecule scaffolds that can mimic 
disaccharide units of GAGs are developed as promising antiangiogenic compounds. 
Typical GAGs such as heparin are composed of repeating disaccharide units that carry 
one carboxyl group and up to four sulfate groups. Utilizing microwave sulfation, a series 
of organic scaffolds are persulfonated to confer a similar charge density with varying 
distances between adjacent sulfate groups. Additionally, since the size is maintained 
under 500 Da, these molecules are similar to GAG disaccharide units which are typically 
in the range of 378 Da to 596 Da. Evaluation of these molecules in vitro in an 
angiogenesis tube formation assay demonstrates their value as glycosaminoglycan 
mimics that can perturb GAG biology.  
By modifying endogenous proteoglycan biology using small molecules, it is 




molecules. In addition, xylosides and other GAG mimics are nontoxic; thus, as part of an 
adjuvant therapy, it is likely that these molecules will dramatically improve the prognosis 
of patients with gliomas and other cancers.  
 
2.2 Differential Effects of Heparitinase I and Heparitinase III 
on Endothelial Tube Formation In vitro 
 
Manuscript reproduced with permission from: Raman, K. and Kuberan, B. (2010) 
Differential effects of Heparitinase I and Heparitinase III on endothelial tube formation in 
vitro, Biochem. Biophys. Res. Commun. 398, 191-193.  
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a b s t r a c t
Heparan sulfate proteoglycans (HSPGs) play vital roles in many steps of angiogenesis under physiological
and pathological conditions. HSPGs on endothelial cell surfaces act as co-receptors for a variety of
pro-angiogenic growth factors such as FGF and VEGF and anti-angiogenic factors such as endostatin.
However, the fine structural requirements of these binding interactions are dependent on the sulfation
patterns of HSPGs. Previous studies have shown that Heparitinases, heparin lyases isolated from Flavobac-
terium heparinum, can cleave heparan sulfate chains. These enzymes have been shown to reduce tumor—
derived neovascularization in vivo in mice. However, the results from these experiments could not conclu-
sively pinpoint the origin of the HS fragments. Thus, in this study we utilized an in vitro assay to assess the
differential effects of Heparitinase I (Hep I) and Heparitinase III (Hep III) on endothelial tube formation.
Hep III was found to be a more potent inhibitor of tube formation than Hep I. In conclusion, differential
cleavage of endothelial cell surface bound HS can affect the extent of inhibition of tube formation.
! 2010 Elsevier Inc. All rights reserved.
1. Introduction
It is well known that solid tumors require extensive angiogene-
sis in order to facilitate their aberrant growth [1]. Targeting angio-
genesis has been proven to be an effective strategy to starve
tumors and increase patient survival. Heparan sulfate proteogly-
cans, present on cell surfaces and within the extracellular matrix,
are intimately involved with endothelial cell function and are
important in angiogenesis and tumor progression [2,3]. By binding
to growth factors such as FGF, HBEGF, and VEGF, heparan sulfates
act as co-receptors that are integral to signal transduction [4].
However, in order to bind growth factors, HS chains need certain
sulfation patterns. A well-studied example, FGF2-binding-HS
chains contain N-sulfated glucosamine units and 2-O sulfated idu-
ronic acid [5]. Additionally, only HS chains containing 6-O sulfated
glucosamine residues and 2-O sulfated iduronic acid along with N-
sulfated glucosamine can bind to FGF receptor [6,7]. Thus, a com-
bination of unique sulfation codes is necessary to potentiate FGF/
FGFR mediated signaling. Tumors tailor their sulfation patterns
using aberrant expression of HS biosynthetic and catabolic en-
zymes to improve their survivability [3,8].
Heparitinases, isolated from Flavobacterium heparinum, have
been found to cleave heparan sulfate chains at defined locations
(Fig. 1). Heparitinase I (Hep I, EC 4.2.2.8) cleaves HS chains contain-
ing glucuronic acid residues adjacent to glucosamine residues con-
taining either N-acetyl or N-sulfate groups [9,10]. Heparitinase III
(Hep III, EC 4.2.2.7) cleaves near sulfated iduronic acid residues
[9–11].
It has been known for a long time that low molecular weight
heparins, formed by treatment of unfractionated heparin with hep-
arin lyases, have anti-angiogenic properties [12]. Previously, it has
also been found that cell surface HS, digested with Hep I and III, re-
duces VEGF165 binding and activity in endothelial cells [13,14]. Hep
I and III also reduced neovascularization in an ex vivo CAM assay
by reducing bFGF binding and subsequent signaling [15]. Addition-
ally, both direct Hep I injections and Hep I-generated fragments
have been found to inhibit myeloma growth in vivo in SCID mice
[16]. Hep I and III have also shown differential effects in reducing
tumor growth and angiogenesis in vivo [17].
Past results have shown the anti-angiogenic activity of Hep I
and III. However, several of these results are muddled due to diges-
tion of tumor derived GAGs or due to digestion of heparan sulfate
chains from surrounding tissue as well as from endothelial cell sur-
faces. The effects of direct Heparitinase digestion of endothelial
GAGs on angiogenesis have not yet been examined. Thus, in this
study we examined the differential effects of Hep I and III on tube
formation of BLMVEC on RGF-BME in vitro.
0006-291X/$ - see front matter ! 2010 Elsevier Inc. All rights reserved.
doi:10.1016/j.bbrc.2010.06.055
* Corresponding author. Address: Department of Medicinal Chemistry, University
of Utah, 30 S 2000 E, Skaggs Hall Room 307, Salt Lake City, UT 84112, USA. Fax: +1
801 585 9119.
E-mail address: kuby@pharm.utah.edu (B. Kuberan).
Biochemical and Biophysical Research Communications 398 (2010) 191–193
Contents lists available at ScienceDirect
Biochemical and Biophysical Research Communications




2. Materials and methods
2.1. Cell culture
Bovine lung microvascular endothelial cells of passage 4–8 (a
kind gift from Dr. Randal Dull) were cultured in MCDB-131 Com-
plete media (Vec Technologies). Hep I and Hep III from F. hepari-
num were expressed and purified as previously described [18].
2.2. Tube formation assay
Reduced growth factor basement membrane matrix (RGF-BME,
Trevigen) was thawed overnight for 16 h at 4 !C. Fifty microliters of
RGF-BME was then plated out in each well of a 96 well plate. Plates
were then incubated in a humidified incubator at 37 !C for 1 h.
BLMVEC were then suspended by incubation with Tryp LE Express
(Invitrogen). 1 ! 105 cells were then added to each well along with
MCDB-131 Complete media and different amounts of Hep I and
Hep III. Plates were then incubated in the incubator for 16 h prior
to Calcein staining and imaging.
2.3. Calcein staining
Media was removed from wells in the 96 well plate by gentle
dabbing with a paper towel. Cells were then washed twice with
PBS and incubated in 100 ll of 2 lM Calcein AM for 30 min in
the humidified incubator at 37 !C. After incubation in the Calcein
AM working solution, the cells were washed once again with PBS
and imaged in a Olympus IX81 microscope with an attached color
CCD Filter and a GFP emission filter using 485 nm excitation/
520 nm emission.
3. Results and discussion
Amounts of Hep I and Hep III needed to have comparable enzy-
matic activity were added to BLMVEC as described in the methods
section. Since BLMVEC form tubes spontaneously on the basement
membrane extract in the culture media, wells without any addi-
tives were used as positive controls. Sulforaphane (included with
the tube formation assay) at 20 lM final concentration was used
as a negative control. Thirty and 100 mU of either enzyme were
added to 200 ll of total volume including cells and media. Hep
III was found to be a much stronger inhibitor of angiogenesis com-
pared to Hep I as shown in Fig. 2. Tube formation in the well con-
taining 100 mU Hep I is comparable to that in the well containing
30 mU Hep III in terms of the qualitative extent of tube formation
and the number of tubes. The 100 mU Hep III well is comparable to
the inhibition shown in the negative control. Additional tests per-
formed at 60 mU of activity also led to the same conclusion (data
not provided).
Angiogenesis is critical to tumor growth and heparan sulfates
play key roles in this process by acting as co-receptors for growth
factors among other functions. Thus, altering heparan sulfate inter-
actions using drugs or enzymes can be a potent method of mitigat-
ing tumor growth and survival. Several studies have already shown
the efficacy of this treatment strategy. Heparin, an antagonist of
P-Selectin mediated interactions with platelets, has been known
to reduce tumor metastasis and increase tumor–monocyte
interactions by inhibiting the formation of a platelet ‘cloak’ [19].
Fig. 1. Site of action of (A) Hep I and (B) Hep III. Hep I fragments NA domains so that
only NS domains are left intact. Hep III fragments NS domains and leaves NA
domains intact. Hep I: Heparitinase I, Hep III: Heparitinase III, NA: N-Acetylated
domain, NS: N-Sulfated domain.
Fig. 2. Hep III and Hep I were added at equal activities onto BLMVEC on GFR
matrigel. (a) Control without enzymes. (b) Control with 20 lM sulforaphane. (c)
Hep I 30 mU. (d) Hep I 100 mU. (e) Hep III 30 mU. (f) Hep III 100 mU. Results are
from three independent experiments performed in triplicate.




Additionally, PI-88, a highly charged heparin analog, has entered
human clinical trials because it prevents angiogenesis mediated
by FGF and VEGF among other effects [20]. By targeting heparan
sulfates, it is possible to reduce cancer growth and increase patient
survival.
Heparan sulfates represent a potent target for angiogenesis
treatments because of their numerous interactions with growth
factors on cell surfaces and within the extracellular matrix. In this
study we found that Hep treatment of endothelial cell heparan sul-
fates reduces their capability to form capillary tubes in vitro. Hep III
was a more potent inhibitor of tube formation when compared
with Hep I at equal activity. We attribute this difference to the sub-
strate specificities of the two enzymes. Hep I cleaves at undersulf-
ated, NA, regions of HS chains whereas Hep III cleaves at highly
sulfated, NS, regions. Hep III therefore may disrupt the growth fac-
tor binding domains that are important for angiogenesis. Hep I, on
the other hand, still generates fragments that retain their growth
factor binding capability and therefore still potentiate tube
formation.
This conclusion is also supported by previous studies that show
that heparan sulfate proteoglycans on endothelial cells are essen-
tial to VEGF and FGF binding (potent pro-angiogenesis factors). Fu-
ture studies will probe the relative importance of the different
sulfate groups in the highly sulfated HS regions with the aid of spe-
cific and reversible biosynthetic inhibitors that are currently under
development in our lab. Utilizing such knowledge will allow
researchers to further understand the structure–function relation-
ships of heparan sulfate proteoglycans in angiogenesis. In conclu-
sion, we have discovered that the NS domains of heparan
sulfates are more important to endothelial tube formation than
the non-sulfated domains.
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2.2.1 Additional Analysis of Data 
 
In order to quantify the effects of treatment with heparitinase I and III, images of 
tubes formed by BLMVEC were processed in ImageJ software and analyzed using an 
Angioanalyzer script developed by Giles Carpentier.1 Additional experiments to discern 
the antiangiogenic potential of heparitinase I and III may include a variety of vessel 
outgrowth assays performed in matrigel, ex vivo chick chorioallantoic membrane (CAM) 






Figure 2.1. Relative mesh area covered by tubes. Tube formation was quantified using 
ImageJ software using an Angioanalyzer script. Statistical analysis was performed using 
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2.3 Click-Xylosides Mitigate Glioma Cell Invasion In vitro 
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Tumor related invasion allows cancers to spread beyond tissue
boundaries and significantly aﬀects patient prognosis. In this
study we show that several click-xylosides markedly inhibit the
invasive capability of a highly invasive glioma cell line in vitro.
These novel xylosides are promising chemical biology tools to
probe the role of the proteoglycan glycome in regulating tumor
biology.
Neuroblastomas, especially glioblastoma multiforme (GBM),
are extremely aggressive cancers characterized by hypoxia-
mediated necrotic centers, extensive tumor-associated angio-
genesis, and significant invasion into nearby neural tissues.1
Invasion provides such cancers with improved nutrition and
greatly increases their capacity to metastasize and eventually
cause cancer-related death. Proteoglycans, composed of a core
protein substituted with several glycosaminoglycan (GAG)
side chains, act as co-receptors for growth factors such as
FGF, VEGF, HBGF, etc. and play several central roles in
modulating the cell-extra cellular matrix interactions involved
in tumor associated invasion and angiogenesis.2–4 Several
GAG based drugs such as PI-88 and Suramin have shown
great promise in clinical trials in combating invasive cancers.5
Additionally, animal derived heparin, a highly sulfated
GAG family member commonly used as an anticoagulant,
has been shown to significantly inhibit cancer metastasis.6
Tumor cell associated chondroitin sulfate and dermatan
sulfate chains have also been shown to regulate proliferation
and angiogenesis.7
Xylosides carrying certain hydrophobic aglycones, which
can act as acceptors for GAG chain elongation in the Golgi,
have been shown to prime free GAGs that are secreted into
ECM.8,9 Xylosides have been used to determine the impor-
tance of GAGs in vitro and in vivo because free GAGs
are known to disrupt the molecular interactions of endogenous
GAGs with their ligands.8,10 Previously, it was found that
2(6-hydroxynaphthyl)-beta-D-xylopyranoside significantly reduced
tumor growth in vivo.11 Recently, it was reported that b-D-xyloside
inhibited the invasive capability of HeLa cells in culture
medium containing SDF-1/CXCL12.12 However, most xylo-
sides studied until now are unstable O-xylosides. It is diﬃcult
to synthesizeO-xylosides in a stereoselective manner to produce
exclusively a b-glycosidic linkage, which is required for GAG
priming activity, due to the lack of a stereodirecting C-6
hydroxyl group. Additionally, a majority of O-xylosides prime
chondroitin sulfate chains of low molecular weight. Our
lab has developed a method to address the limitations of
O-xylosides by utilizing click chemistry to synthesize a library
of click-xylosides containing various aglycone groups.
These xylosides have been shown to produce GAGs of
diﬀering lengths, compositions, and sulfation densities in
CHO pgsA-745 cells (Table 1).13
Based on these findings and the fact that GAGs play
an important role in tumor invasion, we hypothesized that
diﬀerent GAGs produced by click-xylosides would have
variable eﬀects on the invasive nature of U87MG glioma
cells. The results reported here provide the first direct evidence
for the anti-invasive capability of click-xylosides and provide
an opportunity to test the eﬀects of aglycone groups of
click-xylosides to design more potent anti-invasive GAG
primers.
The click-xylosides utilized in this study were found to
inhibit U87MG invasion to diﬀering degrees without aﬀecting
cell viability (ESIw) in vitro at 100 mM concentration (Fig. 1).
The most significant inhibition was seen in xylosides 2 and 5
where upto B70% fewer cells invaded through the matrigel
matrix compared to untreated controls. While it is uncertain
what structural features of xylosides are necessary for inhibiting
invasion, it was found that click-xylosides primed a significant
amount of GAGs in U87MG cells seeded on matrigel (Fig. 2).
In fact, xyloside 4 increased GAG production by B800%
relative to control cells. It is interesting to note that the
priming activity did not seem to have any correlation with
the anti-invasive activity of click-xylosides. However, some
conclusions can be drawn regarding the correlation between
click-xyloside aglycone structure and the ability to inhibit
invasion. Comparing napthalene containing click-xylosides
(2 and 5) vs. phenyl containing click-xylolsides (1, 3, 4
and 6), it can be seen that the inclusion of a naphthalene
ring potentiates the inhibition of invasion. Mani et al. have
earlier observed that O-xyosides carrying napthyl derivatives
inhibited tumor cell proliferation.11 Additionally, comparing
xylosides 3 and 6 which diﬀer by the lengths of their aglycone
linkages, it can be seen that xyloside 3 (a shorter linker) is a
better inhibitor of invasion than xyloside 6. More extensive
studies are required to better define the molecular basis for
these observations.
The eﬀects of click-xylosides on the invasive capability of
U87MG cells were also examined at 10 mM and 500 mM
concentrations by adding them to both the top and bottom
wells of the invasion chamber (Fig. 3). While both xylosides
1 and 3 showed a general increase in inhibition at higher
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concentrations, it is noteworthy that the maximal rate of
change of inhibition occurred at lower concentrations.
Invasion into nearby tissues is a characteristic feature of
malignant cancers. By containing cancers to specific regions, it
may be easier to provide localized treatment and improve
patient survivability. Additionally, if used in combination
with anti-angiogenic treatment, anti-invasive compounds
may eﬀectively destroy cancers without selecting for drug
resistant cells.14,15 Anti-invasive therapy may also control
cancer spread in cases where it is not possible to resect tumors.
Several reviews have detailed the eﬀects of proteoglycans
such as heparan and chondroitin sulfate on promoting as well
as inhibiting cancer growth, invasion, and metastasis.4,7 We
have found a series of xylosides that are potent inhibitors
of invasion without aﬀecting cell viability. These xylosides
have shown to inhibit invasion in vitro in matrigel invasion
chambers at micromolar concentrations (Fig. 1). Additionally,
similar to traditional anticancer drugs, these xylosides show
dose-dependency (Fig. 3). However, as stated in the results, the
slope of the inhibition curve is much steeper at lower concen-
trations. This observation can be expected if the GAG
products of the xylosides bind to specific chemokines present
in serum (such as SDF-1) and saturate this interaction at higher
concentrations. Eﬀorts are currently underway to deduce the
exact mechanism of action that will be disseminated in future
studies.
Click-xylosides oﬀer several advantages if used as drugs.
They possess high diﬀusion coeﬃcients and therefore they can
easily penetrate cells because they are small and contain
hydrophobic groups. Additionally, since they do not aﬀect
cell viability, they cannot select for drug resistant tumor cells.
However, a major disadvantage of xyosides is that the size and
composition of primed GAGs depends on cell type.13 Thus,
the anticancer activity of xylosides may be variable depending







Fig. 1 Click-xylosides inhibit U87MG invasion: Inhibition of inva-
sion is plotted as a percentage of control (untreated) cells and treated
cells with various click-xylosides (100 mM) that passed through the
matrigel invasion chamber at the end of 72 h. Results are from three
independent experiments performed in duplicate.
Fig. 2 Relative priming activity of various click-xylosides in U87MG
cells: Xyloside priming is plotted as a percent of GAGs secreted into
the supernatant from treated cells relative to control cells. Results are
from two independent experiments performed in duplicate.
Fig. 3 Dose dependence of click-xyloside mediated inhibition of
glioma cell invasion. Open squares (&) represent click-xyloside 3
and closed triangles (m) represent click-xyloside 1. Results are represen-
tative of three independent experiments performed at 10 mM, 100 mM,
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on the cells they penetrate. In summary, we have found novel
click-xylosides that selectively inhibit invasion of U87MG
glioma cells in vitro. Future studies will detail the in vivo eﬀects
of these click-xylosides as well as their eﬀects in diﬀerent
cell types.
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Cell Culture: U87MG human glioma cells (generously provided by Dr. Randy Jensen, University of Utah) were cultured in 
DMEM (Invitrogen) with 10% FBS, penicillin/streptomycin in a humidified incubator at 37 °C and 5 % O2.  
 
Matrigel Invasion: U87MG human glioma cells were plated at 1x105 cells/well in the top well of a 6 well matrigel invasion 
chamber (BD Biosciences, San Jose, CA, USA).  HAM S/ F-12  media with penicillin/streptomycin was added to the top well and 25 
HAMS/F-12 (Invitrogen) media with 10% FBS and penicillin/streptomycin (P/S) was added to the bottom well. Upon 
trypsinization  (Tryp LE Express, Invitrogen Inc.), xyloside solutions (Table 1) were added to indicated final concentrations to 
both the top and bottom invasion wells. Invasion chambers were maintained in a humidified incubator at 37 oC for 3 days.  After 
this time period, supernatant from the top well was aspirated and cells with matrigel were removed using a cotton swab and the 
well was washed twice with PBS.  Subsequently the PET membrades were cut from the well using a razor and placed in trypsin to 30 
remove cells that had invaded through and deposited on the bottom side of the PET membrane.  Invaded cells were then counted 
using a hemocytometer. 
 
Priming activity: 500 µl of LDEV-free Matrigel (BD Biosciences) was thawed overnight, added to 6 well plates, and then 
incubated at 37 °C for 1 hr.  U87MG cells were then plated at 1x105 cells per well in HamS/F-12 media supplemented with 10% 35 
dialyzed FBS and pennicilin/streptomycin.  Xylosides and Sulfur-35 (Perkin Elmer) were added to wells to final concentration  s 
of 100 µM and 10 µCi/ml, respectively.  After 3 days, supernatants from the wells were collected.  Subsequently, cell recovery 
solution was added at 2 ml/well and plates were stored at 4 °C for 1 hr. The solubilized matrigel was then centrifuged at 1000 x g 
for 10 min to remove cell debris. Both the supernatants (before and after cell recovery) were then combined and diluted 1:2 with 
0.016% Triton X-100. The diluted supernatant mix was then loaded onto a DEAE Sepharose column (0.5 ml) pre-equilibriated 40 
with 10 column volumes of wash buffer (20 mM NaOAc buffer (pH 6.0), 0.1 M NaCl, 0.01% Triton X-100).  The column was 
then washed with 30 column volumes of wash buffer.  Bound HS/CS chains were then eluted with 6 column volumes of elution 
buffer (20 mM NaOAc,1 M NaCl, pH 6.0).  Priming activity was determined as the counts per minute detectable in 50 µl of 
eluant.   
 45 
Cell Viability: U87MG cells were tested for viability in the presence of xylosides using Cell Titer Blue reagent (Promega).  Cells 
were seeded into triplicate wells of a 96 well plate at 2.5 x 104 cells/well in 125 µl of Ham's F-12 media +10% FBS +P/S.  
Xylosides were added to final concentrations of 100 µM per well and cells were incubated in a humidified incubator for 3 days.  
After the incubation period, negative controls were treated with 50 µl of 3% SDS solution for 10 minutes.  Subsequently 25 µl of 
Cell Titer-Blue reagent was added as per manufacturer's protocol.  Cells were incubated in incubator for 2 hrs and fluorescence 50 
substrate generation was then stopped by addition of 50 µl of 3% SDS to all wells. The fluorescence was measured using a 
Spectra-Max M5 microplate reader (Molecular Devices, Sunnyvale, CA) at an excitation wavelength of 560 nm and an emission 
wavelength of 590 nm
 
















Fig. 1. Viability of U87MG cells 3 days after treatment with xylosides. Data from 
xylosides is plotted as a percentage relative to positive control (untreated cells) and
negative control (cells treated with 5% SDS). Results are from two independent 




2.3.1 Additional Analysis of Data 
 
Additional analysis of data from the click-xyloside experiments are shown in Figure 2.2.  
 
2.4 Novel Glycosaminoglycan Biosynthetic Inhibitors Affect 
Tumor-Associated Angiogenesis 
Manuscript reproduced with permission from: Raman, K., Ninomiya, M., Nguyen, T K., 
Tsuzuki, Y., Koketsu, M., and Kuberan, B. (2011) Novel glycosaminoglycan biosynthetic 
inhibitors affect tumor-associated angiogenesis, Biochem. Biophys. Res. Commun. 404, 86-
89.  






Figure 2.2. Invasion inhibition by click xylosides with statistical significance 
denoted. Inhibition of invasion is plotted as a relative percentage compared to control 
untreated cells. ** indicates that a P<0.05 as determined by a 1-tailed paired t-test 
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a b s t r a c t
Heparan sulfate proteoglycans (HSPGs) are essential players in several steps of tumor-associated
angiogenesis. As co-receptors for several pro-angiogenic factors such as VEGF and FGF, HSPGs regulate
receptor–ligand interactions and play a vital role in signal transduction. Previously, we have employed
an enzymatic strategy to show the importance of cell surface HSPGs in endothelial tube formation
in vitro. We have recently found several fluoro-xylosides that can selectively inhibit proteoglycan synthe-
sis in endothelial cells. The current study demonstrates that these fluoro-xylosides are effective inhibitors
of endothelial tube formation in vitro using a matrigel based assay to simulate tumor-associated angio-
genesis. These first generation scaffolds offer a promising stepping-stone to the discovery of more potent
fluoro-xylosides that can effectively neutralize tumor growth.
! 2010 Elsevier Inc. All rights reserved.
1. Introduction
Inhibiting tumor angiogenesis is a powerful approach to miti-
gate cancer growth [1]. Heparan sulfate proteoglycans (HSPGs),
cell-surface and ECM proteins containing highly sulfated glycos-
aminoglycan (GAG) chains, play vital roles throughout the various
stages of angiogenesis and tumor growth [2–4]. They act as co-
receptors for a variety of pro-angiogenic factors including VEGF
and FGF [5–7]. As co-receptors, HSPGs facilitate receptor–ligand
interactions and signal transduction. HS chains require certain sul-
fation patterns in order to bind to growth factors [8]. In particular,
the binding of HS and FGF2 requires N-sulfated glucosamine units
and 2-O sulfated iduronic acid units [9]. Furthermore, to bind to
FGF receptor, HS chains require 6-O sulfated glucosamine residues
and 2-O sulfated iduronic acid along with N-sulfated glucosamine
[10,11]. Thus, only HS chains containing such a sulfation pattern
can potentiate FGF/FGFR mediated signaling.
Xylosides containing certain hydrophobic aglycone groups can
act as acceptors for GAG biosynthesis in the Golgi [12–14]. The
primed GAGs are then secreted outside the cell and can have a
variety of biological consequences by competing with endogenous
proteoglycan chains [15]. Previously, it was found that b-D-xylopy-
ranoside virtually eliminated the invasion of wound microvascular
endothelial cells into fibrin gels [16]. Xylosides have also shown
efficacy in preventing tumor progression [17–19]. It is also possible
to inhibit proteoglycan synthesis by utilizing fluorine-containing
xylosides [20].
Previously, we have shown that cell surface HS is essential for
tube formation in vitro using heparitinase I and III [21]. Recently,
we found that several novel fluoro-xylosides selectively inhibited
GAG synthesis in vitro in endothelial cells (Table 1) [22]. Based
on these results, we hypothesized that these fluoro-xylosides
would be effective inhibitors of endothelial tube formation as well.
In this article, we utilize the matrigel tube formation assay to show
the anti-angiogenic efficacy of these novel fluoro-xylosides.
2. Methods
2.1. Cell culture
Bovine lung microvascular endothelial cells of passage 4–8 (a
generous gift from Dr. Randall Dull) were cultured in MCDB-131
Complete media (Vec Technologies) in a humidified 37 "C incuba-
tor. Cells were split 24 h prior to conducting tube formation assays
in order to keep them in the log phase of growth.
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2.2. Tube formation assay
Reduced growth factor basement membrane matrix (RGF-BME,
Trevigen) was thawed overnight at 4 !C in a frost free refrigerator.
Fifty microliters of RGF-BME were then added to wells of a chilled
96 well plate using chilled pipette tips. The 96 well plates were
then incubated in a humidified incubator for 1 h. Concurrently,
BLMVEC were suspended by incubation with Tryp LE Express
(Invitrogen). 1 ! 105 cells were then added to each well along with
MCDB-131 complete media and various fluoro-xylosides. The
plates were then incubated at 37 !C for 16 h prior to Calcein stain-
ing and imaging.
2.3. Calcein staining
Media was removed from each well containing cells by gentle
dabbing with a paper towel. The wells were then washed twice
with PBS and then 100 ll of 2 lM Calcein AM was added to each
well. Cells were then stored for 30 min in the incubator. After incu-
bation in the calcein AM working solution, the cells were washed
once again with PBS and imaged with an Olympus IX81microscope
attached to a color CCD Filter and a GFP emission filter using
485 nm excitation/520 nm emission.
3. Results and discussion
Tube formation experiments were performed on reduced
growth factor basement membrane extract (matrigel) which simu-
lates angiogenesis near the tumor microenvironment (Fig. 1). Since
BLMVEC spontaneously form tubes on RGF-BME, wells without any
compounds were used as positive controls. Sulforaphane (provided
by the manufacturer) was used at 20 lM as a negative control.
Initially tube formation experiments were performed at a
300 lM concentration of each fluoro-xyloside as this concentration
has previously been shown to inhibit GAG biosynthesis [22]. As
shown in Fig. 1, only xylosides III and IV were able to inhibit tube
formation at 300 lM concentration. No other fluoro-xylosides
tested had any effect on tube formation at this concentration.
Based on these initial results, two other concentrations of xylo-
sides III and IV were tested for their ability to inhibit tube forma-
tion in order to understand the dose-dependent nature of these
small molecule drug candidates (Fig. 2). Xylosides III and IV did
not inhibit tube formation at 150 lM concentration whereas they
strongly inhibited tube formation at 600 lM concentration. At this
concentration, the extent of inhibition of tube formation is compa-
rable to the Sulforaphane negative control.
Angiogenesis is a complex multistep process whereby blood
vessels sprout from existing vessels. It requires a multitude of
molecular players including integrins, ECM components, proteases,
and growth factors.
Several potent anti-cancer agents such as Bevacizumab (Ava-
stin) have utilized this knowledge to attack tumors in the past
[23]. However, drugs such as Avastin, which act only on singular
molecular targets, may not be as efficacious as drugs that can affect
multiple targets. The fluoro-xylosides presented in this paper rep-
resent a novel and powerful tool to inhibit angiogenesis because of
their ability to target GAG biosynthesis and hence affect the multi-
tude of interactions that are affiliated with cell-surface GAGs and
proteoglycans.
In this paper, we have shown two fluoro-xylosides (III and IV)
that are potent inhibitors of endothelial tube formation in vitro.
There is a direct correlation between the most potent inhibitors
of tube formation and the most potent inhibitors of GAG synthesis
[22]. Since we have previously shown that cell surface heparan sul-
fates are essential players in the process of tube formation, it is
likely that these fluoro-xylosides prevent tube formation by inhib-
iting GAG production [21]. Not only are these fluoro-xylosides
ideal drug candidates due to their small size and their ability to
penetrate cells, they are also excellent chemical biology tools to
probe proteoglycan biology.
It can be argued that these first generation fluoro-xylosides are
ineffective because of their high dosage requirements (300 lM).
However, there are several methods of improving their potency.
Table 1






























































Our lab has previously shown that varying the aglycone moiety at-
tached to the xyloside can greatly affect its ability to prime distinct
GAGs [12]. Additionally, several methods exist for targeting
activated endothelial cells in the tumor microenvironment
[24,25]. Future studies will utilize this information to design more
potent fluoro-xylosides and test them in vivo. In conclusion, we
have found novel fluoro-xylosides that inhibit GAG production in
endothelial cells and also inhibit tumor-associated angiogenesis.
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2.4.1 Additional Analysis of Data 
It is noteworthy that Xyloside I is not as effective at reducing tube formation 
compared to xylosides III or IV (Figure 2.3). For further analysis of the mechanism of 
inhibition, a combination of cell inhibition studies and gene upregulation/knockdown 
experiments may be utilized to probe the effects of F-xylosides on cell invasion, 
migration, and proliferation. For example, it may be possible to upregulate AKT to 
enhance cell migration. The rescue of tube formation in the presence of such 
perturbations would indicate that F-xylosides likely deplete the ability of cells to utilize 
these processes for tube-formation. Similarly alteration of NO production, or 
upregulation of MMP/Heparanase may be utilized to probe other physiological processes 
and determine the mechanism of F-xyloside activity 
 
2.5 Discovery of Novel Sulfonated Small Molecules that 
Inhibit Vascular Tube Formation 
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Figure 2.3. Relative tube formation of BLMVEC with and without treatment with 4-
fluoro-xylosides. Tube formation is quantified as a relative mesh area covered by tube 
formation of control BLMVEC. Tubes are quantified using ImageJ software and analyzed using 
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a b s t r a c t
Tumor-associated angiogenesis is a complex process that involves the interplay among several molecular
players such as cell-surface heparan sulfate proteoglycans, vascular endothelial growth factors and their
cognate receptors. PI-88, a highly sulfonated oligosaccharide, has been shown to have potent anti-angio-
genic activity and is currently in clinical trials. However, one of the major drawbacks of large oligosaccha-
rides such as PI-88 is that their synthesis often requires numerous complex synthetic steps. In this study,
several novel polysulfonated small molecule carbohydrate mimetics, which can easily be synthesized in
fewer steps, are identified as promising inhibitors of angiogenesis in an in vitro tube formation assay.
! 2012 Elsevier Ltd. All rights reserved.
The inhibition of tumor-associated angiogenesis has been one of
the primary methods of controlling cancers for several decades.1–3
Heparan sulfate proteoglycans (HSPGs), composed of sulfonated
glycosaminoglycan (GAG) chains attached to a protein core, are
key players in stimulating tumor-associated angiogenesis.2,4
HSPGs facilitate cell signalling by acting as co-receptors for a vari-
ety of pro- and anti-angiogenic factors such as FGF, VEGF, and
endostatin.5–8 Infact, cell surface HS is essential for endothelial
tube formation in vitro.9
Several studies have utilized HS-/Heparin-based drugs to con-
trol angiogenesis.10 Recently, ReGeneraTing Agents (RGTAs) were
found to enhance angiogenesis by increasing the affinity of
VEGF-165 for its cognate receptor.11 In contrast, low molecular
weight heparin was found to have anti-angiogenic properties in
rat corneas.12 PI-88, a highly sulfonated oligosaccharide (phospho-
mannopentose sulfate) which entered clinical trials, has potent
anti-angiogenic properties.13 Additionally, JG3 (oligomannurate
sulfate), a recently discovered marine-derived oligosaccharide,
inhibits heparanase-associated angiogenesis.14 In vivo testing of
PG545, an HS mimetic, also showed promise in a recent preclinical
study in a murine tumor model.15 These and other heparin-based
inhibitors demonstrate the power of sulfonated saccharides in
anti-cancer treatments. However, nearly all HS mimetics discov-
ered thus far as angiogenesis inhibitors are high molecular weight
oligo- or poly- saccharide derivatives.
High molecular weight HS/heparin derivatives are notoriously
difficult to prepare in a homogenous form. Additionally, distinct
HS sequences possessing different sulfation patterns and/or chain
lengths may have agonistic or antagonistic effects.16,17 Finding
medically relevant HS/heparin derivatives requires exhaustive
library screening, a task made difficult by the problems of synthe-
sis. Thus, we reasoned that small molecules that (1) mimic HS; (2)
are much smaller than oligosaccharides; (3) are homogenous; (4)
are easily prepared; and (5) function as angiogenesis inhibitors,
would be more clinically effective than current HS/Heparin-based
oligosaccharide drugs. Previously we found novel small molecule
fluoro-xylosides that potently reduced tumor-associated angiogen-
esis by inhibiting HS biosynthesis in vitro.18 However, these
molecules required cellular entry to be effective. Small molecule
angiogenesis inhibitors that can assert their action outside cells
are far more desirable than carbohydrate-based oligo- and poly-
saccharides because of their potentially favorable pharmacokinetic
properties.
To test this hypothesis, we designed a library of 18 sulfonated
non-carbohydrate small molecules that can be expected to mimic
heparin/HS due to their highly charged nature. Using a microwave
sulfonation protocol that we previously developed and rigorously
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characterized, we synthesized molecules belonging to the flavone,
flavan, chalcone, stillbene, styrene, and isoquinoline scaffolds,
representing significant diversity at the three-dimensional level
(Fig. 1).19–21 Furthermore, the synthesized molecules contain 1–5
sulfate groups and are under 500 Da in size; therefore, they have
similar charge density, sulfate functionality, and size as HS/heparin
di-/tri-saccharides and should mimic HS/heparin functions.
These molecules were screened in an in vitro assay of
tumor-associated angiogenesis which utilizes reduced growth fac-
tor basement membrane extract (RGF-BME) derived from the
Englebreth-Holm-Swarm (EHS) mouse sarcoma. When bovine lung
microvascular endothelial cells (BLMVEC) are cultured on
RGF-BME, they spontaneously form tube-like structures. The
development of these ‘tubes’ in vitro mimics an important step
in the formation of blood vessels in vivo. An extensive tube-like
network with significant branching and tube length indicates nor-
mal angiogenesis. On the other hand, disjointed groups of cells
forming short tubes that are not interconnected exemplify the
inhibition of angiogenesis. Several previous studies have utilized
this matrigel tube formation assay.18,22
We initially screened the library at a number of different
concentrations and found that several molecules completely abol-
ished tube formation. Control wells contained either no compound
(positive control) or sulforaphane (negative control). Sulforaphane,
found in broccoli and other cruciferous vegetables, is a potent anti-
cancer agent provided by the assay manufacturer.23 Screening of
the 18 molecules (Fig. 1) led to the identification of 4, 5, 6, 7 and
9 as potent inhibitors of angiogenesis at 100 lM (Fig. 2). While un-
treated wells and inactive mimetics showed significant branching
and interconnectivity, endothelial cells treated with these sulfo-
nated molecules were dispersed and formed small cell clumps
without much network formation.
Based on our findings, it is possible to glimpse into structure–
activity relationships that play a role in vascular tube formation;
although, this process is considerably complex and involves a large
number of probable mechanisms. The active molecules, 4, 5, 6, 7
and 9, carry two, three, or four sulfate groups per scaffold
(Fig. 1). However, the inhibitory activity was not proportional to
number of sulfate groups as several tetra- and penta- sulfonated
molecules (e.g., 10–18) were found to be inactive. A comparison
of structures of the molecules that exhibit inhibitory activity
shows that the minimal ‘pharmacophore’ appears to be two sulfate
groups at an optimal distance of 5–10 Å as found in scaffolds 4, 5,
and 7. This suggests that structural selectivity is involved in the
process. Additionally, due to the highly charged nature of these
molecules, they probably inhibit tube formation via a chelation
or competition mechanism outcompeting cell-surface heparan sul-
fates for pro-angiogenic factors such as FGF. We have previously
shown that disruption of cell surface HS by heparitinases and by
GAG biosynthesis inhibitors halts tube-formation.9,18 The current
study presents an alternative approach which utilizes sulfonated
small molecules to inhibit tube formation by competing with the
functions of cell surface HS.
This work presents the first small, synthetic, non-saccharide,
highly sulfonated heparin/HS mimetics that possess anti-angio-
genic function. The compounds in the current study are likely to
be clinically superior to current carbohydrate-based high molecu-
lar weight drugs which have shown significant anti-cancer poten-
tial in clinical trails.13 Molecules 4, 5, 6, 7, and 9 have lower
molecular weights, can potentially modulate a variety of signalling
pathways, are easy to synthesize, and probably exert their activity
outside cells without the need for cell penetration. Due to these
properties, it is expected that the current molecules will have more
favorable pharmacokinetic properties and clinical application.
Additional scaffolds will be developed to identify more potent
angiogenesis inhibitors and to ascertain the mechanism of action
of these molecules. In vivo testing of these compounds will lead
to the identification of potential drug candidates for further
studies.
Experimental information
Tube formation assay: A premixed solution of 1 ! 105 BLMVEC,
heparin/HS mimetic inhibitors, and MCDB-131 media were added
to matrigel in a 96 well plate, in duplicate. After incubation for
16 h at 37 !C, cells were imaged with an Olympus IX81.
Synthesis: All tested compounds were synthesized in one step
from their phenolic and/or alcoholic precursors using microwave-
assisted synthesis, as described previously.19 Briefly, the precursor
and trimethylamine sulfur trioxide complex at a molar ratio of 1:6
per –OH group were mixed in acetonitrile and exposed to micro-
waves (50W) at 90 !C for 30 min. The purity of the sulfonated
compounds was assayed using reverse polarity capillary electro-
phoresis, as previously described20 and found to be >95%. (see
Supplementary material for details).Figure 1. Chemical structures of the library of sulfonated small molecules.




Figure 2. An in vitro tube formation assay was utilized to identify angiogenesis inhibitors. Wells were treated at a concentration of 100 lM. Representative panels in this
figure are: (A) Positive untreated control, (B) sulforaphane negative control, (C) 9, (D) 4, (E) 5, (F) 6, (G) 7, and (H) 12.
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  of	  novel	   sulfonated	   small	  molecule s 	   that	  inhibit	  vascular	  tube	  
formation	   	  
	  
Karthik	  Raman a,# ,	  Rajesh	  Karuturi b,# ,	  Vimal	  P.	  Swarup a ,	  Umesh	  R.	  Desai b,	  Balagurunathan	  Kuberan a,c,d,* 	  
Materials 	  
Bovine	  lung	  microvasc ular	  endothelial	  cells	  (BLMVEC)	  of	  low	  passage	  were	  kindly	  provided	  by	  Dr.	  	  
Randall	  Dull	  of	  the	  University	  of	  Utah.	  	  MCDB -­‐131	  complete	  media	  was	  purchased	  from	  Vec	  
Technologies	  (Rensselaer,	  NY).	  	  Reduced	  growth	  factor	  basement	  membrane	  matrix	  (RGF -­‐BME ),	  
ca lcein,	  and	  sulforaphane	  were	  purchased	  from	  Trevigen	  Inc.	  	  (Gaithersburg,	  MD).	  	  Tryp	  LE	  Express	  was	  
purchased	  from	  Invitrogen	  Inc.	  	  (Carlsbad,	  CA).	  	  All	  other	  reagents	  were	  purchased	  from	  Aldrich	  Chemical	  
(Mi lwaukee,	  WI)	  and	  used	  without	  further	  purificati on.	  	  Polyphenolic	  precursors	  used	  in	  the	  synthesis	  of	  
sulfonated 	   molecules	  were	  either	  synthesized	  in	  the	  laboratory	  as	  described	  earlier [1] 	   or	  purchased	  from	  
Indofine	  (Somerville,	  NJ)	  and	  Sigma	  (St.	  	  Louis,	  MO). 	  
In	  vitro	  m atrigel	  tube	  formation	  assay 	  
BLMV EC	  were	  cultured	  in	  MCDB -­‐131	  media	  in	  a	  humidified	  37	  ∫C	  incubator.	  	  Cells	  were	  split	  24	  hrs	  prior	  
to	  conducting	  tube	  formation	  assays	  in	  order	  to	  keep	  them	  in	  the	  log	  phase	  of	  growth.	  	  RGF -­‐BME 	  was	  
thawed	  overnight	  at	  4	  ∫C	  in	  a	  frost	  free	  refrigerator.	  	  Fi fty	  µl	  of	  RGF -­‐BME 	  was	  then	  plated	  out	  in	  wells	  of	  a	  
chilled	  96	  well	  plate	  using	  chilled	  pipette	  tips.	  	  The	  RGF -­‐BME 	  was	  allowed	  to	  solidify	  to	  form	  the	  matrigel	  
matrix	  in	  the	  humidified	  incubator	  at	  37	  ∫C.	  	  Concurrently,	  BLMVEC	  were	  suspended	  by	  incubation	   with	  
Tryp	  LE	  Express	  and	  counted	  using	  a	  hemacytometer.	  	  After	  the	  matrigel	  had	  formed,	  a	  premixed	  
solution	  of	  1	  x	  10 5	   cells,	  heparan	  sulfate 	   mimetic	  inhibitors,	  and	  MCDB -­‐131	  media	  were	  then	  added	  to	  
wells	  in	  the	  96	  well	  plates	  in	  duplicate.	  	  The	  plates	  we re	  then	  incubated	  in	  the	  humidified	  incubator	  for	  16	  
hrs	  prior	  to	  Calcein	  staining	  and	  imaging.	  Cells	  were	  first	  observed	  under	  a	  light	  microscope	  to	  observe	  
their	  morphology.	  	  Subsequently,	  media	  was	  removed	  from	  each	  well	  containing	  cells	  by	  gentle	  dabbi ng	  
with	  a	  paper	  towel.	  	  The	  wells	  were	  then	  washed	  twice	  with	  chilled	  PBS	  and	  100	  µl	  of	  2	  µM	  Calcein	  AM	  
was	  added	  to	  each	  well.	  	  After	  incubating	  cells	  for	  30	  minutes	  in	  the	  incubator,	  the	  cells	  were	  washed	  
twice	  with	  chilled	  PBS.	  	  They	  were	  immediately	  im aged	  with	  an	  Olympus	  IX81	  microscope	  attached	  to	  a	  
color	  CCD	  Filter	  and	  a	  GFP	  emission	  filter	  using	  485	  nm	  excitation/520	  nm	  emission. 	  
Synthesis	  of	   sulfonated 	  m olecules 	  
P rocedure	  for	   microwave -­‐assisted	   sulfonation :	  To	  a	  stirred	  solution	  of	  the	  polyphenol	  o r	  polyalcohol	  in	  
MeCN	  (1	   ñ 	   5	  mL)	  at	  RT,	  Et 3N	  (10	  eqv	  per	   ñOH	  group)	  and	  Me 3N:SO 3	   complex	  (6	  eqv	  per	   ñOH)	  were	  
added.	  The	  reaction	  vessel	  was	  sealed	  and	  micro -­‐waved	  (CEM	  Discover	  synthesizer,	  Cary,	  NC)	  for	  30	  
min	  at	  90	   0C.	  Several	  reaction	  tubes	  were	  pooled 	   for	  isolation	  of	  the	  product.	  The	  MeCN	  layer	  was	  
decanted	  and	  pooled,	  while	  the	  residue	  was	  washed	  with	  MeCN	  (5	  mL)	  and	  centrifuged.	  The	  combined	  
MeCN	  layers	  were	  concentrated	  in	  vacuo.	  Water	  (5	  mL)	  was	  added	  to	  the	  residue	  and	  stirred	  for	  10	  min.	  
The	  wat er	  layer	  was	  concentrated	  to	  approximately	  2	  mL,	  loaded	  onto	  a	  Sephadex	  G10	  column	  (160	  cm)	  
and	  chromatographed	  using	  water	  as	  eluent.	  Fractions	  were	  combined	  based	  on	  capillary	  electrophoresis	  
profiles,	  concentrated	  and	  re -­‐loaded	  onto	  a	  SP	  Sephadex	  C25	  co lumn	  for	  sodium	  exchange.	  Appropriate	  




Sch eme	  1.	  	  A	   general 	  reaction	  scheme	  for	   syn thesizing	   sulfonated 	  sma ll	  molecular	   sca ffolds .	   	  
	  
Spectral	  characteristics	  of	  the	   s ulfonated 	  compounds	  not	  reported	  earlier	  are	  as	  follows:	   	  
	  
5 : 	   1H	  NMR	  (DMSO,	  400	  MHz):	  7.09	  (m,	  6	  H),	  3.06	  (t,	  2	  H,	   J =	  2.04Hz),	  2.81	  (t,	  2	  H,	   J =2.04Hz).	   13 C	  NMR	  
(DMSO,	  100	  MHz):	  153.5,	  151.3,	  149.6,	  136.13,	  128.38,	  120.38,	  109.33,	  39.74,	  35.23.	  ESI -­‐MS	   (-­‐ve) 	  m/z	  
Calcd	  for	  C 15 H 10 Na 4O 17 S 4:	  681.84;	  found,	  659.02	  (M -­‐Na) + .	   	  
	  
6 :	   1H	  NMR	  (DMSO,	  400	  MHz):	  8.18	  (m,	  1	  H),	  7.85	  (m,	  1	  H),	  7.6	  (m,	  6	  H).	   13 C	  NMR	  (DMSO,	  100	  MHz):	  
178.22,	  157.34,	  154.92,	  151.63,	  136.1,	  133.7,	  131.22,	  130.71,	  125.08,	  124.74,	  123.88,	  122.35,	  12 1.77,	  
120.01,	  118.46.	  ESI ñMS	   (+ve)	  m/z	  Calcd	  for	  C 15 H 8Na 2O 10 S 2:	  458.33;	  found,	  481.08	  (M+Na) + .	   	  
	  
8 : 	   1H	  NMR	  (DMSO,	  400	  MHz):	  7.97(m,	  2	  H),	  7.83	  (m,	  1	  H),	  7.55	  (m,	  1	  H),	  7.41	  (m,	  2	  H),	  7.24	  (m,	  1	  H).	  
13 C	  NMR	  (DMSO,	  100	  MHz):	  172.84,	  158.09,	  155.24,	  153.19,	  1 35.17,	  131.82,	  128.49,	  125.99,	  123.92,	  
122.53,	  120.38,	  118.46,	  106.79.	  ESI -­‐MS	  ( -­‐ve)	  m/z	  Calcd	  for	  C 15 H 7Na 3O 14 S 3:	  576.33;	  found,	  530.14	  (M -­‐
2Na) + .	   	  
	  
10 : 	   1H	  NMR	  (DMSO,	  400MHz):	  7.91	  (m,	  1	  H),	  7.61	  (d,	  1	  H,	   J =3.2	  Hz),	  7.55	  (m,	  2	  H),	  7.35	  (d,	  1	  H,	   J =2.1	  
Hz),	  7. 05	  (m,	  1	  H).	   13 C	  NMR	  (DMSO,	  100	  MHz):	  175.4,	  155.5,	  151.04,	  135.6,	  131.12,	  127.18,	  119.1,	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  2.5.1 Additional Analysis of Data 
Additional analysis of data from the persulfonated mimetics experiments are 
presented in Figure 2.4.  
 
2.6 Chemogenesis of an Anti-Angiogenic 
Glycosaminoglycan 
Manuscript reprinted with permission from: Raman, K., Arungundram, S., and Kuberan, B. 
(2014) Chemogenesis of an antiangiogenic glycosaminoglycan, ACS Med. Chem. 
Lett..Copyright 2014 American Chemical Society. 






Figure 2.4. Relative tube formation when BLMVEC are treated with persulfonated HS 
mimetics. ** indicates P<0.05 as determined by a one-tailed paired t-test. Relative tube formation 
indicates the relative total mesh area covered by tubes. It is evident that mimetic 39 is not as 
efficacious as 1 or 42 at inhibiting tube formation. Due to their highly charged nature, sulfated 
mimetics are likely to exert their activity outside of cells by competing with cell-surface heparan 
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ABSTRACT: In this letter we report a facile chemical
conversion of heparin, a potent anticoagulant with minimal
antiangiogenic activity, into an eﬀective antiangiogenic
glycosaminoglycan through optimized chemical approaches.
This work highlights the potential for industrial scale
production of a therapeutic anticancer glycosaminoglycan.
KEYWORDS: Acharan sulfate, angiogenesis, heparan sulfate, synthesis, heparin
Glycosaminoglycans (GAGs) such as heparan sulfate (HS)and chondroitin sulfate (CS) are linear polyanionic
molecules typically linked to proteins. Because of their
molecular diversity, they are involved in a variety of
pathophysiological processes including cell signaling and
development, growth and morphogenesis, angiogenesis, in-
ﬂammation, and tumor progression.1−3
Acharan sulfate is a sulfonated GAG from the giant African
snail Achatina fulica.4 It has a unique structure that is unlike
heparin or heparan sulfate. In naturally occurring glycosami-
noglycans, sulfate groups may be located on the 2-N, 3-O, and
6-O positions of glucosamine residues, as well as the 2-O
position of uronic acid residues. Heparin is primarily composed
of trisulfated disaccharides of 2N-sulfamido-6-O-sulfo-α-D-
glucopyranoside (1 → 4)-2-O-sulfo-α-L-idopyranosyluronate,
whereas heparan sulfate is primarily composed of monosulfated
disaccharides of 2N-sulfamido-α-D-glucopyranoside(1 → 4)-β-
D-glucopyranosyluronate. Conversely, the primary structure of
acharan sulfate is composed of 2N-acetamido-α-D-glucopyrano-
side (1→ 4)-2-O-sulfo-α-L-idopyranosyluronate. This sequence
is rarely produced in human tissue as epimerization of
glucuronic acid to iduronic acid requires the presence of
neighboring N-sulfo groups.5
On the basis of its unique structure, acharan sulfate is a
potentially valuable molecular medicine for treating cancers.
Previously, several studies have discussed heparin’s inherent
anticancer properties.6 However, unfractionated heparin is a
potent anticoagulant and cannot be used for cancer therapy due
to bleeding complications. The presence of 3-O, 6-O, and N-
sulfo groups on heparin allow it to bind to antithrombin
through a unique pentasaccharide sequence.6 Unlike heparin,
acharan sulfate is nonanticoagulant and mitigates ﬁbroblast
growth factor (FGF) signaling without binding to FGF
directly.7 Acharan sulfate lacks all three critical sulfate groups
required for binding antithrombin and acting as an anticoagu-
lant. Additionally, acharan sulfate eﬀectively prevents vascular
endothelial growth factor-induced (VEGF) angiogenesis in
models of inﬂammation.8 Furthermore, acharan sulfate shows
no toxicity in vitro when tested at concentrations as high as 5
mg mL−1.7
Current methods for procuring acharan sulfate require
tedious isolation from snail tissue. Additionally, there is a
possibility of contamination with other sulfated polysaccharides
when isolating acharan sulfate directly from tissue. To
overcome these challenges, there is a need for a chemical or
chemoenzymatic process to synthesize acharan sulfate.
In this letter, we report a facile preparation of a GAG similar
to acharan sulfate from heparin, a widely available poly-
saccharide that can be obtained in large quantities (Scheme 1).
This GAG is synthesized from the pyridinium salt of heparin in
three steps including: complete 6-O desulfation, N-desulfation,
and N-acetylation. As reported previously, there is a
concomitant removal of 3-O-sulfates when heparin is subjected
to 6-O- or N-desulfation.9,10 The presence of repeating
disaccharides of N-acetyl-D-glucosamine (GlcNAc) and 2-O-
sulfo-iduronic acid in the synthesized polymer was conﬁrmed
by nuclear magnetic resonance (NMR) and strong anion
exchange high performance liquid chromatography (SAX-
HPLC) analysis (Figure S1 and Table S1, Supporting
Information). The molecular weight of the resultant polymer
was analyzed on size exclusion chromatography (SEC)-HPLC
(Figure S2, Supporting Information). As expected, desulfation
of the low molecular weight heparin precursor leads to a
removal of sulfate residues and a reduction in the ability to
attract water molecules. Additionally, since heparin was utilized
as the precursor, the ﬁnal product has a very high iduronic acid
content as conﬁrmed by NMR analysis (Figure S5, Supporting
Information).
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Complete 6-O-desulfation results in the generation of a C6-
hydroxyl group on the GlcNAc residues, in agreement with
resonances for H6 a,b (1H NMR, 3.90 ppm; 13C NMR, 59.84
ppm). In comparison, the H6 a,b proton signals resonate at
∼4.3 ppm in the heparin starting material. Upon complete de-
N-sulfation and N-acetylation, a new signal appears at 2.09 ppm
1H and 22.07 ppm 13C, in agreement with the N-acetyl CH3
group. The H2 proton signal of the newly formed GlcNAc
residue is shifted downﬁeld to 4.03 ppm (53.76 ppm 13C) from
the 3.3 ppm signal observed for that of GlcNHSO4.
The proton signal corresponding to the sulfonated OH−C2
appears at 4.29 ppm conﬁrming the presence of 2-O-sulfated
hydroxyl group on the IdoA residues. The structural assignment
of the synthetic acharan sulfate-like molecule (Table S1,
Supporting Information) is in agreement with the published
data.4,11 However, the mimetic diﬀers from natural acharan
sulfate due to the lower abundance of 2-O-sulfate groups
present on the polymer backbone. Natural acharan sulfate has
more than 90 percent 2-O sulfated disaccharide residues,
whereas heparin, the precursor for the current synthesis, also
includes several disaccharides that do not contain 2-O
sulfates.12
To conﬁrm the antiangiogenic activity of the newly
synthesized GAG, a robust in vitro tube formation assay was
utilized (Figure 1). In this assay, vascular endothelial cells were
grown on matrigel where they form tube-like structures. The
eﬃcacy of antiangiogenic compounds can be determined by
examining their eﬀects on tube branching, number, and length.
It is evident that the synthesized acharan sulfate-like GAG was
eﬀective at 1 and 2 mg/mL concentrations. Observing the
Scheme 1. Synthesis of an Acharan Sulfate-Like GAG from
Heparin
Figure 1. Inhibition of BLMVEC tube formation upon treatment with
the acharan sulfate-like polysaccharide. Representative panels are (A)
control tube formation, (B) 1 mg/mL mimetic, and (C) 2 mg/mL
mimetic. Experiments were performed three times in duplicate wells.
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branching, number, and length of tubes shows that, upon
treatment, endothelial cells formed very few tubes and that the
majority of cells form clusters that are not connected to a
branched network. In contrast, heparin had a negligible eﬀect
on tube formation at 1 and 2 mg/mL concentrations (Figure
S3, Supporting Information). Additionally, the mimetic was less
eﬀective at 0.5 mg/mL (Figure S4, Supporting Information). It
is likely that increasing the 2-O sulfate content of the mimetic
will likely enhance its antiangiogenic potential.
For decades, it has been known that preventing tumor-
associated angiogenesis is an eﬀective method for controlling
cancer growth.13 While several angiogenesis inhibitors such as
Avastin have been developed previously, these therapies
typically target singular molecular functions.14 Proteoglycans,
present on cell membranes and in the extracellular matrix, are
integral components in tumor progression and angiogenesis. In
contrast to typical antiangiogenic therapeutics, proteoglycan-
based therapeutics have the potential to aﬀect several signaling
pathways involved in tumor-associated angiogenesis, invasion,
and metastasis.15 However, although several GAG-based
therapeutic agents such as PI-88 have been discovered, very
few of them have been utilized to treat patients.16,17 One of the
primary reasons for the lack of clinical application of GAG-
based therapeutics is their tedious synthesis, frequently
involving several low-yield steps and diﬃcult puriﬁcation
techniques.18 Additionally, naturally derived therapeutic
GAGs such as acharan sulfate cannot be obtained in suﬃcient
quantities to be utilized in the clinic.
In this letter, we provide a novel and simple method for
synthesizing an antiangiogenic acharan sulfate-like GAG from
heparin, a readily available and widely used clinical anticoagu-
lant. The newly synthesized polymer is biologically active at low
concentrations, eﬀectively inhibits tube formation in vitro, and
can be produced in large quantities. Because of its similarity to
acharan sulfate, the mimetic is also likely to be non-
anticoagulant. Further optimization and preclinical evaluation
of this molecule is currently underway to determine its in vivo
eﬃcacy. Further studies are necessary to determine the exact




Experimental details, SAX-HPLC analysis, eﬀect of heparin on
tube formation, eﬀect of other acharan sulfate concentrations,
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H-1/C-1 5.14/93.82 5.23/99.37 
H-2/C-2 4.03/53.76 4.29/63.68 
H-3/C-3 3.58/69.99 4.37/73.52 
H-4/C-4 3.81/76.61 4.05/70.72 
H-5/C-5 3.91/71.2 or 69.88 4.93/67.31 
H-6a,-6b/C-6 3.90, 3.90/59.84  














































































































2.6.1 Additional Analysis of Data 
Additional analysis of data from acharan sulfate experiments is presented in 





Figure 2.5. Relative tube formation when BLMVEC are treated with Acharan 
Sulfate-like glycosaminoglycan. Relative tube formation indicates the relative total 
mesh area covered by tubes. P values are determined using a 1-tailed paired t-test vs. 
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As an adjuvant therapy to xylosides and other GAG mimetics which alter tumor 
angiogenesis and invasion, a drug delivery vehicle that can deliver toxic cargo and alter 
tumor growth is necessary. It is likely that attacking cancer growth using 
chemotherapeutics, in addition to attacking invasion and angiogenesis using xylosides, 
will yield a more potent and effective treatment strategy than the state of the art. 
However, a majority of DDV developed are simple carriers that target toxic cargo to 
tumors and are then excreted. By utilizing a GAG-based DDV, it is possible to develop a 
dual-action vehicle where both the drug cargo as well as the carrier may be therapeutic. 
Additionally, PG-based DDV are naturally biodegradable and biocompatible. Previously, 
several heparin-based DDV have been developed and conjugated to a variety of small 
molecule cargo such as paclitaxel. While such conjugates showed efficacy in vitro and in 
vivo, these studies were not translated into the clinic due to heparin’s inherent 
anticoagulant activity.  
Therefore, in order to develop a proteoglycan based carrier that is not 




systematically tested for their ability to internalize into cells and localize to the nucleus in 
multiple cancer cells. The rate of internalization, saturation point, cellular localization, 
and internalization mechanisms of these were investigated. It was found that heparosan 
and N-sulfo heparosan are the most promising GAGs for use as drug delivery vehicles 
due to their ability to internalize into cells the greatest extent relative to heparin. 
Heparosan was even found to localize to the nucleus of U87 Mg glioma cells. Sulfation 
pattern significantly affects the ability of modified heparins to internalize into cells. 
However the mechanism of nuclear entry of GAGs remains a mystery.  
Next, heparosan and N-sulfo heparosan were conjugated to doxorubicin and tested 
for their relative ability to reduce cell viability of various cancer cells compared to a 
heparin-doxorubicin conjugate. Against doxorubicin-sensitive cells, heparosan and N-
sulfo heparosan were more efficacious than heparin at delivering doxorubicin. Against 
doxorubicin-resistant cells, heparosan was not effective whereas N-sulfoheparosan was 
more effective than heparin. All doxorubicin-conjugates were able to enter the nuclei of 
U87Mg and HT-29 cells. Additionally, it was not necessary to attach doxorubicin to the 
polymers using a labile linker. Therefore, not only are GAG-based polymeric DDV 
excellent at overcoming drug resistance in cells, but they are also much more stable than 
traditional DOX-polymer conjugates which require labile linkers to function. 
Furthermore, with a natural ability to target cellular nuclei, GAG-based DDV represent a 
significant advancement over other state-of-the-art polymeric doxorubicin delivery 
vehicles. However, it is noteworthy that GAGs serve several biological roles and may 
affect multiple cellular processes when utilized as DDV. Rigorous clinical and animal 




3.2 Sulfation Patterns Determine Cellular Internalization of 
Heparin-like Polysaccharides 
Reprinted with permission from: Raman, K., Mencio, C., Desai, U. R., and Kuberan, B. 
(2013) Sulfation patterns determine cellular internalization of heparin-like polysaccharides, 
Mol. Pharm., 10, 1142-1449. Copyright 2013 American Chemical Society.  
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ABSTRACT: Heparin is a highly sulfated polysaccharide that
serves biologically relevant roles as an anticoagulant and
anticancer agent. While it is well-known that modiﬁcation of
heparin’s sulfation pattern can drastically inﬂuence its ability to
bind growth factors and other extracellular molecules, very
little is known about the cellular uptake of heparin and the role
sulfation patterns serve in aﬀecting its internalization. In this
study, we chemically synthesized several ﬂuorescently labeled
heparins consisting of a variety of sulfation patterns. These
polysaccharides were thoroughly characterized using anion
exchange chromatography and size exclusion chromatography. Subsequently, we utilized ﬂow cytometry and confocal imaging to
show that sulfation patterns diﬀerentially aﬀect the amount of heparin uptake in multiple cell types. This study provides the ﬁrst
comprehensive analysis of the eﬀect of sulfation pattern on the cellular internalization of heparin or heparan sulfate like
polysaccharides. The results of this study expand current knowledge regarding heparin internalization and provide insights into
developing more eﬀective heparin-based drug conjugates for applications in intracellular drug delivery.
KEYWORDS: heparin, cellular uptake, internalization, nucleus localization, heparan sulfate, heparosan
■ INTRODUCTION
Heparin is a complex, biocompatible, biodegradable, and water-
soluble glycosaminoglycan that is commonly found within mast
cell granules. While its biological role is unclear, heparin is
utilized clinically for its anticoagulant properties. As an agonist
of antithrombin, heparin is an eﬀective treatment against deep-
vein thrombosis and pulmonary emboli.1 Recent studies have
also shown that heparin has potent anticancer properties
including an ability to hinder cancer invasion, metastasis, and
tumor-derived angiogenesis.2−4
It is well-known that altering heparin’s sulfation pattern can
aﬀect its biochemical properties. N-Desulfation of heparin,
removal of 2-O sulfate groups from iduronic acid residues, and
removal of 6-O sulfate groups from glucosamine residues within
heparin can inhibit heparin−FGF interactions.5−7 Additionally,
N-sulfate and 3-O sulfate groups are critical to heparin’s
anticoagulant activity.8,9
Several recent publications have utilized covalently con-
jugated heparin-based drug delivery vehicles (DDV) to deliver
anticancer molecules such as paclitaxel and litocholate.10,11
Conjugation to heparin provides additional therapeutic value
because both the DDV and the drug prevent cancer
progression. However, it is still unclear how altering heparin’s
sulfation patterns can aﬀect its cellular internalization, local-
ization, and eﬃcacy as a DDV. Previously, researchers have
identiﬁed heparin scavenger receptors; however, these
receptors have not yet been isolated and their substrate
speciﬁcities remain unknown.12−14
In this article, we chemically modify heparin and heparosan, a
heparin precursor isolated from E. coli K5, to show that
modiﬁcation of heparin’s sulfation pattern leads to increased
cellular uptake, providing hints to deﬁne the ligand speciﬁcities
of heparin receptors in cells. These exciting results provide new
insight into heparin/heparan sulfate biology and the design of
more eﬀective heparin-conjugates for drug delivery.
■ MATERIALS AND METHODS
Materials. HT-29 colon cancer cells and BXPC-3 pancreatic
cancer cells were provided by Dr. Scott Kuwada (University of
Hawaii). U87-Mg glioma cells were obtained from Dr. Randy
Jensen (University of Utah). Hog mucosal heparin was
obtained from Ming Han Chemicals (Oakland, CA). K1
CHO cells were obtained from the ATCC. DEAE-Sepharose
gel was purchased from Amersham Biosciences. The analytical
grade strong anion exchange column, size exclusion column,
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and weak anion exchange column were obtained from Dionex
and Tosoh Biosciences. Disaccharide standards for strong anion
exchange were obtained from Iduron Inc. (Manchester, U.K.).
Heparitinase I, II, and III from Flavobacterium heparinum were
expressed as previously described.15 Cell culture reagents were
from Invitrogen Inc. Internalization inhibitors chlorpromazine
(CPZ), ﬁlipin (FIL), dynasore (DYN), 5-(N-ethyl-N-isoprop-
yl) amiloride (EIPA), and all other reagents and solvents were
from Sigma-Aldrich.
Synthesis of Modiﬁed Heparins (M. Heps). Brieﬂy,
heparosan (NA), N-sulfo heparosan (NS), completely
desulfated heparin (CDSHep), completely desulfated N-
resulfated heparin (CDSNS), and 2-O desulfated heparin
(2ODS) were synthesized as described in the literature.16−19
After extensive dialysis, each substrate was digested with a
cocktail of heparitinase I, II, and III and subjected to
disaccharide analysis by strong anion exchange chromatog-
raphy.20 More speciﬁcally, the substrates were prepared as
described in the following sections.
Heparosan (NA). Heparosan capsular polysaccharide was
ﬁrst isolated and puriﬁed from E.Coli K5 as previously
described in the literature.16 The resulting polysaccharide was
then further puriﬁed by dialysis against running water through a
3000 MWCO membrane for 3 days. After complete
lyophilization, the product was weighed and characterized
through anion exchange chromatography as described in the
Supporting Information.
N-Sulfated Heparosan (NS). As described in the literature,
N-sulfated heparosan was prepared by N-deacetylation of
heparosan followed by N-sulfation.17 N-deacetylation was
carried out by treating 1 g of heparosan with 2.5 M NaOH
in water at 55 °C overnight. Next, N-deacetylated heparosan
was neutralized to pH 7.0 and treated with 2.5 g each of NaCO3
and triethylamine−sulfur trioxide complex and stirred for 24 h
at 48 °C. The pH of this reaction was maintained below pH 10
by the addition of HCl. Subsequently, an additional 2.5 g each
of NaCO3 and triethylamine−sulftur trioxide complex was
added, and the reaction was stirred for an additional 24 h. The
resulting polysaccharide was dialyzed, lyophilized, and chemi-
cally characterized in a similar manner to NA.
Completely Desulfated Heparin (CDSHep). CDSHep was
prepared by utilizing published protocols.18 The pyridinium salt
of heparin was ﬁrst synthesized by passing a solution of 1 g of
heparin in water through a column packed with Amberlite
cation exchange resin. The resulting eluant was collected on ice,
adjusted to pH 9 with pyridine, stirred for 30 min, and then
concentrated in a rotary evaporator. One-hundred milligrams of
the pyridinium salt of heparin was then completely desulfated
by stirring overnight at 100 °C in a 10 mL mixture of 9:1
DMSO/methanol. The resulting polysaccharide was dialyzed,
lyophilized, and characterized as stated before.
Completely Desulfated N-Resulfated Heparin (CDSNS). To
synthesize CDSNS, CDSHep was subjected to N-sulfation as
previously described for NS preparation.
2-O Desulfated Heparin (2ODS). According to a previously
published protocol, 10 mg of heparin was mixed with 1 mg of
NaBH4 in 10 mL of 0.4 N NaOH.
19 This mixture was then
frozen in a −80 refrigerator and lyophilized to dryness. The
resulting crusty yellow solid was subsequently redissolved in
water and neutralized to pH 7 with acetic acid. This polymer
was then dialyzed for 3 days, lyophilized, and characterized as
stated before.
Fluoresceinamine Conjugation to M. Heps. First, a
stock of 100 mg of ﬂuoresceinamine (FA) was dissolved in a 1
mL mixture of 3:2:1 DMSO/acetonitrile/acetone. Additionally,
a s t o c k c o n t a i n i n g 2 2 mg o f 1 - e t h y l - 3 - ( 3 -
dimethylaminopropyl)carbodiimide (EDC) in 1 mL of water
was created. Next, 100 mg of each M. Hep substrate was
dissolved in 1 mL of water. Three-hundred microliters of the
FA stock was added to the M. Hep along with 300 μL of the
EDC stock. This mixture was stirred overnight at room
temperature and subsequently dialyzed and lyophilized.
Utilizing FA modiﬁed heparins, the molecular weight of FA−
M. Heps was analyzed by size exclusion high-performance
liquid chromatography (HPLC) as described previously.20 The
charge density of each substrate was analyzed by weak anion-
exchange HPLC as described previously.20
Cell Treatment with FA−M. Heps. Approximately 50 000
cells were trypsinized and added into wells of a 96 well plate
with DMEM containing 10% FBS and 1% penicillin/
streptomycin (P/S). After approximately 16 h, cells were
adherent, and the media was replaced with HAMS F-12
containing 10% FBS and 1% P/S. To these wells, 200 μg of
each FA−M. Hep was added, and cells were incubated for 6 h
in a humidiﬁed cell culture incubator.
Fluorescence-Assisted Cell Sorting. After treatment with
FA−M. Heps, cells were resuspended in trypsin without phenol
red. Trypsin was neutralized with HAMS F-12 media
containing 10% FBS, and cell suspensions were analyzed on a
FACScan instrument (Becton Dickenson Immunocytometry
Systems, Mountain View, CA) with computer-aid from
CellQuant software. A minimum of 5000 gated events were
captured for each sample and used for comparison purposes.
Confocal Imaging. For confocal imaging, approximately
50 000 cells were grown on glass coverslips within 35 mm cell
culture dishes with 1 mL of media. Subsequently, 200 μg of
FA−M. Hep conjugates were added, and cells were allowed to
internalize M. Heps for 16 h in a humidiﬁed incubator.
Subsequently, the media was removed, and cells were washed
twice with PBS. Five-hundred microliters of 4% paraformalde-
hyde solution was then added to the cells, and cells were
maintained for 10 min at room temperature. Next, cells were
washed twice with PBS and stained with DAPI and Rhodamine
Phalloidin for 10 min each. After incubation with cellular stains,
cells were mounted onto microscope slides and imaged with an
FV1000-XY Confocal Olympus IX81 microscope with a 60× oil
immersion lens.
■ RESULTS
The central goal of this study is to determine whether
modulation of heparin’s sulfation pattern aﬀects its cellular
internalization. To achieve this goal, a library of ﬂorescein-
amine-conjugated M. Heps was synthesized (Figure 1) and
extensively characterized via analysis of sulfation pattern, charge
density, and size (Table S1 and Figure S1, Supporting
Information). A variety of cells were incubated with each M.
Hep, and FACS was utilized to analyze the total amount of
conjugate that was internalized after 6 h (Figure 2). Next, the
cellular localization of each conjugate was assessed using
confocal microscopy in two diﬀerent cell lines, HT-29 colon
cancer cells and U87-Mg glioma cells (Figures 3 and 4). The
rate and mechanism of uptake of each conjugate was also
assessed using FACS (Figures 5 and 6).
Sulfation Pattern Aﬀects the Internalization of M.
Heps into Multiple Cell Types. To determine the eﬀects of
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sulfation pattern on internalization, experiments were con-
ducted to test the relative internalization of several M. Heps in
the following cell lines (Figure 2): bovine lung microvascular
endothelial cells (BLMVEC), chinese hamster ovary K1 cells
(CHO K1), BXPC-3 human pancreatic cancer cells, HT-29
human colorectal cancer cells, and U87-Mg human glioma cells.
All cells were incubated with ﬂuoresceinamine-conjugated M.
Heps for 6 h and subsequently subjected to analysis by FACS
(Figure 2). Relative to heparin, M. Hep substrates showed
drastically altered internalization into diﬀerent cell types. NA,
NS, and CDSNS ﬂuoresceinamine conjugates were internalized
into all cell types signiﬁcantly more than heparin. However, a
partially positively charged polymer, CDSHep, was not
internalized to the same extent as NA, NS, or CDSNS in all
the cell lines tested. Furthermore, NS, not NA, was internalized
to the greatest extent in all cell types tested; thus, these results
indicate that uptake may be receptor-mediated and that the
receptor recognizes and internalizes NS more than other M.
Heps tested.
M. Heps Are Found Throughout Cellular Bodies. To
examine the eﬀect of sulfation patterns on cellular localization,
U87-Mg and HT-29 cells were incubated with FA−M. Hep
conjugates overnight, and localization was analyzed by confocal
microscopy (Figures 3 and 4). Rhodamine Phalloidin was
utilized as a red dye to identify cellular actin, and DAPI was
utilized to label the cellular nuclei. Z-Slices were chosen so as to
minimize colocalization of the actin stain with the nuclear stain.
Confocal images indicate that NS, CDSNS, 2ODS, CDSHep,
and heparin all colocalize with cellular actin in U87-MG cells
and are found throughout cell bodies. Interestingly, NA
colocalizes with DAPI, showing that this substrate may enter
the nuclei of U87-MG cells. However, in HT-29 cells, all the M.
Heps are found in cell bodies, thus indicating that nuclear
localization may be both sulfation pattern-dependent and cell-
speciﬁc.
Sulfation Patterns Aﬀect the Rate of Internalization of
M. Heps into Cells. In addition to the extent of internal-
ization, the eﬀects of sulfation pattern on the rate of substrate
internalization into HT-29 cells was analyzed by incubating
Figure 1. Structures of modiﬁed heparins prepared in this study.
Figure 2. Sulfation patterns determine the total amount of cellular uptake of M. Heps at 6 h. The diﬀerent panels indicate M. Hep uptake in (A)
BLMVEC, (B) K1 CHO, (C) BXPC-3, (D) HT-29, and (E) U87-Mg cells. Values are normalized against heparin and show that M. Heps such as
NA, NS, and CDSNS show enhanced cell uptake relative to heparin. Internalization of M. Heps was determined by ﬂuorescence assisted cell sorting
analysis as described in the experimental section. Cellular auto ﬂuorescence at the settings used was minimal.
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equal amounts of each substrate with cells for various time
points (Figure 5). Compared to the amount of each substrate
internalized after 30 h, NA and CDSHep saturated the fastest.
NS, CDSNS, and 2ODS saturated at an intermediate rate, while
heparin saturated at a slower rate. Cellular recognition of GAG
sulfation patterns probably determines the rate of saturation.
In contrast, sulfation patterns do not determine the
concentration dependence of internalization (Figure 6). Only
CDSHep showed a signiﬁcant departure from heparin by
saturating at lower concentrations than all other polymers
tested. This is most likely due to its amine functionality, as NA
and other substrates did not show similar concentration
dependence.
■ DISCUSSION
In recent years, heparin-based conjugates have shown promise
in preclinical studies as drug delivery vehicles. One of the
reasons for their eﬃcacy is because heparin−drug conjugates
are able to attack cancer cells using multiple pathways; both the
drug and the DDV are able to mitigate tumor progression.21−24
However, the role of sulfation patterns in the cellular uptake of
heparin is largely unknown. In this article, chemically modiﬁed
heparosan from E. coli K5 and chemically modiﬁed heparin are
utilized to show that sulfation patterns determine heparin
cellular uptake into several cell types. This knowledge inspires
new designs of chemically modiﬁed heparin−drug conjugates
that are favorable for drug delivery but lack heparin’s inherent
Figure 3. Sulfation patterns determine the cellular localization of M. Heps in U87-Mg cells. Panels in this image are ﬂuorescence from Rhodamine
Phalloidin (actin), DAPI (nucleus), ﬂuoresceinamine (M. Heps), and an overlay of all ﬂuorophores. Representative substrates are (A) NA, (B) NS,
(C) CDSNS, (D) 2ODS, (E) CDSHep, and (F) Heparin. It is evident that NA polymers colocalize with DAPI in the nucleus of U87-Mg cells.
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drawbacks such as bleeding complications and heparin-induced
thrombocytopenia. Additionally, the results of this study further
provide hints to illuminate the ligand speciﬁcities of elusive
heparin scavenger receptors.
Previous studies have found that modiﬁcation of sulfation
pattern can alter the biological properties of heparin.
Controlling the amount of 2-O, 3-O, and 6-O sulfation can
drastically aﬀect heparin’s ability to bind ligands.5,8,9,25 To test
our hypothesis that sulfation patterns aﬀect cellular internal-
ization and the eﬀectiveness of heparin as a DDV, we designed
a library of heparins to represent a diverse group of polymers
with diﬀerent sulfation patterns and densities (Figure 1).
CDSHep was the only substrate determined to have free amine
groups, and hence, it had the least negative charge density.
Unaltered heparin had the highest negative charge, while other
substrates had intermediate charge density. We also speciﬁcally
designed molecules derived from heparosan that were non-
epimerized and those derived from heparin that contained high
iduronic acid content. Analysis by size exclusion chromatog-
raphy revealed that only minor diﬀerences in size and
polydispersity exist among the diﬀerent substrates (Table S1
and Figure S1, Supporting Information).
After structural characterization, a variety of cell types were
treated with M. Heps and analyzed via FACS to determine the
uptake of each M. Hep (Figure 2). The experiment was
designed to include both tumorigenic and nontumorigenic cell
types. As hypothesized, modifying the sulfation patterns of
heparin and heparosan signiﬁcantly altered cellular internal-
Figure 4. Sulfation patterns determine the cellular localization of M. Heps; however, no nuclear localization is visible for any substrate in HT-29
cells. Panels in this image are ﬂuorescence from Rhodamine Phalloidin (actin), DAPI (nucleus), ﬂuoresceinamine (M. Heps), and an overlay of all
ﬂuorophores. Representative substrates are (A) NA, (B) NS, (C) CDSNS, (D) 2ODS, (E) CDSHep, and (F) Heparin.
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ization. One would expect that CDSHep, the most positively
charged polymer, would be internalized by cells to the greatest
extent. However, NA, NS, and CDSNS accumulated inside the
cell to a much larger extent than CDSHep, 2ODS, and heparin
in all cell types tested. This indicates that sulfation pattern, not
charge density, determines cellular internalization of M. Heps.
These results also give a glimpse into the substrate speciﬁcities
of elusive heparin uptake receptors.12−14 While researchers
have not yet isolated these receptors, it is clear that sulfation
pattern greatly aﬀects cellular uptake of heparin and that these
receptors prefer N-sulfo heparosan to any of the other M. Heps
tested. Further evidence that heparin uptake may be receptor
driven is determined by the concentration dependence of the
internalization of M. Heps (Figure 6). If internalization was a
purely diﬀusion-driven process, then the concentration depend-
ence of internalization would be linear with concentration.
However, it is evident that incubating cells with ﬁve times and
ten times more substrate does not lead to a linear dose-
dependent increase in internalization.
Next, the cellular localization of M. Heps was sought after to
determine the eﬀects of sulfation pattern on subcellular
targeting. Previously, it was found that glycosaminoglycans
(GAGs) and proteoglycans (PGs) such as syndecan-1 and
glypican-1 can enter the nucleus.26−30 Additionally, antiproli-
ferative GAGs primed by xylosides can enter cellular nuclei and
modulate histone 3 acetylation and cellular growth.31 Heparin-
poly-β-amino ester complexes have also been found to
Figure 5. Sulfation patterns determine rate of entry of M. Heps into HT-29 colon cancer cells. Values are normalized to the 30 h time points for each
substrate. Representative panels indicate the time-dependent internalization of (A) NA, (B) NS, (C) CDSNS, (D) 2ODS, (E) CDSHep, and (F)
Heparin.
Figure 6. Sulfation pattern has little eﬀect on the concentration
dependence of internalization. Representative bars indicate the relative
ﬂuorescence measured by FACS when 20 μg (black), 100 μg (gray), or
200 μg (white) of M. Heps were incubated with cells for 24 h. Values
are normalized to the total substrate internalized after 24 h when 200
μg of the respective substrate are added.
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modulate nuclear transcription factors.32 However, researchers
have not yet identiﬁed if sulfation patterns aﬀect the nuclear
entry of these PGs and GAGs. Therefore, we examined the
cellular localization of M. Heps tagged with ﬂuoresceinamine by
utilizing confocal microscopy (Figures 3 and 4). The majority
of M. Heps were found throughout cell bodies and excluded
from the nucleus in both HT-29 and U87-Mg cells. However,
in U87-Mg, NA was found to colocalize with DAPI. On the
basis of these results, it may be possible to deduce that sulfation
patterns can aﬀect the nuclear entry of GAGs. It is unlikely that
charge density was responsible for nuclear entry, as CDSHep
did not enter the nuclei. Additionally, none of the epimerized
substrates were visible in the nucleus suggesting that chain
ﬂexibility may aﬀect nuclear entry as well. However, additional
biochemical proof will be necessary to further understand the
diﬀerential localization of heparin and heparin-like polymers.
In conclusion, this research presents the ﬁrst comprehensive
evidence that sulfation pattern, not charge density, determines
heparin/heparan sulfate cellular uptake into several cell types.
While the M. Heps are found throughout cells, nuclear
localization of these GAGs may be both sulfation pattern and
cell-type dependent. The results of this study have broad
implications in cell biology, heparan sulfate biochemistry, and
drug delivery vehicle design. However, several new questions
now surface: Why do NS and NA polymers enter cells to a
greater extent than heparin? Do NA or NA/NS domains of
heparan sulfate promote cellular uptake and nuclear localization
of syndecans and glypicans? Additionally, would developing
NA-, NS-, or CDSNS-based DDV yield better tumor-targeting
capability than heparin-based DDV? In-depth analysis of
nuclear localization and in vivo drug targeting is necessary to
answer these intriguing questions.
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Supplementary Information 
 
Analysis of substrate sulfation density was carried out utilizing weak anion exchange 
chromatography (Table S1). Substrates that elute earlier have less charge (fewer sulfate 
groups) than those that bind more strongly and elute later. Thus, with regard to sulfation 
density, heparin migrated the slowest on the weak anion exchange column – indicating 
that it was the most highly sulfated GAG. On the other hand, complete desulfation of 
heparin using solvolysis drastically lowered its retention time. In order of sulfation 
density (as determined by the peak retention time at max height), the substrate order is: 












Table S1. M. Hep retention times as determined by weak anion exchange 
chromatography.  
 
To analyze the sulfation patterns of the M. Heps, all substrates were digested with 
heparitinase I, II, and III to yield disaccharide units. These disaccharides were assessed 
using strong anion exchange chromatography and compared to known disaccharide 
standards. Heparin predominantly contains ǻIdoA2S-GlcNS6S disaccharides as reported 
previously.[1, 2] Other abundant disaccharide fragments include ǻUA-GlcNS6S and 
ǻUA-GlcNS. As expected, 2-O desulfation under alkaline conditions completely 
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Similarly, complete desulfation yielded a polymer containing only ǻUA-GlcNH2 residues 
(CDSHep). N-resulfation of this substrate yielded a polymer containing ǻUA-GlcNS 
residues (CDSNS). NS is structurally similar to CDSNS, except that it lacks iduronic acid 
residues (epimerization). Additionally, CDSHep includes N-amine groups instead of N-
Acyl groups and is more positively charged than NA.    
 
To further characterize the molecules, size exclusion chromatography was utilized to 
probe the molecular weight and polydispersity of the various substrates (Fig. S1). 
Molecular weight analysis revealed that the NA and NS that we produced are slightly 
larger polymers than Heparin and CDSHep. Alkaline treatment of HS chains (2ODS) and 
complete desulfation/N-resulfation (CDSNS) yielded smaller polymers than native 
heparin. Only minor differences in polydispersity were observed among the library of 






 - SI 3 - 
 
Figure S1. Size exclusion chromatography traces of the M. Heps. Substrates that elute 
earlier are larger in size. Representative traces are: A) NA, B) NS, C) CDSNS, D) 2ODS, 
E) CDSHep, F) Heparin.  
 
After internalization experiments, we pursued the mechanism of internalization of NS 
and Heparin into BLMVEC to determine why NS entered cells to a far greater extent than 
any other substrate (Fig. S2). Previous research has suggested that heparin may enter 
through receptor mediated internalization using scavenger receptors, but researchers have 
not determined the internalization mechanisms of NS.[3-5] A series of inhibitors were 
utilized to determine the mechanism of internalization of NS into BLMVEC. While 
neither Filipin nor Chlorpromazine had an effect on the uptake of NS, sucrose-, EIPA-, 
and dynasore- treatment all significantly reduced BLMVEC uptake of NS. It is likely that 
NS utilizes multiple pathways to enter cells including receptor-mediated endocytosis, 





















Figure S2. NS enters BLMVEC through dynamin, macropinocytosis, and receptor 
mediated endocytosis. BLMVEC were treated with inhbitors including chlorpromazine 
(CPZ, a clatherin-mediated endocytosis inhibitor), Filipin (Fil, a caveolin-mediated 
endocytosis inhibitor), dynasore (Dyn, a dynamin-mediated internalization inhibitor), 5-
(N-Ethyl-N-isopropyl) amiloride (EIPA, a macropinocytosis inhibitor), and sucrose (a 
broad-spectrum receptor-mediated internalization inhibitor). Initially a range of 
concentrations of each inhibitor were tested. This data represents the maximal inhibition 
of NS internalization without significant cell death.  
 
To further analyze the mechanism of internalization, a combinatorial treatment with 
multiple inhibitors was utilized to test if NS uptake could be reduced further (Fig. S3). It 
was found that combinatorial treatments with multiple inhibitors further reduced uptake 
of NS and heparin. However, higher dosages of the inhibitors led to significant reduction 
in cell viability. This reduction in cell viability was expected because Heparan sulfates, 
analogues of heparin and NS, are rapidly turned over in cells and play integral roles in 
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heparin internalization may also interfere with heparan sulfate recycling and thus enhance 
cell death.  
   
 
Figure S3. Treatment of NS and heparin with a multiple concentrations of a mixture of 
inhibitors reveals that NS and heparin enter cells by utilizing dynamin, receptor mediated 
endocytosis, and macropinocytosis. The concentrations of inhibitors tested included: 0.02 
M sucrose with 8 uM dynasore and 20 uM EIPA (inhib 1), 0.04 M sucrose with 16 uM 
dynasore and 40 uM EIPA (inhib 2), 0.06 M sucrose with 24 uM dynasore and 60 uM 
EIPA (inhib 3), and 0.08 M sucrose with 32 uM dynasore and 80 uM EIPA (inhib 4). 
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3.2.1 Additional Analysis 
 
Internalization of variably sulfated polymers is shown in Figure 3.6. It is 
noteworthy that cell association was distinguished from cell internalization by washing 
cells thoroughly with PBS prior to fixation. Additionally, for FACS studies, the use of 
trypsin to degrade cell surface proteins and untether cells from the surface also decreases 
association of polymers with cell surface.  
 
3.3 A Potent Heparin-Based Doxorubicin Conjugate 
Overcomes Drug Resistant Cancer Cells 
3.3.1 Introduction  
 
Proteoglycans, composed of a protein core decorated with several 
glycosaminoglycan side chains, are critical components of the extracellular matrix and 
play a variety of roles during cancer progression.1-3 Heparin, the most highly sulfated 
natural glycosaminoglycan, is primarily used as a clinical anticoagulant but also has 
potent anticancer activity, including an ability to inhibit tumor invasion, metastasis, and 
angiogenesis.4, 5 Furthermore, Heparin contains several carboxyl and amine functional 
groups that are amenable for conjugating drugs or other molecular cargo. Due to these 
favorable properties, several researchers have designed heparin-based drug conjugates for 
use as drug delivery vehicles for cancer.  
Nanoparticles composed of heparin-drug conjugates are particularly effective in 
vivo against tumors. Recently it was found that heparin-all-trans-retinoic acid 
nanoparticles (LHR) loaded with paclitaxel effectively reduced the size of breast cancer 





Figure 3.6. Internalization of variably sulfated polymers into different cell types. 
Cells utilized were: A) BLMVEC, B) K1 CHO, C) BXPC-3, D) HT-29, and E) U87 Mg. 
Relative fluorescence denotes the amount of fluorescence (and therefore substrate) 
detected within cells by FACS. ** indicates P<0.05 as determined by a 1-tailed paired t-




properties.6 Heparin-folic acid-paclitaxel nanoparticles loaded with additional paclitaxel 
(HFT-T) were also found to effectively treat folic acid-positive neck cancers in tumor 
bearing mice.7 Direct conjugates of heparin and drugs such as paclitaxel and litocholate 
have also been developed.8, 9   
It is well known that changing the sulfation patterns of heparin or heparan sulfate 
can have dramatic effects on their ability to bind to the FGF-1, FGF-2 and FGF-4.10, 11 
Additionally, a particular pentasaccharide sequence consisting of a 3-O sulfate group, an 
N-sulfate group, and a 6-O sulfate group is responsible for heparin’s potent anticoagulant 
activity.12 However, researchers are yet to determine the effects of sulfation pattern on 
heparin’s potency as a drug delivery vehicle.  
Recently, we have shown that sulfation patterns determine the uptake of heparin 
and heparin-like polysaccharides into various cell types including HT-29 colon cancer 
cells, K1 CHO cells, bovine lung microvascular endothelial cells, and U87 Mg brain 
cancer cells.13 This work also demonstrated that heparosan (NA) and N-sulfo heparosan 
(NS) can be internalized into cells through a receptor-mediated mechanism at a higher 
rate and to a greater extent than heparin.  In some cell lines, NA was found to colocalize 
specifically within the nucleus, similar to a recent discovery that hyaluronic acid-drug 
conjugates can enter cellular nuclei.14 Therefore, we hypothesized that generating drug 
conjugates of these heparin-like polysaccharides would yield superior anticancer effects 
to heparin-based conjugates.  
To test this hypothesis, we developed doxorubicin conjugates of NA, NS, and 
heparin and tested their efficacy against drug-resistant and drug-sensitive cell lines. We 




mechanism of action of their enhanced anticancer activity.  Taken together, this study 
provides new insights into the design of a glycosaminoglycan-based drug delivery 
vehicle and suggests that conjugates of heparin-like polysaccharides and 
chemotherapeutics have great potential in overcoming drug-resistant tumors.  
 
3.3.2 Materials and Methods  
 
HT-29 human colon cancer cells were provided by Dr. Scott Kuwada (University 
of Hawaii). Hog mucosal heparin was obtained from Ming Han Chemicals (Oakland, 
CA). DEAE-Sepharose gel was purchased from Amersham Biosciences. The analytical 
grade strong anion exchange column and size exclusion column were obtained from 
Dionex, and Tosoh Biosciences, respectively. Disaccharide standards for strong anion 
exchange were obtained from Iduron Inc (Manchester, UK). Heparitinase I, II and III 
from flavobacterium heparinum were expressed as previously described.15 Cell culture 
reagents were from Invitrogen Inc. The cell titer blue cell viability assay kit was from 
Promega Inc. The Caspase-3 activity assay kit was obtained from Roche Applied Science 
Inc. All other reagents and solvents including doxorubicin hydrochloride were from 
Sigma-Aldrich. 
To synthesize the DOX conjugates of NA, NS, and heparin, an EDC/Sulfo-NHS 
conjugation procedure was utilized. First, 10 mg of polysaccharide was incubated in 2 
mls of pH 8.5 HEPES buffer. Next, 3 equivalents of N-Ethyl-N′-(3-
dimethylaminopropyl)carbodiimide hydrochloride were added to the reaction along with 
2 equivalents of N-Hydroxysulfosuccinimide sodium salt and stirred for 2 hours at room 
temperature. Then, 1.2 equivalents of doxorubicin hydrochloride were added to the 




loaded onto a DEAE Sepharose column (0.5 ml) preequilibriated with 10 column 
volumes of wash buffer (20 mM NaOAc buffer (pH 6.0), 0.1 M NaCl, 0.01% Triton X-
100).  The column was then washed with 30 column volumes of wash buffer.  Bound 
conjugates were then eluted with 6 column volumes of elution buffer (20 mM NaOAc,1 
M NaCl, pH 6.0). Finally, polymer conjugates were dialyzed through a 1000 MWCO 
filter membrane and lyophilized to dryness.  
Polysaccharide conjugates were analyzed by strong anion exchange 
chromatography to confirm polysaccharide purity as previously described.16 Size 
exclusion chromatography was utilized to analyze conjugate molecular weight and to 
assess the amount of free drug as previously described.16 Dynamic light scattering 
(Malvern Inc.) was utilized to analyze conjugate hydrodynamic radius.  
Polymer-drug conjugate concentration in stock solutions was analyzed using a 
carbazole assay for uronic acid content, as previously described.17 Briefly, various 
standards of heparosan polymer were prepared and 50 µl of each standard concentration 
was loaded into wells of a 96 well plate in triplicate. Polymer-conjugates were also 
loaded into wells of the 96 well plate in duplicate. Next, 200 µl of sodium tetraborate 
solution (25 mM sodium tetraborate in concentrated H2SO4) was added to each well 
containing sample and heated in boiling water for 10 minutes. Next, plates were cooled 
and 50 µl of carbazole solution (0.125% carbazole in ethanol) was added to each well. 
Plates were heated in boiling water once again for 10 minutes, cooled, and the absorbance 
of solutions was read at 520 nm. Drug loading on the polymers was analyzed through 
fluorescent spectroscopy by comparing known quantities of the polymer-conjugate 




excitation/emission at 470 nm/600 nm. 
Cell viability upon drug or conjugate treatment was assessed using a Cell Titer 
Blue viability assay kit according to the manufacturer’s protocol. Briefly, 25,000 cells 
were added into wells of a 96 well plate in 200 µl of HAMS F-12 media. After cells 
attached, the media was replaced with fresh HAMS F-12 media and appropriate amounts 
of each drug or drug conjugate were added into each well. Cells were grown for 3 days in 
a humidified incubator and subsequently the media was replaced with 125 µl of fresh 
HAMS F-12 media in addition to 50 µl of cell titer blue reagent. After 3 hours of 
incubation in a cell culture incubator, 25 µl of 3% SDS was added into each well to stop 
cellular metabolic activity and plates were read in a fluorescent spectrometer with 
excitation/emission 560 nm/590 nm.  
Caspase-3 activity upon treatment with DOX conjugates was analyzed using a 
caspase-3 activity assay according to the manufacturer’s protocol. First, a monolayer of 
HT-29 cells was grown in 96 well plates. On the next day, media from the wells was 
replaced with 100 µl of HAMS F-12 and 10 µM of DOX or equivalent DOX 
concentrations were added and left overnight in a cell culture incubator. Subsequently, 
after 16 hours, nonsterile 96 well plates were coated with Anti-Caspase 3 antibody in 
coating buffer for 1 hour at 37̊ C. Then cells were lysed in 100 µl of lysis buffer (DTT 
solution) for 1 minute on ice within the cell culture plate. The lysate was added onto the 
anticaspase plate and left at 37 for 1 hour. After washing, the caspase substrate was added 
and incubated for 3 hours at 37̊ C. Subsequently, upon conversion of the caspase 
substrate to a fluorescent substrate, the plate fluorescence was measured at 




For confocal imaging, approximately 50,000 cells were grown on glass coverslips 
within 35 mm cell culture dishes with 1 ml media. Subsequently, drug conjugates with 1 
µM of equivalent drug concentration were added into each well, respectively, and cells 
were allowed to internalize the conjugates for 16 hours in a humidified incubator. Next, 
the media was removed and cells were washed twice with PBS. Cells were then fixed 
with 500 µl of 4% paraformaldehyde solution for 10 minutes at room temperature. Next, 
cells were washed twice with PBS and stained with DAPI for 10 minutes. After 
incubation with the nuclear stain, cells were mounted onto microscope slides and imaged 





The central goal of this study is to determine whether the sulfation patterns of 
heparin and heparin-like polysaccharides affect their ability to deliver anticancer drugs to 
drug resistant tumors. To accomplish this goal, NA-DOX, NS-DOX, and HEP-DOX 
conjugates were chemically synthesized and characterized (Figure 3.7). Subsequently, the 
in vitro anticancer activities were tested with both DOX-sensitive HT-29 colon cancer 
cells and DOX-resistant A2780 AD ovarian carcinoma cells using a cell viability assay 
(Figure 3.8). Confocal microscopy was utilized to evaluate the cellular localization of the 
conjugates in multiple cell types including HT-29 cells, U87 Mg human glioma cells, and 
A2780 AD cells (Figure 3.9). Additionally, to assess the mechanistic details of how DOX 
and DOX-conjugates affected cell viability, the effects of the free drug and the conjugates 










Figure 3.8. Evaluation of DOX conjugate anticancer efficacy against. A) DOX-
sensitive HT-29 human colon cells, n = 3. B) DOX-resistant A2780 AD human ovarian 
carcinoma cells, n = 4. Percentages are calculated relative to control, untreated cells. ** 
indicates P<0.05 as determined by a 1 tailed paired t-test vs. control cells. Error bars 






Figure 3.9.  Localization of free DOX and DOX-conjugates in U87 Mg human 
glioma cells. Representative panes are A) DOX treated cells, B) NA-DOX treated cells, 






Figure 3.10. Caspase-3 activation upon treatment with DOX or DOX conjugates 
determined using FIENA. Fluorescence in the FIENA indicates caspase activity upon 
treatment. Relative percentages are based on control, untreated cells. ** indicates P<0.05 
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To evaluate the in vitro anticancer activity of DOX conjugates of NA and NS vs. 
heparin-DOX, a cell viability assay was utilized (Figure 3.8). HT-29 colon cancer cells 
were incubated with each conjugate and with the free drug for 3 days in duplicate wells. 
It was found that, compared to heparin-DOX, both NA-DOX and NS-DOX conjugates 
had significantly more antitumor activity. Interestingly, in triplicate experiments, it was 
found that the anticancer activity of both the heparosan conjugates was comparable to the 
free drug. When DOX-resistant A2780 cells were treated with each conjugate, it was 
observed that free DOX and NA-DOX were not effective against these cells even at high 
concentrations. HEP-DOX was partially effective against the DOX-resistant cells, while 
NS-DOX was the most effective anticancer agent and overcame cellular drug resistance.  
Next, to evaluate the cellular localization of the doxorubicin conjugates, confocal 
microscopy was utilized to assess the differences in cellular internalization of DOX alone 
and DOX conjugates in three different cell lines (Figure 3.9, and see supplement). Images 
were taken with identical exposure settings so that differences in signal intensity could 
also be observed. After incubation with appropriate substrates for 1 day, it was found that 
the free drug and all the conjugates were found throughout cells in vesicles. Free DOX 
and DOX conjugates were also found in the nucleus in HT-29 and U87 Mg cells. 
Heparin-DOX clearly had lower signal intensity compared to DOX alone or NA-DOX 
conjugates. Additionally, when incubated with A2780 AD cells, all the polymers were 
internalized to a lesser extent compared to DOX-sensitive cells. 
 To discern the molecular mechanism of drug action, HT-29 cells were incubated 
with 10 µM DOX or conjugates containing 10 µM equivalent DOX concentrations and 




(FIENA). It was found that upon treatment, the free drug elicited a three-fold increase in 
Caspase-3-driven apoptosis activity. Similarly, both the NA-DOX and the NS-DOX 
conjugates increased caspase-3 apoptosis activity dramatically while HEP-DOX did not 




For over a decade it has been known that targeted drug delivery to cancers using 
polymeric carriers overcomes drug resistance, improves therapeutic efficacy, and 
minimizes drug side effects. More recently, there has been increasing interest in 
developing novel polymeric scaffolds that are biocompatible, biodegradable, and highly 
hydrophilic. Heparin, a highly sulfated, natural, anticoagulant glycosaminoglycan, meets 
these criteria and also intrinsically serves as an excellent anticancer polymer because of 
its ability to inhibit tumor associated angiogenesis, metastasis, and invasion.1, 4, 5 Due to 
its unique properties, and the ease with which it can be modified, several heparin-based 
drug delivery vehicles have been developed.6-9 However, researchers have not yet 
investigated the putative correlation between heparin’s sulfation pattern and its efficacy 
as a drug delivery vehicle. From our previous studies, we have discovered that 
modification of heparin’s sulfation pattern can dramatically affect its internalization into 
a variety of cell types as well as its nuclear localization.13 In particular, NA and NS are 
internalized almost 10- fold more than heparin. In this article, we developed doxorubicin 
conjugates of NA and NS in order to quantify drug delivery efficacy as a function of 
sulfation pattern. 
Doxorubicin conjugates were synthesized using EDC-NHS chemistry (Figure 3.7) 




supplement). Disaccharide analysis using strong anion exchange chromatography 
confirmed that NA contained only ΔUA-GlcNAc disaccharides while NS contained 
ΔUA-GlcNS disaccharides and HEP contained a mixture of disaccharides with the 
majority being ΔUA2S-GlcNS6S, as previously described in literature (see supplement 
).16, 18, 19 Dynamic light scattering experiments revealed that extremely dilute solutions of 
the conjugates contained particles that were ~3 nm in size while more concentrated 
solutions consisted of polydisperse particles that were ~200 nm in size (see supplement ). 
It can be argued that these particle sizes are incorrect because they are too large for such 
small polymers. However, aggregation of heparin in solution into tightly bound self-
assembled particles has been described previously.20, 21 Self-aggregation makes it difficult 
to determine the hydrodynamic radius of each individual polymer. Additionally, 
aggregates may trap free drug and confound the relationship between molecular weight 
and particle size. It is still unknown how heparin-like GAGs form molecular aggregates. 
As micromolar concentrations of heparin and the other polymers were utilized in viability 
assays, it can be assumed that all the conjugates were being utilized in the self-assembled 
state. 
To test the efficacy of the doxorubicin conjugates, a cell viability assay was 
performed (Figure 3.8). Against DOX-sensitive HT-29 cells, it was found that DOX, NA-
DOX and NS-DOX were all more effective than HEP-DOX. However, against DOX-
resistant A2780 cells, the order of effectiveness followed the pattern: DOX < NA-DOX < 
HEP-DOX < NS-DOX. However, to determine a more precise IC50 of these conjugates, 
experiments utilizing a set of serial dilutions may be necessary.  




therefore, it is likely that particle size was not a determinant in the effectiveness of the 
polymers. With regard to charge density, NA-DOX has the lowest charge density while 
HEP-DOX has the highest charge density (as determined by the number of sulfate groups 
per chain). However, as NS-DOX was the most effective polymer against both DOX-
sensitive and DOX-resistant cells, charge density did not determine the effectiveness of 
the polymers. Therefore, it can be concluded that the sulfation pattern of NS uniquely 
affected its effectiveness as a drug delivery vehicle, and this suggests that NS-DOX is 
recognized by cells differently compared to NA-DOX and HEP-DOX. While the 
mechanism of NS-DOX uptake was not specifically tested, previous studies with NA-
Fluorescein and NS-Fluorescein polymers indicate that uptake occurs through several 
mechanisms including macropinotytosis, dynamin-mediated endocytosis, and receptor-
mediated endocytosis.  
Next, the cellular localization of all the conjugates was visualized using confocal 
microscopy to further understand why NS-DOX was the most effective vehicle (Figure 
3.9 and see supplement). It was found that like free DOX, all the conjugates co-localized 
with DAPI, a nuclear stain. However, subtle differences were observed among the 
different treatments. In DOX-sensitive cells, HEP-DOX had the lowest fluorescent 
intensity in the nucleus (and it was the least effective treatment against DOX-sensitive 
cells). DOX and NA-DOX brightly stained the nucleus as well as other components of 
the cell body. NS-DOX was the only conjugate to brightly label the nucleus specifically. 
In DOX-resistant cells, no noticeable differences were observed between any of the 
treatment samples (see supplement). Previous studies corroborate our results that heparin-




Syndecan-1, consisting of protein cores and several heparin-like glycosaminoglycan side 
chains, enter cellular nuclei and modulate transcription.22-24 Heparan sulfate, a sulfated 
glycosaminoglycan present on cell surfaces and in the extra cellular matrix, has also been 
found within the nuclei of hepatocytes.25 Heparin-Poly(beta-amino ester) conjugates were 
also found to enter cellular nuclei and modulate cell death.26  
Additionally, the mechanism of action of the conjugates was investigated to 
understand the differential cytotoxicity of the DOX-conjugates (Figure 3.10). Caspase-3 
activation is commonly linked to the induction of cellular apoptosis through a variety of 
pathways that degrade DNA and prevent DNA repair as is the case with DOX.27 Using a 
fluorescent immunosorbent enzyme caspase-3 activity assay, it was determined that NA-
DOX and NS-DOX conjugates were significantly more effective than HEP-DOX at 
enhancing Caspase-3 activity. After 16 hours of treatment, HEP-DOX only slightly 
increased cellular apoptotic activity while free DOX, NA-DOX, and NS-DOX drastically 
increased caspase-3 activity in DOX-sensitive cells. It is interesting to note that these 
polymers were all effective even though the doxorubicin-polymer linkage was 
synthesized via a nonlabile amide bond. Recently, conjugates of doxorubicin and 
hyaluronic acid, a similar glycosaminoglycan, have been shown to affect cancer cells 
without the need for a labile linker.14 It is thus likely that heparin-based DOX conjugates 
may function through similar mechanisms as hyaluronic acid-DOX conjugates.  
This study presents the first biochemical evidence that glycosaminoglycan sulfation 
patterns determine their efficacy as drug delivery vehicles. Heparin-like polysaccharides 
discussed in this article demonstrate differential internalization, cytotoxicity, cellular 




not necessary for drug efficacy, these conjugates are easier to produce and more scalable 
than traditional hydrazone conjugates of DOX. Therefore, heparin-based drug delivery 
vehicles offer a promising approach to treat drug-resistant cancers. Future efforts will 
focus on assessing the therapeutic utility of these polymer-DOX conjugates in vivo 
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3.3.6 Supplementary Information  
 
Polysaccharide conjugates were analyzed by utilizing size exclusion 
chromatography and measuring absorbance at 480 nm. Results revealed that no free drug 
was present in the conjugates. All the conjugates were also of similar sizes. NA-DOX and 
NS-DOX were found to be slightly larger than HEP-DOX (Figure 3.S1). However, it is 
unlikely that these minor size differences affect biological activity as it has previously 
been determined that large differences in molecular weight are required for changes in 
pharmacokinetic and pharmacodynamic properties of biodegradable polymers.1 
Samples were also analyzed by utilizing strong anion exchange chromatography 
to determine the disaccharide composition of each polymer (Figure 3.S2). 
Polysaccharides were first digested with heparitinase I, II, and III and then analyzed on a 
linear 1 M NaCl gradient from 0-100% over 50 minutes, as previously described.2 
Elution time is dependent on the charge density of disaccharides. Heparin, as expected, 
had the highest charge density while NS has a median charge density, and NA had the 
lowest density.  
A Malvern Zetasizer dynamic light scattering instrument was utilized to analyze 
the hydrodynamic radius of the DOX conjugates of heparin and heparin-like 
polysaccharides. As reported in literature, heparin self assembles when utilized in 
concentrated samples (Table 3.S1, Figure 3.S3) whereas dilute samples reveal a much 
lower hydrodynamic radius (Table 3.S2).3, 4 Samples show a large polydispersity due to 
the inherent heterogeneity in heparin.  
Drug loading on the polysaccharides was analyzed by utilizing a fluorescence 





Figure 3.S1. Size exclusion chromatographs of DOX conjugates determined by 
measuring absorbance at 480 nm. Representative traces are: NA( ), NS ( ), 






Figure 3.S2. Disaccharide composition of polysaccharides determined by measuring 
absorbance at 232 nm. Representative panels are: A) NA B) NS and C) HEP. NA 
contains only ΔUA-GlcNAc disaccharides (1), while NS contains ΔUA-GlcNS  
disaccharides (2). Heparin contains a complex sulfation pattern with the majority of 
disaccharides being ΔUA2S-GlcNS6S (5). Additional disaccharides include ΔUA-GlcNS 






Figure 3.S3. DLS results with 5 µM samples of NA-DOX, NS-DOX, and HEP-DOX. 
Scattering intensity correlates with the size of the particles in the samples. Higher 







Figure 3.S4. Localization of free DOX and DOX-conjugates in HT-29 colon cancer 
cells. Representative panels are A) DOX treated cells, B) NA-DOX treated cells, C) NS-
DOX treated cells, and D) HEP-DOX treated cells. BF represents bright field images of 






Figure 3.S5. Localization of free DOX and DOX-conjugates in A2780AD DOX-
resistant ovarian carcinoma cells. Representative panels are A) DOX treated cells, B) 
NA-DOX treated cells, C) NS-DOX treated cells, and D) HEP-DOX treated cells. Scale 











































conjugates as described in the methods section. The weight percent of DOX (Table 3.S3) 
was calculated using the formula: 
 
Based on the weight percentages identified, approximately 1 molecule of DOX is 
attached per polymer chain. An alternative means of measuring DOX concentration may 
be to use acid hydrolysis of DOX and detect the aglycon.5  
To determine the cellular localization of DOX-conjugates, confocal microscopy 
was utilized (as described in the methods section). In addition to determining the cellular 
localization of polymers in U87 Mg glioma cells, HT-29 colon cancer cells and A2780 





Table 3.S3. Drug loading on DOX conjugates.  
Substrate DOX wt%  # of DOX per polymer chain 
NA-DOX 1.54 ~1 
NS-DOX 1.63 ~1 
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IN VITRO AND IN VIVO EVALUATION OF A COMBINATION  
 
THERAPY USING CLICK-XYLOSIDE AND  
 





Proteoglycans (PG) are composed of core proteins attached to multiple 
glycosaminoglycan (GAG) side chains. Located on the cell surface and within the 
extracellular matrix, PGs are critical components of multiple pathophysiological 
functions because of their ability to bind growth factors, chemokines, and lectins.1-3 PG 
side chains include heparan sulfate, chondroitin sulfate, dermatan sulfate, and keratan 
sulfate. It is well known that the sulfation patterns of GAGs are necessary for their 
function in a variety of pathophysiological processes.4, 5 As an example, heparin is a 
GAG that binds antithrombin and elicits anticoagulant activity in the body; however, its 
activity requires the presence of a pentasaccharide sequence composed of N-sulfated 
glucosamine, 6-O sulfated glucosamine, and 3-O sulfated glucosamine residues in close 
proximity.6, 7 
 Previously we have demonstrated that sulfation patterns determine the cellular 
internalization and nuclear localization of multiple heparan sulfate GAGs in a variety of 
cancer cells.8 Relative to heparin, N-acetyl heparosan (NA) and N-sulfo heparosan (NS) 




developed doxorubicin conjugates of NA, NS, and heparin as shown in the previous 
chapter. In vitro data suggest that both NA and NS are more effective at delivering 
doxorubicin to the nucleus of cancer cells than heparin. Doxorubicin activity is preserved 
even when the drug is attached covalently via an amide linkage. It is likely that NA and 
NS doxorubicin conjugates will be more chemically stabile during long term storage 
compared to traditional doxorubicin conjugates such as those that utilize hydrazo- 
linkages to attach DOX to the vehicle.9, 10   
Previously, we have also demonstrated that xylosides, small molecules consisting 
of a xylose residue attached to an aglycone, have the ability to inhibit tumor progression. 
When cells are treated with xylosides, these small molecules enter cellular golgi and 
prime GAG chains.11-13 Without cellular anchors, the primed GAGs are released into the 
surrounding ECM and are able to compete with endogenous PGs. In our studies we have 
found that click-xylosides can reduce tumor invasion and 4-fluoro-xylosides mitigate 
tumor-associated angiogenesis. Researchers have also found that 2(6-hydroxynaphthyl)-
beta-D-xylopyranoside significantly reduces tumor growth in vivo.14 Additionally, it has 
been reported that β-D-xyloside inhibits the invasive capability of HeLa cells in culture 
medium containing SDF-1/CXCL12.15 Xylosides may effectively reduce tumor invasion 
and angiogenesis when used as part of a combinatorial therapy regime with a 
chemotherapeutic agent. 
To deliver chemotherapeutics, several GAG-based drug vehicles have been 
developed previously.16-18 However, the majority of these vehicles have been unable to 
cross the blood brain barrier (BBB) to deliver their drug cargo to gliomas. In order to 




ability of the vehicle to partition across the blood brain barrier and release its cargo. 
Methods for increasing BBB penetration include increasing the hydrophobicity of the 
carrier, enhancing BBB permeability transiently, modification of carriers with brain 
targeting macromolecules or peptides, and inhibition of brain efflux pumps.19-21 
Enhancement of temporary BBB transcytosis is typically achieved by utilizing hypertonic 
mannitol infusions or bradykinin to contract brain capillary endothelial cells and increase 
intercellular space.22, 23 Additionally, a variety of macromolecules may also increase BBB 
penetration including holo-transferrin, aprotinin, and angiopep, which utilize receptor-
mediated endocytosis to enter the brain parenchyma.24, 25 To reduce brain efflux of drugs, 
PG-1 and BCRP inhibitors such as elacridar have been successfully utilized in previous 
studies.26, 27 
In this study, we develop heparosan-doxorubicin-aprotinin (HDA) conjugates and 
test their effectiveness at reducing tumor growth in vitro and in vivo in flanks and in the 
brain. HDA conjugates are analyzed for their ability to enter cellular nuclei and to reduce 
cellular viability. In conjunction with HDA conjugates, click-xyloside is utilized to 
reduce tumor invasion, and the combination therapy with HDA and xyloside is tested for 
its efficacy in vivo against intracranial and flank tumors. In vivo the biodistribution of 
HDA conjugates is also assessed and an infusion of both bradykinin and elacridar is 
evaluated for its ability to enhance the efficacy of the combination therapy in the brain. 
This study demonstrates that both xylosides and HDA conjugates are effective anticancer 






4.2 Materials and Methods 
 
Heparosan from E. Coli K5 and Heparitinase I, II and III from flavobacterium 
heparinum were expressed and purified as previously described.28 Bovine lung aprotinin 
for synthesis of conjugate was acquired from Sigma Aldrich. HT-29 colon cancer cells 
were a kind gift from Dr. Scott Kuwada (University of Hawaii). The analytical grade 
strong anion exchange column and size exclusion column were acquired from Dionex 
and Tosoh Biosciences, respectively. HPMA standards for size exclusion 
chromatography were acquired from Dr. Jindrich Kopecek (University of Utah). 
Disaccharide standards for strong anion exchange were obtained from Iduron Inc 
(Manchester, UK). The transwell invasion assay kit and matrigel for animal experiments 
were acquired from BD Biosciences. The cell titer blue viability assay kit was acquired 
from Fisher Scientific. Doxorubicin was acquired from Aksci Inc. All other materials 
were acquired from Sigma Aldrich.  
Ten mg of Heparosan was dissolved in 600 µl of water and stirred at 150 rpm at 
room temperature. Next, 1.5 equivalents of 1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride (EDC) per disaccharide and 1.5 
equivalents of N-Hydroxysulfosuccinimide sodium salt (Sulfo-NHS) per disaccharide 
were added after dissolving in a total of 400 µl of EDC coupling buffer (10 mM HEPES 
buffer, pH 8.5). The mixture was then stirred for 2 hours prior to addition of 1 equivalent 
of doxorubicin-hydrochloride per disaccharide dissolved in 300 µl of 200 proof ethanol. 
This reaction was capped and stirred overnight at room temperature. After 20 hours, the 
mixture was centrifuged at 4000 rpm for 10 minutes. It was then filtered through a 3000 




Subsequently, the polymer-doxorubicin conjugate was diluted to 1 ml with EDC coupling 
buffer. An additional 1.5 equivalents each of EDC and Sulfo-NHS was added and stirred 
for an additional 2 hours prior to addition of 1 equivalent of aprotinin per disaccharide. 
This mixture was stirred overnight once again and on the following day it was 
concentrated through a 10,000 MWCO centrifugal filter to remove any unreacted 
heparosan-doxorubicin conjugate and excess aprotinin. Next, the conjugate was loaded 
onto a DEAE Sepharose column (0.5 ml) preequilibriated with 10 column volumes of 
wash buffer (20 mM NaOAc buffer (pH 6.0), 0.1 M NaCl, 0.01% Triton X-100).  The 
column was then washed with 30 column volumes of wash buffer.  Bound GAGs were 
then eluted with 6 column volumes of elution buffer (20 mM NaOAc,1 M NaCl, pH 6.0). 
Finally, the concentrated mixture was filtered through 100,000 and 30,000 MWCO 
centrifugal filters to remove aggregates.  
Subsequently, the HDA conjugates were analyzed by size-exclusion 
chromatography using a G3000 SWxL column operated at a constant flow rate of 0.5 
ml/minute of size exclusion buffer (100 mM KH2PO4, 150 mM NaCl, pH 6.0). 
Conjugates were also analyzed using dynamic light scattering (Malvern Zetasizer) at a 10 
µM concentration of doxorubicin and via transmission electron microscopy at a 1 mg/ml 
concentration of heparosan. To analyze the sulfation pattern of heparosan, strong anion 
exchange chromatography was utilized. Fifty µg samples of heparosan were digested 
with a cocktail of heparitinase I, II, and III and eluted at a rate of 1 ml/minute with an 
increasing gradient of NaCl from 0.1 M to 1 M over the course of 75 minutes. 
Disaccharides were detected using an inline UV detector at 232 nm absorption.  




concentration in solution as previously described.29 Briefly, multiple standards of 
heparosan polymer were prepared and 50 µl of each standard was loaded into wells of a 
96 well plate in triplicate. HDA was also loaded into wells of the 96 well plate. 
Subsequently, 200 µl of sodium tetraborate solution (25 mM sodium tetraborate in 
concentrated H2SO4) was added to each well containing sample. After mixing, the sample 
was heated in boiling water for 10 minute. Next, plates were cooled for 10 minutes and 
50 µl of carbazole solution (0.125% carbazole in 200 proof ethanol) was added to each 
well. Plates were heated again in boiling water for 10 minutes, cooled, and the 
absorbance of solutions was read at 520 nm.  
Drug loading on the HDA conjugates was analyzed through fluorescent 
spectroscopy by comparing known quantities of the polymer-conjugate solution to a 
standard curve of DOX. Plates were read using fluorescence excitation/emission at 470 
nm/600 nm.  
Cell viability upon drug or conjugate treatment was assessed using a Cell Titer 
Blue viability assay. Twenty five thousand cells were added into the wells of a 96 well 
plate in 200 µl of HAMS F-12 media. Cells were left to attach for 4 hours. Next, the 
media was replaced with fresh HAMS F-12 media and appropriate amounts of each drug 
or drug conjugate were added into each well in 200 µl of total volume per well. Cells 
were treated for 3 days in a humidified incubator and subsequently the media was 
replaced with 125 µl of fresh HAMS F-12 media. Fifty µl of cell titer blue reagent was 
added into the well and after a 3 hour incubation, 25 µl of 3% SDS was added into each 
well to stop cellular metabolic activity. Plates were then read in a fluorescent 




Approximately 50,000 cells were grown on glass coverslips within 35 mm cell 
culture. One µM of equivalent drug concentration were added into each well and cells 
were incubated in a humidified incubator for 16 hours. The media was removed and cells 
were washed twice with PBS. Subsequently, cells were fixed with 500 µl of 4% 
paraformaldehyde solution for 10 minutes at room temperature. Next, cells were washed 
twice with PBS and stained with a DAPI solution for 10 minutes. After incubation with 
the nuclear stain, cells were washed again and mounted onto microscope slides and 
imaged with an FV1000-XY Confocal Olympus IX81 microscope using a 60X oil 
immersion lens.  
F98 Rat Glioma cells were added to the top well of a 6 well Boyden chamber at a 
density of 1x105 cells/well in.  Next, HAMS/ F-12 media with penicillin/streptomycin 
was added to the top well and media with 10% fetal bovine serum was added to the 
bottom well. Xylosides or other solutions were added to both the top and bottom well in 
appropriate quantities and mixed together well with media. Invasion chambers were 
maintained in a humidified incubator at 37 ̊C for 3 days while cells migrated.  After this 
time period, supernatant from the top well was aspirated and the top half containing 
matrigel was removed using a cotton swab. The top well was then washed twice with 
PBS.  Subsequently the PET membranes were cut from the well using a razor and placed 
in trypsin to remove cells that had invaded through and deposited on the bottom side of 
the PET membrane.  Invaded cells were then counted using a hemacytometer. 
F98 cells (1 x 106 cells) were suspended in 100 µl of matrigel and injected into the 
flanks of athymic CD-1 nu/nu male nude mice of 12 weeks of age. The flank xenografts 




CD-1 nu/nu athymic nude mice were anesthetized under isoflurane. An incision 
was made above the scalp, the cerebral membrane was scraped away, and a needle-guide 
system was used to inject approximately 50,000 F98 cells (in 3 µl of matrigel) 1 mm 
axial and 1 mm sagittal to the bregma. The injection was carried out over the course of 1 
minute. Subsequently, dental cement was used to close the injection hole and 
biocompatible glue was used to seal the scalp. 
I.P. injections were carried out without anesthesia in the peritoneal cavity near the 
rear right leg. I.V. infusions were carried out by inserting a 28 guage needle into the 
lateral tail vein. Mice were anesthetized under isoflurane anesthesia and injections were 
performed using an injection pump and a 40 µl catheter attached to the needle. Infusions 
were given over 10 minutes into the tail vein. Doxorubicin was injected at a 1 mg/kg dose 
given as one bolus in i.p. injections and as an infusion in i.v. injections at a rate of 0.2 
mg/kg/minute over 10 minutes. Bradykinin was injected at a rate of 20 µg/kg/minute for 
i.v. injections. Elacridar was injected at a rate of 0.25 mg/kg/minute for i.v. injections. 
Dosing of HDA conjugates and Doxorubicin were equivalent in i.v. add i.p. injections. 
For i.p. injections xyloside was dosed at 30 mg/kg. For i.v. injections, xyloside was 
injected at a rate of 3 mg/kg/minute for 10 minutes. All mice were injected once with 
multiple therapeutics being injected as a cocktail.  
Mice were injected with Doxorubicin (2 mg/kg) and HDA conjugates (2 mg/kg 
equivalent dox), each dissolved in PBS i.p. on Day 1. After 24 hours, mice were 
sacrificed using carbon dioxide and cervical dislocation and organs were harvested and 
chilled at -20 ̊C. Analysis was performed by first washing tissues with PBS solution three 




lysis buffer (10 mM Hepes, 1 mM MgSO4, 1 mM CaCl2, pH 7.4) using a microtip 
sonicator. One hundred µl of the homogenate was then dissolved in 900 µl of extraction 
buffer (0.01% TritonX-100, 0.015% acidified isopropanol v/v [81 mM HCl in 
isopropanol]) and extracted overnight at -20 ̊C. The next day, samples were centrifuged at 
12,000 rpm for 10 minutes and doxorubicin fluorescence was quantified using a plate 




The goals of this part of the dissertation research are to demonstrate that HDA 
conjugates and xylosides are both effective antitumor agents in vitro and in vivo. 
Additionally, this research seeks to determine if either molecule is effective at bypassing 
the blood brain barrier to treat intracranial gliomas. Furthermore, the combination therapy 
consisting of both xylosides and the HDA conjugate is evaluated to determine its relative 
efficacy compared to either treatment individually in both flank and intercranial tumors. 
In order to reach these goals, HDA conjugates are synthesized through EDC coupling 
chemistry and characterized using strong anion exchange chromatograpy, size exclusion 
chromatography, dynamic light scattering, and transmission electron microscopy. Next, 
HDA conjugates and xylosides are tested in vitro for their efficacy singularly and in 
combination against a variety of cancer cells. Both molecules are also tested for their 
ability to reduce glioma invasion in vitro and the cellular localization of HDA conjugates 
is tracked. The in vivo biodistribution of HDA conjugates are also analyzed prior to 
treatment of flank and intercranial tumors. 
HDA conjugates were synthesized using EDC chemistry by first attaching 




aprotinin to the heparosan-dox conjugates (Figure 4.1 and see supplement). The full HDA 
conjugates are approximately 20 kDa – 30 kDa in size when compared to HPMA 
standards of sizes 40 kDa and 80 kDa (Figure 4.2a). The starting heparosan polymer is 
approximately 8-10 kDa in size and aprotinin is approximately 6500 Da in size. Less than 
1 % of free drug remains in the solution when comparing the AUC of the HDA conjugate 
vs. the small peak that elutes at 45 minutes corresponding to small molecules such as 
fluoresceinamine. The amount of polymer in a unit of solution is determined using the 
carbazole assay for uronic acid content (see supplement). The doxorubicin loading on the 
polymer can be determined using a fluorescence-based standard curve. Each polymer 
chain is found to carry approximately 6-10 doxorubicin molecules (see supplement). To 
corroborate the high loading of DOX on these polymers, an alternative method might 
include acid hydrolysis of the conjugate and subsequent detection of the DOX aglycon. 
Additionally, a BCA assay for protein content is performed to determine that 1-2 
aprotinin molecules are attached per chain of polymer (see supplement).   
The HDA conjugates form aggregates in solution and these aggregates are visible 
under TEM imaging to be approximately 50 nm or more in length (Figure 4.2b). 
Previously, several other research groups have noted that heparin, a similar 
glycosaminoglycan, forms aggregates in solution.30, 31 High DOX loading on these 
polymers may also be one cause for aggregation. DLS measurements also show that the 
nonaggregate particles are approximately 6.8 nm in size (Figure 4.2c). Additionally, after 
digesting heparosan with heparitinase I, II, and III, a characteristic ΔUA-GlcNAc 
disaccharide is found to elute at approximately 10 min, indicating that the polymer 











Figure 4.2. Characterization of Heparosan-Dox-Aprotinin conjugate. A) Size 
exclusion profile of Heparosan starting material and final conjugate. Representative 
traces are HPMA 80,000 Da ( ), HPMA 40,000 Da ( ), Heparosan-Dox-
Aprotinin conjugate ( ), Heparosan starting material ( ), and Fluorescein 
amine ( ). B) TEM image of conjugate. C) DLS profile of conjugate with a size of 
6.83 nm ± 0.84 nm. D) Disaccharide profile of heparosan starting material corresponding 




(Figure 4.2d).  
After synthesis and characterization, HDA conjugates were tested for their 
therapeutic efficacy in vitro (Figure 4.3). Cell lines tested included F98 rat glioma cells, 
CH157 human meningioma cells, and HT-29 human colon cancer cells. The indicated 
concentrations of HDA were based on equivalent doxorubicin concentration so that cell 
treatments could be normalized and compared to control untreated cell proliferation. 
Xylosides were also tested for their effects on cell viability and were utilized at 100 µM 
concentrations because previous studies indicated that at this concentration in vitro cell 
invasion was severely thwarted. Based on these results it is apparent that HDA conjugates 
are as effective as doxorubicin at the concentrations tested. Additionally, xylosides have 
no effect on cell viability in vitro in combination with HDA or as singular therapies. 
Furthermore, aprotinin-dox conjuates are not as effective as heparosan-dox-aprotinin 
conjugates, demonstrating that heparosan increases the therapeutic efficacy of the drug 
conjugate.   
To determine the cellular localization of HDA conjugates, CH157 cells were 
treated transiently with the conjugates for 1 day, fixed, and then imaged using a confocal 
microscope (Figure 4.4). Meningioma cells were utilized because they are large and easy 
to visualize. At equivalent settings, it is apparent that both doxorubicin and HDA 
conjugates can enter cellular nuclei. Typical polymer conjugates of doxorubicin utilize 
labile schiff bases to release the drug within the cell so that it may exert its anticancer 
activity in the nucleus.9, 10 However, HDA conjugates utilize covalent linkages between 
the drug and the polymer and are still able to target cellular nuclei to deliver the drug. 





Figure 4.3. Viability assays of HDA conjugates and Xylosides with multiple cell 
lines. A) F98 glioma viability with Xyloside alone, Dox alone, HDA conjugate alone, 
and combination therapy with HDA + Xyloside. B) CH157 meningioma cell viability 
showing efficacy of Dox alone, HDA alone, Xyloside alone, combination therapy, and 
Aprotinin-Dox as a control to demonstrate improved efficacy with heparosan polymer vs. 
without heparosan polymer. C) HT-29 colon cancer cell viability with HDA alone, 
Xyloside alone, and with HDA + Xyloside. In combination therapy xylosides were 
utilized at 100 µM concentration. Concentration values in µM are equivalent doxorubicin 
concentrations, except in xyloside-only treatments. ** indicates P<0.05 as determined by 






Figure 4.4. Localization of doxorubicin and HDA conjugate in CH157 meningioma 















Figure 4.5. Relative inhibition of F98 glioma invasion. For each set of results, the 
invasion with xylosides is normalized to invasion without xyloside. ** indicates P<0.05 
as determined by a one-tailed paired t-test vs. control cells that were not treated with 


























the invasion assay performed, a two-well Boyden chamber assay is utilized to determine 
the efficacy of antiinvasive therapeutics. Here, the top well consists of a floor made out 
of PET membrane with 8 µm pores layered with matrigel on top. Cells are added on top 
of the matrigel layer and a chemotactic gradient causes cells to invade through the 
matrigel layer and deposit on the bottom of the PET membrane over the course of 3 days. 
Cells found below the PET membrane are then counted and recorded. Based on the 
results, it was found that xyloside effectively reduced the invasion of F98 cells in this in 
vitro invasion assay. With xyloside treatment, F98 invasion through the matrigel was 
reduced approximately 50 percent. Additionally, the effectiveness of the xyloside was not 
hindered in combination with doxorubicin or with HDA conjugate. As expected, HDA 
and DOX treatment significantly reduced cell viability. Therefore, values displayed in 
Figure 4.5 are paired and normalized to treatments without xyloside.  
The biodistribution of HDA conjugates and doxorubicin was determined by 
injecting CD-1 nu/nu male mice with conjugates and harvesting organs after a period of 
24 hours (Figure 4.6). After homogenizing tissue in nuclear lysis buffer (doxorubicin 
localizes to nuclei), acidified isopropanol was used to extract the doxorubicin from the 
homogenized tissue. Data were normalized to PBS treated mice that had no doxorubicin 
in order to account for tissue auto-fluorescence. It is apparent that the conjugate entered 
the brain significantly more than doxorubicin, which is known not to enter the brain in 
therapeutic quantities. Additionally, the HDA conjugate localizes to the tumor more 
effectively than doxorubicin. Furthermore, relative to doxorubicin, the conjugate does not 
localize to the heart tissue as effectively. As doxorubicin is a known cardiotoxic agent, it 





Figure 4.6. Relative biodistribution of DOX and HDA conjugate in mice 24 hours 
after an injection of 2 mg/kg i.p. Relative DOX fluorescence indicates tissue levels of 
the drug. Representative peaks are PBS injected mice ( ), 2 mg/kg i.p. doxorubicin 
injected mice ( ), and 2 mg/kg equivalent dose of HDA conjugate injected mice ( ). 
** indicates P<0.05 as determined by a one-tailed paired t-test comparing each set of 




To test the efficacy of HDA conjugates in vivo, a flank model of F98 rat gliomas 
was utilized (Figure 4.7). F98 tumor xenografts were grown in the flanks of CD-1 nu/nu 
male mice until tumors were palpable and subsequently mice were treated with 
doxorubicin or HDA i.p. once per week. Mice received xyloside five times per week, as 
indicated, respectively. When mice were noticeably showing signs of pain or sickness, 
they were sacrificed according to established IACUC protocols. Once all PBS treated 
mice were sacrificed, the experiment was ended and the data were analyzed. Future 
studies will follow mice for a longer period of time. Data from these experiments indicate 
that the HDA conjugate was as effective as DOX at reducing flank tumor growth. 
Additionally, it was found that xyloside was as effective as DOX at reducing flank tumor 
growth. Combination treatment with both xylosides and HDA conjugates did not show 
significant improvement compared to individual treatments according to growth data. 
Combination therapy may even be deleterious to the individual efficacies of each 
treatment (HDA or xyloside). However, in terms of survival, it was found that only one 
mouse went into remission with no noticeable sign of tumors in the flank or brain. This 
mouse was being treated using the combination therapy and warrants further 
investigation. These data also indicate that mice with late stage tumors can be effectively 
treated with DOX, HDA conjugates, and xyloside. After determining that HDA 
conjugates and xylosides were effective at treating tumor xenografts in the flank, the 
treatment strategy was tested in an orthotopic intercranial F98 glioma model (Figure 4.8). 
Cells utilized in this model are extremely invasive and stably transfected with luciferace 
for ease of imaging. I.P. injections of luciferin are quickly metabolized by luciferase and 





Figure 4.7. Treatment efficacy of HDA conjugate and combination therapy against 
F98 cells in mouse flanks. (n=5) DOX and HDA conjugates were injected i.p. at 1 
mg/kg dose or dose equivalent of DOX once per week. Xyloside was injected at 30 
mg/kg five times per week. Treatment days refer to the numerical number of days after 
treatment was started because tumors were established. Average tumor volume prior to 
treatment start was 184 ± 78 mm3. Representative panels are: A) Treatment initiated after 
2 weeks, Control mice ( ), DOX treatment group ( ), and HDA treatment 
group ( ). B) Treatment initiate after 3 weeks. Traces for Control mice ( ), 
Xyloside-treated mice ( ), Doxorubicin treated mice ( ), HDA treated mice (







Figure 4.8. Efficacy of conjugate and combination therapy against orthotopic 
intracranial F98 glioma. Representative panels are described. A) Intercranial tumor 
growth after i.p. injection of PBS ( ), Xyloside ( ), 1 mg/kg Doxorubicin (
), 1 mg/kg equivalent HDA conjugate ( ), and 1 mg/kg equiv. dose HDA 
with 30 mg/kg xyloside ( ). Treatments initiated 1 week after implantation of 
tumors in the brain. B) Intercranial tumor growth after i.v. infusion of PBS ( ) and 
0.2 mg/kg/min equiv. dose of HDA and 3 mg/kg/min xyloside in combination with 20 
µg/kg/min bradykinin and 0.25 mg/kg/min elacridar ( ). Treatments initiated 2 days 
after tumor implantation in the brain. C) Survival curve after i.v. infusion of PBS  
( ) and combination therapy with bradaykinin and elacridar ( ). D) Internal 
control demonstrating increased D-luciferin permeability upon i.v. infusion of bradykinin 
and elacridar. ** indicates P<0.05 as determined by a one-tailed paired t-test. Error bars 





injected slowly within the brain near the bregma. The skull was resealed with dental 
cement and tumors were allowed to establish prior to treatment. Initially, orthotopic 
tumors were treated with doxorubicin (once per week), HDA conjugates (once per week), 
xylosides (five times per week), and combination therapy via i.p. injections. However, as 
these treatments were unable to reduce tumor growth (Figure 4.8a), a follow-up 
experiment was conducted where the following experimental modifications were devised: 
a) treatments were initiated 2 days after tumor implantation, b) bradykinin was infused 
i.v. with the injection to increase BBB penetration and c) elacridar was infused with the 
injection to reduce drug efflux through BCRP and PG-1, and d) all combination therapy 
treatments and PBS for control mice were given 3 times per week. Through this 
experiment it was found that bradykinin and elacridar increased luciferin signal in the 
brain, thus indicating that BBB penetration was increased (Figure 4.8d). However, even 
with these improvements, it was found that a combination therapy with HDA conjugates 
and xylosides was unable to reduce brain tumor growth and coincidentally mouse 




In recent years, a plethora of novel drug delivery systems designed to target 
tumors have been developed. However, the majority of these vehicles are designed to 
merely deliver their therapeutic cargo and then to be excreted. Very few DDV have been 
designed where both the drug as well as the carrier may be therapeutic. 
Glycosaminoglycans provide a novel scaffold on which to design DDV because they 
have several inherent advantages: GAGs are biologically active and can be tailored to 




several functional groups which can be modified with targeting moieties and therapeutic 
cargo. GAGs such as heparin, acharan sulfate, and PI-88 have demonstrated significant 
antitumor efficacy by mitigating tumor growth, invasion, metastasis, inflammation, and 
angiogenesis in animal models.32-34 Thus, we tested the efficacy of several different 
GAGs as potential drug delivery vehicles by analyzing their internalization properties and 
cellular localization. Heparosan, an unsulfated GAG, showed promise in our studies due 
to its rapid internalization and nuclear localization in U87Mg glioma cells. Heparosan-
DOX conjugates were able to target cellular nuclei and induce apoptosis without the need 
for a labile hydrazone linker between the drug and the polymer indicating that the 
conjugate would be more attractive because of its shelf stability. Additionally, through 
conjugation of aprotinin with heparosan-DOX, HDA conjugates were expected to 
traverse the BBB and to reduce tumor-associated inflammation due to aprotinin’s 
intrinsic biology whereby Aprotinin utilized LRP-1 to permeate the brain via receptor-
mediated endocytosis.25  
In addition to novel drug delivery vehicles, there has been a growing demand for 
nontoxic anticancer therapeutics. Chemotherapeutics are notorious for their devastating 
side effects whereby patients undergoing therapy typically have nausea, hair loss, weight 
loss, and several other symptoms that reduce their quality of life. Xylosides, small 
molecules that increase GAG biosynthesis in cells and GAG secretion, provide a novel 
methodology for treating cancers without toxic side effects. By utilizing GAGs generated 
by xylosides, it is possible to fight tumor growth without the introduction of unnatural 
and toxic organic molecules. Xylosides have successfully been utilized at molar 




In this study, the efficacy of a combination therapy composed of HDA conjugates 
and click-xyloside against flank and cranial tumors was assessed. First, HDA conjugates 
were characterized via size exclusion chromatography, transmission electron microscopy 
(TEM), dynamic light scattering (DLS), and strong anion exchange chromatography 
(Figure 4.2). The HDA conjugates are approximately 20 kDa – 30 kDa in size with less 
than 1 percent free drug. In solution the conjugates are approximately 6.8 nm in size 
when analyzed by DLS and larger when analyzed by TEM. It is expected that heparosan 
also aggregates in solution like heparin.30, 31  
Next, the in vitro efficacy and localization of HDA conjugates and combination 
therapy were assessed (Figure 4.3 and 4.4). It was determined that HDA conjugates are as 
effective as doxorubicin in reducing F98 cell viability and growth. Xyloside had minor 
effects on cell viability and a combination therapy with HDA conjugates and xyloside 
showed similar efficacy as the equivalent HDA conjugate. Aprotinin conjugates of 
doxorubicin were not as effective as HDA conjugates at reducing cell viability. It is likely 
that heparosan improves the overall drug delivery efficacy by improving cellular uptake 
as shown previously.8 F98 glioma cells, HT-29 colon cancer cells, and CH157 
meningioma cells all showed similar results. Confocal microscopy also confirmed that 
HDA conjugates localized to cellular nuclei. It is noteworthy that HDA conjugates could 
deliver the drug and affect cell viability without utilizing a cleavable linker between the 
doxorubicin and the polymer. Previously, several studies have demonstrated that GAGs 
are able to localize to cellular nuclei.37-39 Additionally, Hyaluronic acid-DOX conjugates 
have been found to reduce tumor viability without the use of a labile linker. Perhaps 




affect cell viability. Additionally we have shown that heparosan is able to enter the 
nucleus of U87 Mg cells.8 However, the mechanisms of uptake of GAGs into cellular 
nuclei and drug action without a labile linker remain unclear. Therefore, it is likely that 
the polymer conjugate remains intact and shuttles doxorubicin to the nucleus of cells 
where the drug is active. Surprisingly, the attached polymer does not significantly affect 
the efficacy of the drug. Subsequently, when the invasive capability of F98 cells was 
assessed, it was found that xyloside dramatically lowered the invasive capability of cells 
in vitro. The addition of HDA conjugates and doxorubicin had little effect on the efficacy 
of xylosides.  
The in vivo evaluation of HDA conjugates was carried out by determining the 
biodistribution of the conjugate, testing the efficacy of therapy in mouse flanks, and 
subsequently testing in mouse brains. Biodistribution data were assessed 24 hrs after a 
single dose of 2 mg/kg DOX or HDA conjugate (Figure 4.6). Organs in animals were 
harvested and tissue was lysed to release doxorubicin in cell nuclei. The released 
doxorubicin was extracted into acidified isopropanol and sample fluorescence was 
analyzed. It was found that compared to doxorubicin, HDA conjugates localized 
significantly more to the brain and the tumor. Additionally, conjugates were found in the 
liver and heart to a lesser extent than doxorubicin. It is likely that aggregation and the 
enhanced permeability and retention effect were responsible for the localization of HDA 
conjugates in tumor tissue.40 Furthermore, aprotinin is known to target inflammatory sites 
and may have aided tumor targeting.41, 42 As doxorubicin is a known cardiotoxic 
chemotherapeutic, the reduction in localization to the heart may indicate that the HDA 




conjugates may be effective in targeting and treating intracranial gliomas.  
Treatment of F98 xenografts grown in mouse flanks was evaluated after growing 
tumors for 2 weeks (Figure 4.7A) or 3 weeks (Figure 4.7B). HDA conjugates were as 
effective as DOX at reducing F98 growth in the flank. Compared to mice treated with 
PBS, both DOX and HDA conjugates significantly slowed growth of the tumors and 
improved the quality of life. These results indicate that HDA conjugates are effective at 
reducing tumor growth both in vivo and in vitro. Additionally, it was found that xyloside 
effectively reduced tumor growth in the flanks at a dose of 30 mg/kg. As this xyloside 
has been found to be nontoxic at high concentrations in vitro, these results indicate that 
click-xylosides may be promising anticancer therapeutics. Previously, it has been found 
that various O-xylosides inhibit the growth of tumors in mice.14 However, these xylosides 
were unstable O-xylosides which could undergo hydrolysis or be cleaved by glycosidases 
to release toxic organic moieties (free naphthol and benzyl groups). Furthermore, these 
xylosides only primed low molecular weight GAGs. Therefore, their mechanism of 
action against tumors and chemical toxicity in vivo was difficult to discern. In contrast, 
click-xyloside, utilized in this study, is hydrolytically stable and able to prime large 
molecular weight GAGs.  
The efficacy of HDA conjugates and xyloside against orthotopic gliomas was 
evaluated after growing intracranial tumors for 1 week and subsequently initiating 
treatment with i.p. injections (Figure 4.8A). Results demonstrate that there was no 
significant effect of treatment on glioma growth in any of the treatment groups. To 
further improve the efficacy with which treatments cross the BBB, treatments were given 




known to cause contractions of brain capillary cells and to chemically open the BBB.22, 
23Additionally, elacridar prevents the efflux of drugs through PG-1 and BCRP efflux 
pumps in the BBB.26, 27 However, chemical opening of the BBB and reduction of drug 
efflux did not show any synergistic effect with combination therapy on brain tumor 
growth or mouse survival (Figure 4.8B and Figure 4.8C). Confirmation of BBB chemical 
opening was observed by testing luciferin signal in the brain with and without bradykinin 
and elacridar (Figure 4.8D). Luciferin uptake into brain tumor cells was enhanced 60 
percent after bradykinin and elacridar infusion in the tail vein. Since DOX, HDA, and 
xyloside all effectively treated flank tumors, it is likely that these therapeutics cannot 
cross the BBB without modification and therefore are unable to treat orthotopic gliomas. 
It is noteworthy that the use of HDA conjugates with XYL as a combination therapy 
against orthotopic brain tumors yielded poorer results than control untreated mice. The 
mechanism behind the antagonistic relationship between these treatments is still unclear.  
In conclusion, HDA conjugates and xyloside show promise as potential therapeutics to 
target and treat cancers. HDA conjugates are likely to be less toxic than DOX, can be 
modified with a variety of imaging and targeting moieties, and have the unique ability to 
interfere with tumor nuclei without the need for cleavable drug linkers. Additionally, 
xylosides are nontoxic modulators of tumor growth and have tremendous potential for in 
vivo use as anticancer therapeutics. However, further modification is necessary to 
improve their flux across the BBB. Efforts are currently underway to directly infuse these 
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4.6 Supplementary Information 
 
Table 4.S1. Summary of Characterization Data 
Molecular Weight 
Starting Materials 
Heparosan 10,000 Da approx. 
Aprotinin 6511 Da 
Doxorubicin 579.98 Da 
Final Conjugate 
Conjugate MW 20,000-30,000 Da appox. 
DOX molecules per chain 6-10 molecules per chain 
Aprotinin molecules per chain 1-2 molecules per chain 
Free Drug % < 1% by AUC 
Hydrodynamic Size 
Conjugate Size by DLS 6.83 nm ± 0.84 nm 
Aprotinin Size by DLS 1.65 nm.1 




















Figure 4.S1. Uronic acid calibration curve and trendline based on 520 nm 
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Figure 4.S2. Doxorubicin concentration calibration curve and trendline based on 
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Figure 4.S3. Aprotinin concentration calibration curve and trendline based on 560 
nm absorbance of a BCA reagent.  
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Cancer remains a challenging disease to treat. Glioblastomas, in particular, are a 
devastating form of cancer that are difficult to treat because of the sensitivity of brain 
tissue and the difficulty of circumventing the blood brain barrier. The current treatment 
regime consists of temozolomide and radiation and increases two-year survival of 
patients to 27 percent.1 In this dissertation, we develop novel glycosaminoglycan based 
therapeutics and drug delivery vehicles for targeting and treating glioblastomas and other 
cancers. Chapter 2 describes the development of several xylosides and 
glycosaminoglycan mimetics that can hinder tumor angiogenesis and invasion. Chapter 3 
describes the development and evaluation of novel glycosaminoglycan-based drug 
delivery vehicles which are biocompatible, biodegradable, target tumor nuclei, and 
overcome drug resistance. Chapter 4 describes the in vivo efficacy of HDA, in 
combination with xyloside therapy, against aggressive flank and intercranial tumors. 
These studies demonstrate that glycosaminoglycan-based therapeutics and vehicles are 
extremely effective against tumors outside the brain. However, further optimization is 
necessary to deliver them systemically and treat brain tumors.  
Among the different novel therapeutics developed and tested in this dissertation, 




small sugars, which are nontoxic and induce glycosaminoglycan synthesis after enter cell 
Golgi. The newly released glycosaminoglycans then compete with cell surface 
glycosaminoglycans and alter cell signaling and biology. Interestingly, we have found 
that they not only reduce cell invasion in vitro but also dramatically affect tumor growth 
in vivo in mouse flanks. No anticancer activity was detected against intracranial gliomas. 
However, as these molecules induce no cell toxicity in vitro, it may be possible to utilize 
them at much higher dosages in vivo and further reduce tumor growth without any 
concomitant toxicity. It may even be possible to directly infuse these small-molecules 
into the brain. Previously, researchers have found that O-xylosides can inhibit tumor 
growth, but these molecules were toxic to cells due to the unstable hydrolytically-
cleavable linkages between the sugar and the aglycone.2 Click-xylosides evaluated in this 
dissertation are a significant advancement over this previous technology and ongoing 
studies are evaluating the antitumor potential of Click-xylosides as part of a directly 
infused therapy into the brain.  
Fluoro-xylosides, sulfated small-molecule GAG mimetics, and sulfated polymeric 
GAG mimetics also provide alternate strategies to reduce tumor growth. As demonstrated 
in Chapter 2, fluoro-xylosides dramatically reduce glycosaminoglycan synthesis and also 
affect tumor-associated angiogenesis. However, systemic introduction of these molecules 
is likely a major challenge due to myriad of roles that GAGs play in physiology. Targeted 
xyloside therapy may provide one solution to the effective use of fluoro-xylosides in 
vivo.3 Alternatively, GAG mimetics may be utilized to affect tumor angiogenesis. Both 
small-molecule and polymeric mimetics are promising because of their inherent 




production-scale quantities of small molecule GAG mimetics. Additionally, the 
polymeric mimetic discussed in Chapter 2 can be quickly synthesized from heparin, a 
globally-available clinical anticoagulant. Future studies will determine the in vivo 
efficacy of these molecules. 
The studies performed as part of this dissertation also demonstrate the efficacy 
and clinical relevance of a novel GAG-based drug delivery vehicle. After thorough 
analysis of the effect of sulfation pattern on GAG uptake into cells, Heparosan and N-
sulfo heparosan were both found to have several advantages as drug delivery vehicles. It 
was found that both polymers were significantly more effective at delivering doxorubicin 
into cells compared to heparin. Additionally, DOX conjugates of both polymers were 
able to target cellular nuclei and deliver DOX without the need for labile drug-polymer 
linkers. A DOX conjugate of N-sulfoheparosan was also found to overcome doxorubicin 
resistance in cells at low concentrations. Furthermore, both polymers are simple to 
produce, biodegradable, and biocompatible.  
Further evaluation of the DOX conjugates from Chapter 3 in vivo was carried out 
by conjugating aprotinin to heparosan-DOX. With aprotinin, it was expected that the 
conjugates would circulate systemically and localize to all organs including the brain. In 
vivo efficacy experiments with an aprotinin conjugate of heparosan-DOX (HDA) 
indicated that the conjugate dramatically reduces tumor growth in mouse flanks. 
However, the conjugates did not demonstrate any antiglioma efficacy. Further 
modification and evaluation is necessary to enhance the brain penetration of HDA 
conjugates. While co-infusions of bradykinin/elacridar were attempted as a method to 




antiglioma efficacy. Perhaps conjugation of Angiopep to heparosan-DOX may yield 
promising results similar to recent conjugates of angiopep and paclitaxel.4  
In addition to individual treatments with xyloside and HDA conjugates, 
combination therapy with both HDA conjugates and click-xyloside was also evaluated. It 
was found that combination therapy was equally effective at reducing tumor growth in 
mouse flanks and in mouse brains. No significant advantage was identified between 
individual treatment with HDA conjugates and combination therapy consisting of HDA 
conjugates along with click-xyloside. Varying the dosage of either treatment may affect 
the in vivo efficacy of the combination therapy. It may be possible that alternative 
dosages of either xyloside or conjugate have a synergistic effect in vivo whereby the 
combination of both therapies is more effective than either therapy alone.5 Nonetheless, 
click-xylosides and HDA conjugates remain promising targets for further development 
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In addition to studies on a combined drug delivery strategy to target and treat 
cancers, studies were performed on heparan sulfate biosynthesis and biology. The current 
state of understanding of the biosynthesis of heparan sulfates involves a series of steps 
that starts with the assembly of a linkage tetrasaccharide where xylose is first attached to 
the serine residue of a core protein. Subsequently three more sugar residues are added 
onto this chain (galactose, galactose, and glucuronic acid). After the assembly of this 
region, the chain is elongated and N-sulfated by N-Deacetylase-N-sulfotransferase 
(NDST) enzymes. Next, C5-epimerase (C5-EPI) converts some glucuronic acid residues 
to iduronic acid residues. Subsequently the chain is concurrently modified by 2-O-
Sulfotransferase, 3-O-Sulfotransferase, and 6-O-Sulfotransferase. It is necessary for 
NDST to act on the chain before C5-EPI due to the substrate specificity of the C5-EPI. 
Additionally, C5-EPI does not modify the polymer after O-Sulfotransferases act on the 
chain. Therefore, conventionally it is known that NDST is a gateway modification and 




 not just a gateway modification during heparan sulfate biosynthesis. Using 
chemoenzymatially synthesized heparan sulfate polymers we show that NDST may act 
even after O-sulfotransferases modify a growing chain unlike C5-EPI.  
 
A1.2 Is N-Sulfation Just a Gateway Modification During 
Heparan Sulfate Biosynthesis? 
Manuscript reproduced with permission from: Raman, K., Nguyen, T. K., and Kuberan, B. 
(2011) Is N-Sulfation just a gateway modification during heparan sulfate biosynthesis? FEBS 
Lett., 585, 3420-3423.  
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a b s t r a c t
Several biologically important growth factor–heparan sulfate (HS) interactions are regulated by HS
sulfation patterns. However, the biogenesis of these combinatorial sulfation patterns is largely
unknown. N-Deacetylase/N-sulfotrasferase (NDST) converts N-acetyl-D-glucosamine residues to N-
sulfo-D-glucosamine residues. This enzyme is suggested to be a gateway enzyme because N-sulfation
dictates the final HS sulfation pattern. It is known that O-sulfation blocks C5-epimerase, which acts
immediately after NDST action. However, it is still unknown whether O-sulfation inhibits NDST
action in a similar manner. In this article we radically change conventional assumptions regarding
HS biosynthesis by providing in vitro evidence that N-sulfation is not necessarily just a gateway
modification during HS biosynthesis.
! 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
1. Introduction
Heparan sulfate proteoglycans (HSPGs) are composed of core
proteins attached to sulfated glycosaminoglycan (GAG) side chains.
They play important roles as co-receptors for several molecules
including fibroblast growth factors (FGF), hepatocyte growth factor
(HGF), glial cell derived neurotrophic factor (GDNF), and vascular
endothelial growth factors (VEGF) [1]. By acting as co-receptors,
they are involved in a variety of pathological and physiological pro-
cesses such as tumor progression and embryonic development [2–
4]. The role of HS as a co-receptor depends greatly on its sulfation
pattern. For example, HS–FGF2 interactions require the presence of
N-sulfated glucosamine units, 2-O sulfated iduronic acid units, and
6-O sulfated glucosamine units [5,6].
To generate the diverse sulfation patterns present in HS chains,
the biosynthesis of HS involves a complex interplay between several
enzymes that are predicted to be co-localized within GAGOSOMEs
[7–12].HSbiosynthesisbeginswith the formationofa linkage region
composed of one xylose residue, two galactose residues and one
glucuronic acid residue. Next, the HS chain is extended by Ext-1
andExt-2.As thepolymerizationtakesplace,N-deacetylase/N-sulfo-
trasferase enzyme isoforms (NDST) convertN-acetyl-D-glucosamine
residues in the nascent chain into N-sulfo-D-glucosamine residues.
There are four known NDST isoforms that have different deacetyla-
tion/sulfation abilities andare expressedvariably indifferent tissues
[13–17]. The N-sulfate groups added by these enzymes determine
the domain structure of HS because subsequent modifications by
C5-epimerase, 2-O sulfotransferase, 3-O sulfotransferase, and 6-O
sulfotransferase are dictated by the location of N-sulfate groups
[18]. The order of modifications will have enormous implications
in generating diverse structures of biological significance [19].
It is well known that C5-epimerase, which converts glucuronic
acid residues to iduronic acid residues after NDST modification, is
inhibited by O-sulfation [20]. However, it is unknown whether
NDST, which confers the first modification of HS chains, is influ-
enced similarly by the presence of nearby O-sulfate groups. Earlier
studies have shown that NDST can act on a variety of substrates
[21–28]. However, these studies have not elucidated the site of ac-
tion of NDST within the larger heparanome (which contains non-
sulfated (NA), heavily sulfated (NS) and mixed (NA/NS) domains).
Earlier studies estimated the levels of radioactive [35S]-sulfate
incorporation into a variety of substrates in the presence of NDST
without analyzing the corresponding disaccharides. Therefore, it
is unknown whether O-sulfation inhibits NDST activity, i.e. NDST
could just be modifying N-acetyl glucosamine (GlcNAc) residues
in the non-sulfated NA domains within the heparanome.
This study utilizes NDST-2, a robust enzyme isoform which
shows equal N-deacetylase and N-sulfotransferase activity, to
determine the site of action of NDST on HS for the first time and
to probe whether O-sulfation affects N-deactylation/N-sulfation.
0014-5793/$36.00 ! 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
doi:10.1016/j.febslet.2011.09.030
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These in vitro results are obtained from studying the action of
NDST-2 on a mature HS chain and on a synthetic enzymatically-
generated substrate.
2. Materials and methods
2.1. Materials
Heparan sulfate from bovine kidney was procured from Sei-
kagaku. DEAE-Sepharose gel was purchased from Amersham Bio-
sciences. [35S]Na2SO4 and Ultima-FloAP scintillation fluid were
purchased from Perkin Elmer Life and Analytical Sciences. [32S]PAPS
and HS disaccharide standards were purchased from Iduron and
Sigma–Aldrich. SF-900 II SFM media was purchased from Invitro-
gen. [35S]PAPS was prepared as reported earlier [19]. Heparitinases
I, II, and III from flavobacterium heparinum were cloned and ex-
pressed as previously described. All other reagents and solvents
were from Sigma–Aldrich.
2.2. Purification of NDST-2
Fifteen millilitres of NDST-2 viral stock was added to 2 ! 109 Sf9
cells in 1 l of SF900 II SFM media. Infected cells were shaken at a
rate of 150 rpm in a humidified incubator maintained at 28 !C for
4 days. After 4 days, the cell suspension was centrifuged at
1000!g for 30 min to pellet cells. To the supernatant, PIPES solu-
tion was added to a final concentration of 10 mM and the pH of
the solution was adjusted to 7.0. Next, a solution containing phen-
ylmethylsulfonyl fluoride in 10 ml isopropanol was added to a final
concentration of 1 mM. The supernatant was then chilled on ice for
1 h prior to centrifugation at 4000!g for 1 h. The supernatant was
then diluted 1:2 with ddH2O and filtered through a 0.45 lm pore-
size PES membrane under vacuum. This solution was then loaded
onto a 100-ml column of ToyoPearl AF heparin 650 M. The column
was washed with 600 ml of PCG-50 (10 mM PIPES, pH 7.0, 2% glyc-
erol, 0.6% CHAPS, 50 mM NaCl) and eluted with a 450-ml linear
gradient of 50–1000 mMNaCl in PCG. Aliquots of selected fractions
were then analyzed to check NDST-activity as described later in the
methods section utilizing a heparan sulfate substrate instead of
K5NS. Positive fractions were then pooled and concentrated using
an Amicon YM-10 membrane.
2.3. Preparation of partially N-sulfated 6-O-sulfated K5 heparosan
All reactions were performed in a buffer consisting of 25 mM
MES (pH 7.0), 0.02% Triton X-100, 2.5 mM MgCl2, 2.5 mM MnCl2,
1.25 mM CaCl2 and 0.75 mg/ml BSA. Four hundred and eighty
micrograms of K5 heparosan was combined with 200 lg of
[32S]PAPS and 40 ll of NDST-2 in a 600 ll reaction volume. The
product was analyzed after digestion with Heparitinases I, II, and
III, using strong anion exchange HPLC (SAX-HPLC) with an inline
UV detector measuring absorbance at 232 nm. Ten micrograms of
partially N-sulfated K5 heparosan was incubated with 10 ll of 6-
OST-3 and 3 ll of [35S]PAPS (0.5 ! 107 CPM) in a 50 ll reaction.
An aliquot of the radioactive sample was then desalted through a
3000 MWCOfilter, digestedwith Heparitinases I, II, and III, and ana-
lyzed using SAX-HPLC with an inline radiometry detector. Radioac-
tive disaccharides were eluted with a linear gradient of 0–1 M NaCl
in 70 mM phosphate buffer (pH 3.0) for 60 min and co-injected HS
disaccharide standards were used to confirm their identity.
2.4. Enzymatic reactions of NDST-2
Heparan sulfate or K5NAc/NS6S were treated with NDST-2 by
incubating 10 lg of substrate with 10 ll of NDST-2, 10 ll of MES,
and 3 ll of [35S]PAPS (0.5 ! 107 CPM) in a 50 ll reaction overnight.
The next day, an additional 10 lg of [32S]PAPS was added along
with 10 ll of NDST-2 to saturate all possible modification sites.
The modified products were then desalted, digested, and analyzed.
3. Results and discussion
To demonstrate that N-sulfation is not just a gateway modifica-
tion and to elucidate the site of action of NDST enzymes on a ma-
ture HS chain, bovine kidney HS was incubated with NDST-2 in the
presence of [35S]PAPS. The resulting polymer chain was treated
with Heparitinases I, II, and III, and the resulting radio-labeled
disaccharides were co-injected with disaccharide standards and
analyzed by strong anion exchange chromatography (Fig. 1a). A
chromatogram of the HS from bovine kidney is included in the
Supplementary materials (Fig. S1).
After NDST-2 treatment of HS, the disaccharides generated by
heparitinase treatment are: DUA-GlcN[35S] and DUA-GlcN[35S]6S
Fig. 1. Radiometric traces of disaccharides formed by digesting polysaccharides
with Heparitinases I, II, and III. (a) Disaccharides formed when HS is treated with
NDST-2 and digested with Heparitinases I, II, and III. (b) Disaccharides of partially
N-sulfated, 6-O sulfated heparosan, a synthetic substrate designed to test the
activity of NDST-2 without neighboring group effects from other O-sulfates. The
ratio of GlcNS6S/GlcNAc6S peaks is "0.6. (c) Disaccharides of NDST-2 treated
partially N-sulfated, 6-O sulfated heparosan. After NDST-2 addition, the GlcNS6S/
GlcNAc6S ratio increases. Thus 6-O sulfation does not inhibit NDST-2 action. The
peaks in the chromatograms were determined by comparison to co-injected
standards.





Thus, onlyDUA-GlcNAc andDUA-GlcNAc6S residues on mature HS
chains can be N-sulfated. Surprisingly, the HS chains did not have
any additional modification sites. One would expect that small
amounts of (GlcA/IdoA)2S-GlcNAc sequences would also be sul-
fated by NDST, however the expected disaccharide product,
DUA2S-GlcN[35S], was not found after digestion of the polysaccha-
rides with Heparitinases I, II, and III. This observation points to the
possibility that other O-sulfates may inhibit NDST action. However,
such a claim is difficult to test because of the rare nature of N-acet-
ylated 2-O sulfated disaccharide units and the difficulties involved
in synthesizing such substrates using chemoenzymatic methods.
While NDST was found to act on 6-O sulfated residues in HS, it is
difficult to analyze the true sites of modification because nearby
sulfate groups can influence the action of the enzyme on the poly-
mer chain. To further confirm the hypothesis that NDST modifies
GlcNAc6S sites on HS, and to negate any such neighboring group
effects, a synthetic substrate consisting of this residue was synthe-
sized by 6-O-sulfation of 50% N-sulfated heparosan with 6-OST-3
in the presence of [35S]PAPS (Fig. 2, polysaccharide 1). Treating this
polysaccharide with NDST-2 in the presence of [32S]PAPS then al-
lowed us to observe the conversion of GlcNAc6[35S] residues to
GlcNS6[35S] residues (Fig. 1b and c). It is noteworthy that all Glc-
NAc6[35S] residues were converted to GlcNS6[35S] residues – con-
firming that 6-O-sulfation does not inhibit NDST enzymatic action.
Based on these results, it is evident that the conventional view
of NDST, as a gateway enzyme, provides incomplete information.
This study provides in vitro evidence showing that NDST acts on
the mature HS chain and modifies it after it has been 6-O-sulfated
– thus NDST-mediated modification is not necessarily just a gate-
way modification during HS biosynthesis (see Fig. 3). Extending
the findings reported here to probe the action of NDST in vivo is be-
yond the scope of the current work. Nevertheless, one can conclu-
sively state that current and previously reported in vitro
experiments have undoubtedly helped demonstrate that O-sulfa-
tion differentially affects the action of two early biosynthetic en-
zymes, NDST and C5-epimerase [9,20]. One can envision that
in vivo evidence delineating the exact sequence of HS biosynthetic
events and the exact action of biosynthetic enzymes may require
complex cellular experiments involving isotope enriched mole-
cules and sophisticated instruments [29]. In conclusion, the results
of this study redefine the role of NDST during HS biosynthesis and
provide new insights into the actions of GAGOSOMES.
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